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INTRODUCTION 
 
niqK!niqK!lieqmvib<!hqxk<kz<!niqK< < << < << < < !
nkeqEl<!niqK!%e<?!GVM?!osuqM?!OhM!fQr<gq!hqxk<kz<!niqK< < Q < < << < Q < < << < Q < < < !
nkeqEl<!niqK!RieLl<!gz<uqBl<!fbk<kz<!niqK< < < < < << < < < < << < < < < < !
nkeqEl<!niqK!kieLl<!kuLl<!osb<uK!niqK< < < << < < << < < < !
. Ytjubii<< <<!
 Human is wonderful creation of the nature. The ancient Tamil poet ovvaiyar said 
to be born a human is most venerable.  From the above lines we well known have born 
with good health is a great gift of god. 
   
    “dml<hiI!npqbqz<!dbqviI!npqui<< < << < << < <!
! kqml<hm!olb<Riel<!OsvUl<!lim<miI< < < < << < < < << < < < < !
! dml<jh!uti<g<Gl<!dhibl<!nxqf<Ok< < < < < << < < < < << < < < < < !
! dml<jh<<< !uti<k<Oke<!dbqi<!uti<k<OkOe/< < < < < << < < < < << < < < < < ”!
. kqV&zi<!kqVlf<kqvl<< < << < << < <!
 Body and soul are bridge each other. If the body is disturbed, soul also 
disturbed. From this concept diseases are not affect only the body. It also affects the 
sole, so care about the good health is essential to live.  
All the diseases are not occurring at birth, Diseases are caused by foods and daily 
activities. The following words said that, 
“...............ogcbie!nXSjubqe<!Ohkk<kiZl<< < << < << < <!
kith<hi!kgikkl<!fmg<jg!biZl</////////////< < < << < < << < < < ”!
 YugiMooniver has classified 4448 as a result of the aforementioned causes. 
From the classification Siddhar yugi muniver has classified vatha diseases into 80 
types in yugi vaithiya chinthamani 800.  Pakkavatham is one among them.  
 The great crisis of the world is how to save the human race from extinction 
through degeneracy. Siddha medicine plays a vital role in presenting human life on 
the earth. 
  Siddha system of medicine not only classified the diseases, and he provide the 
medicine for cure that diseases. The siddhar yogi in his classification described eighty 
vatha diseases, fourty pitha diseases and twenty kaba diseases. Of this vatha disease 
pakkavatham, most of the clinical features (Inability to use one half of the body, loss 
of function of upper and lower limps, presence of circumduction gait, deviation of 
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mouth, difficulty to close the eyelids or partially closed, drolling of saliva, unable to 
speak) of pakkavatham in siddha medicinal aspect are closely bear a resemblance to 
that of “hemiplegia” in modern medical aspect. 
Hemiplegia is the paralysis of one half of the body including upper and lower 
extremities due to opposite sided pyramidal lesion. When the face is affected the 
hemiplegia is called completeand when the face is affected the it is called  incomplete 
hemiplegia, lesion is usually located below the level of pons. Most of the symptoms 
present in hemiplegia and those of pakkavatham are similar.  
The author has selected pakkavatham which is explained under the vatha 
diseases by yogi munivar in yogi vaithiya chointhamani perunool-800. It is 
comparable to hemiplegia in modern medicine. The prevalence of this disease is now 
a day’s increasing due to lack of discipline schedule in everyday life and also 
increasing physical stress. 
Since, ancient days, in the treatment of disease in siddha system first they use 
root and then leaves if it is not cured then they given medicines prepared from metals 
and minerals. Since hemiplegia is awful disease the author of this dissertation has 
selected the siddha formulation tablet prepared from the metal and mineral drugs. 
The author choices of drugs for the clinical study are: 
INTERNALLY: 
VISHNU CHAKRA MATHIRAI   
                         Ref : Siddha vaithiya thirattu 
EXTERNALLY: 
            KODIVELI THYLAM  
                     Ref : Gunapadam mooligai vaguppu 
  The drugs were prepared personally by the author and tried in 25 cases in the 
in-patients and another 13 patients in the out-patient ward. The success of this study 
depends on the doctor, the patient and the drug. 
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AIM  AND  OBJECTIVES 
 
AIM: 
  To evaluate the therapeutic efficacy of siddha formulation “VISHNU 
CHAKRA MATHIRAI” (INTERNAL) and “KODIVELI THYLAM” 
(EXTERNAL) in “PAKKAVATHAM” (HEMIPLEGIA) for the ability to perform 
day to activities well. 
 
OBJECTIVE: 
Primary objective: 
To evaluate the clinical efficiency of siddha drugs “VISHNU CHAKRA 
MATHIRAI” (Internal) and “KODIVELI THYLAM” (External) in 
“PAKKAVATHAM” (HEMIPLEGIA). 
 
Secondary objective: 
 To study the effect of Varmam and Thokkanam in the management of 
pakkavatham  
 To examine the siddha basic principles like Envagai thervugal and modern 
clinical parameter. 
 To bring out the biochemical analysis and pharmacological action of the trail 
drug. 
 
  
4 
 
REVIEW OF LITERATURE 
SIDDHA ASPECT 
 
Philosophies are the basic concet of siddha. According to this human body 
works on 96 philosophies. This 96 philosophies are classified into three catogories. 
The first and second categories contain 30 each, and third categoriy contain 36 
philosophies. Among them the first thirty is considered very fundamental and the rest 
are the manifestation or extention of the first 30 philosophies. These are not only 
deals with the physical components of the human body but also the mental, logical 
components like passions qualities, knowledge, function of sence organs and motor 
organs and their co ordination. 
The siddha system of medicine deals all part of science, when viewed in its 
appropriate prospective, the body is nothing less than an evolutionary speculate, an 
unbelievably complex instrument capable of supporting limitless possibilities for 
human life. 
Siddha system based on five elements, which is the marvel nature can be 
studied from many points view , the conceptual model that “siddha” uses to 
understand the principles of nature functioning is called “pancha pootham” or the “the 
theory of five elements” and 96-thathuvams, three humours and seven thathus. 
Normally the thathus(vatham, pitham, kabam) are present as a normal ratio in the 
body. When alteration in the thathus that produce disease in the body. 
According to yogi vaithiya chintamani perunool – 800 vadha diseases are 80 in 
numbers. Pakkavathem is one of the vatha disease. So , before evaluating the 
pakkavatham, evaluating the features of vatham is essential. 
 
VATHAM 
Otherwise known as - vatham, vayu 
Natural properties of vatham: 
 Functioning the mind 
 Inspiration and expiration 
 Briskness 
 Functioning the seven udal kattukal uniformly 
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QUALITIES OF VATHAM: 
OWN QUALITIES: 
Kadinam Rough 
Varatchi Dry 
Elesu Light 
Kulirchi Cold 
Asaidhal Unstable 
Anuthuvam Subtle 
 
OPPOSITE QUALITIES: 
Miruthu Soft 
Pasumai Unctuous 
Paluvu Heavy 
Akkini Hot 
Sthiram Stable 
Katti Solid 
 
RELATION WITH TASTE: 
HtqKui<!uqR<Sr<!gxqbii<!H,iqg<Gl<!uikl<///////////!
 
The taste which increases vathum are, 
 sour  
 astringent 
!
uikl<!Olzqm<miz<!lKvl<!HtqBh<H//////////////////!
The Taste which neutralizes wathem are, 
 Sweet 
 Sour 
 salt  
!
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PATHOPHYSIOLOGY : 
The arouse vathum has the following symptoms. 
 Body pain 
 Tearing and pricking pain 
 Nerve weakness 
 Shivering 
 Dryness 
 Dislocation of joints 
 Weakness of organs 
 Polydypsia 
 Limbs paralysis 
 Constipation 
 All tastes is like to be an astringent 
 Excessive salivation 
 Darkness of skin 
 Mental illness 
 Difficulty or inability to do flexon and extention of the limbs 
 
CLASSIFICATION:  
Vatham is classified into ten types. 
 Piranan  
 Abanan 
 Udhanan 
 Viyanan 
 Samanan 
 Nagan 
 Koorman 
 Kirukaran 
 Dhevathathan 
 Dhananjeyan  
  Among 10 types of vatham, five types are very important and its controls 
essential body functions. 
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 Pranan – controls circulation 
 Abanan – controls excretion 
 uthanan – controls breathing and speech 
 viyanan – controls will  
 Samanan – control digestion 
 
ETIOLOGY: 
       “we<eOu!uikf<ki!oe{<hkiGl<!
! !!!!!!-gk<kqOz!leqki<gTg<!ogb<BliX 
!!!!hqe<eOu!ohie<kjeOb!OsivR<osb<K!
! !!!!!!ohiqObiIgt<!hqvil{jvk<!K~m{qk<Kl<!
!!!!ue<Okus<!osik<kqz<!OsivR<osb<K!
! !!!!!!liki!hqki!GVju!lxf<k!OhIg<Gl<!
!!!!ge<eOu!Oukk<jk!fqf<jk!osb<kiz<!
! !!!!!!gibk<kqx<!gzf<kqMOl!uikf<!kiOe”!
. B,gq!juk<kqb!sqf<kil{q!himz<!< < << < << < < .!354!
    “kioee<x!gsh<OhiM!Kui<h<Hjxh<H!
! !sikglib<!lqR<sqgqZl<!sjlk<k!u{<{l<!
!!Noee<x!uixqeK!Hsqk<kiZl<!
! Ngibk<!OkxzK!Gck<k!ziZl<!
!!hioee<x!hgZxg<g!lqvi!uqpqh<H!
! hm<ceqob!lqgUXkz<!hivolb<kz<!
!!Okoee<x!olipqbiI!Olx<!sqf<jkbikz<!
! sQg<gqvlib<!uiklK!oseqg<Gf<!kiOe”!
. B,gq!juk<kqb!sqf<kil{q!< << << < –!himz<!355<<< !
  “uikui<k<kq!kjegiz!OlOki!oue<eqz<!
! !lVUgqe<x!uieqgi<g<!gmgliGl<!
!Nkjuh<!hsqObiM!giIk<kqjg!ke<eqz<!!
! !nmVOl!lx<xli!kr<gt<!ke<eqz<!
!OhikOu!slqg<Ggqe<x!gizliGl<”/!
. B,gq!juk<kqb!sqf<kil{q!< << << < –!himz<!356<<< !
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“Neie!uve<xjeOb!lkqbi!lif<ki<!
! ngkq!hvOksqbi<gm<!ge<e!lQbiI!
!Ogieie!GVolipqjb!lxf<k!Ohi<gt<!
! ogijz!gtU!ohib<!gilr<!Gxqk<k!Ohi<g<G!
Deie!smf<ke<eqz<!uikl<!uf<K!
! dx<huqg<Gl<!Oukk<kqe<!d{<jlkiOe”!
. B,gq!juk<kqb!sqf<kil{q!< << << < –!himz<!364<<< !
“hgvOu!uiklK!Ogihqk<kh<Ohi!
! h{<high<!oh{<OhiglK!kie<!osb<bqz<!
fgvOu!ouGK~v!upq!fmg<gqz<!
! ftqvie!gix<XOl!heqOlx<hm<miz<!
lqgvOu!gib<gt<!geq!gqpr<G!ke<jl!
! lqg!uVf<kq!lQxqOb!kbqIkie<!ogi{<miz<!
LgvOu!LKogZl<jh!LXg<gq!ofif<K!
! Lpr<giZl<!gj{g<giZl<!gMh<H!d{<miGOl”!
. B,gq!juk<kqb!sqf<kil{q!< << << < –!himz<!356<<< !
!
!
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PAKKAVATHAM 
 
Pakkavatham is one of the vatha disease , and  the name is derived from the 
classical feature of the disease (It has a specific symptom of disability or inability to 
use upper and lower limbs of one half of the body). 
Yougi muniver classified and describe the vatha diseases into 80 types. 
Pakkavatham is one on it. And he clearly speaks about the clinical manifestations of 
the disease. The following literature evidence from the yugi vaithiya chinthamani 800 
clearly describe that,  
 
Sign and Symptoms of pakkavatham: 
  In yugi vaithiya chinthamani perunool-800 described the sign and symptoms 
are follows 
d{<jlbi!Bml<ohz<zil<!uiB!uigq!
!!!!!! !! dbv<gqe<x!ficbK!njsU!lqe<xqg<!
g{<jlbib<g<!giblQ!kqeqOz!Obxqg<!
!!!!!! !! gsg<gqOb!bqpqf<KOl!uzqk<Kg<!gi[l<!
!!!! ! h{<jlbib<h<!hg<gk<kq!zqsqU!L{<mib<h<!
!!!!!! !! hivqk<Kh<!hj{g<jgBr<!giZr<!Ogi[l<!
!!! !!!!!ou{<jlbi!Bml<ohr<Gl<!uqbv<ju!gi[l<!
!!!!!! !! olzqUhg<g!uikk<kqe<!uquvf<!kiOe/!
 Total or fractional loss of power one side of limb. 
 Body pain 
 Difficulty in walking 
 No hand grip 
 Piloerection and paresthesia over the affected limbs 
 Excessive sweating 
 Rigidity over the hand and leg 
In “thanvanthiri vaithiyam” are described as follows 
yV!Hxl<!uiBk<kiOe!Ubv<f<K!Hxk<kqZt<t!
sQjvGmx<!ux<xqbqf<kh<!higkmjk!bbvs<!osb<K!
kVuqpq!&g<G!giK!sv{l<!fik<!kip<f<kbv<f<K!
lVuqb!G{r<gt<!hg<guikk<kqe<!lgqjl!kiOe/!
Thanvanthri vaithiyam – 21 
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 Loss of power in all muscles of one side of the body 
 There is also deviation of mouth 
 There is obliteration of nasolabial fold 
 The eyes also involved with paralysis of muscles of eye 
 There is also dysarthria 
 
uik!ge<l!uvziX<<< !
! “F~oze<x!uikl<!uf<k!ujgkiOeK!
! ! F{<jlbibg<!ge<lk<kqe<!ujgjbg<!OgT!
! gizqOz!Okie<xqbK!gMh<hOkK!
! ! jggizqz<!Lmg<gqbK!uQg<gOlK!
! OgizqOz!hMgqe<x!uqVm<slie!
! ! Gpf<jk!lvf<ke<je!oum<mz<!Olz<Okiz<!sQuz<!
! fiuqOz!sQuosf<K!giz<Lxqk<kz<! !
! ! fz<z!ogil<H!kijp!Lxqk<kz<!fzqk<kz<!giO{”!
. ngk<kqbi<!ge<l!gi{<ml<!< < < < << < < < << < < < < .411!himz<!67<<< !
Many diseases are said to be precipitated by kanma which means the deeds 
good or bad committed by an individuals in his previous and the present birth 
 vatha diseases, according to agasthiyar kanma kandam – 300 may also be 
precipitated by kanmma. 
 
DIAGNOSIS: 
Piniyari muraigal (method of diagnosis) is based upon three main principles,!
2/!ohixqbix<Oxi<kz<!
3/!Hzeizxqkz<!
4/!uqeiUkz<!
!
2/!ohixqbix<Oxi<kz<!)< < << < << < < Inspection*!
2/!&g<G!
3/!fi!)uib<*!
4/!g{<!
5/!Okiz<!)olb<*!
6/!osuq!
  Poriyal arithal means examining the pori of the patient by the physician for 
proper diagnosis. 
11 
 
GNANTHRIYAM 
S.No. Gnani Physiological function Features in pakkavatham 
1. Mei 
Feels the sensation of 
touch 
Affected 
(parasthesia present in upper 
limb) 
2. Naa Analyses taste 
Affected 
(Tastelessness) 
3. Kan For vision 
Affected 
(Diplopia, Blindness) 
4. Mooku For smell Not affected 
5. Sevi For hearing Not affected 
 
KANMENTHIRIYAM: 
S.No. Kanmenthiriyam Physiological function 
Features in 
pakkavatham 
1. Kai For Handle the things 
Affected (difficulty or 
inability to use right or 
left hand) 
2. Kal For Walking 
Affected (difficulty or 
inability to use right or 
left leg) 
3. Vaai For speaking 
Affected (Deviation of 
angle of mouth) 
4. Eruvaai For defaecation 
Affected (incontinence 
of urine may present) 
5. Karuvaai For reproduction Not affected 
 
3/!Hzeizxqkz<<<<!
2/!fix<xl<!)l{l<*!
3/!Sju!
4/!ytq!
5/!DX!
6/!Yjs!
lVk<Kui<!Jl<Hze<gjtg<!ogi{<M!Ofijb!g{qg<g!LcBl</!
12 
 
4/!uqeiUkz<<<<!
! lVk<Kui<! Ofibitqbqml<! uqeiUkz<! &zl<! Ofijb! g{qg<gLcBl</!!
Ofibitqbiz<! Ohs!Lcbik! Ofvk<kqz<! nue<! Sx<xk<kiiqmLl<! uqeiUkz<! &zl<!
Ofijb!g{qg<gLcBl</!
!!
Envagai Thervugal : 
 Naadi, sparisam, naa, niram, mozhi, vizhi, malam, moothiram. 
 
Naadi (pulse) 
 “g{<miObi!sqOzx<hek<kqz<!uik!fic!
gzf<kqMgqz<!ubqX!ohiVlz<!gek<k!uQg<gl<!
d{<miOzi!Yr<givR<!sk<kq!uqg<gz<!
dXkqvm<js!uib<Uuzq!sf<fq!Okiml<!
bq{<miOz!-jth<hqVlz<!Osijh!hi{<M!
uqmhigl<!uqm$jz!hg<g!uikl<!
gq{<miM!fisqgi!hQmr<!gg<gz<!!
!!!!!!sqvOfib<gt<!hzUl<uf<K!sqg<Gf<!kiOe/”!
Vitiated vatha causes difficulty in walking or impaired function of lower 
extremities.  The examination of naadi has been recognised as one of the principle 
means of diagnosis and prognosis of disease from times immemorial. 
In pakkavatham normal 1:1/2:1/4 mathirai pattern or animal gait pattern of 
Hen, turtle, frog of vatham, pitham, kabam is affected giving rise to elevated mathirai 
of kabam and vatham than normal. 
 
Sparisam (skin) 
 In pakkavatham the temperature may be raised , but in long standing residual 
paralysis there may be subnormal temperature. 
 
Naa (Tongue) 
 In pakkavatham the patient may have lost taste sensation  
 
Niram (colour) 
 In pakkavatham no abnormality is seen I niram. But it is noted to confirm the 
predominant uyir thathu involved 
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Mozhi (Speech) 
 In pakkavatham the patient may have slurring speech, aphasis or dysarthria 
Vizhi (Eye) 
 The patient may have defective closure of eyelid due to muscle paralysis. 
There may be loss of vision or double vision. 
Malam (stools) 
 In patcha vatham the amount of faeces is reduced. The consistency becomes 
hard due to vitiation of vatham 
 
Moothiram (urine) 
&k<kqvl<< << << <!
• fQIg<Gxq!
• ofb<g<Gxq!
fQIg<GxqQ <Q <Q < !
! “nVf<Klixq!vkLl<!nuqOviklib<!
! n0gz<!nzi<kz<!ngizU,e<!kuqi<f<kpx<!
! Gx<xtuVf<kq!dxr<gq!jugjx!
! Ncg<!gzsk<!kiuqOb!giKohb<!
! okiV!L%Ik<kg<!gjzg<Gm<hM!fQiqe<!
! fqxg<Gxq!ofb<g<Gxq!fqVlqk<kz<!gmOe”!
. Ofib<fimz<!Ofib<Lkz<fimz<!hGkq!< < < < << < < < << < < < < –!I!
!! d{<[gqe<x! nXSjuh<! ohiVt<gTl<! ye<Xg<ogie<X!
Oux<XjlbjmbilZl<?! hsqg<Gk<! kg<ghc! Gjxkz<?! nkqgiqk<kz<! gizf<kuxq!
d{<[kz<! Lkzqb! Gx<xr<gT{<migi! u{<{l<! Hsqk<K! dxr<gq?!
uqcbx<gizk<kqz<! hcg! hik<kqvk<kqz<! ohb<k! fQjv! NuqOhigikhc! 3 ¾ 
fipqjgg<Gt<! nke<! fqxg<GxqjbBl<! nkqz<! w{<o{b<uqm<Mh<! hiIk<K!
gi{h<hMgqe<x! GxqjbBl<! gueqk<K! hq{qgtqe<! kQVl<?! kQvig<! Gxqgjt!
nxqbzil</!
!
sqXfQiqe<!ohiKg<G{l<Q < < <Q < < <Q < < <!
! “uf<k!fQIg<giqwjm!l{l<!FjvwR<soze<!
! jxf<kqbZtuju!bjxGK!LjxOb”!
. Ofib<fimz<!Ofib<!Lkz<fimz<hGkq!< < < < << < < < << < < < < –!I!
! !
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-bx<jg!fQI!-zg<g{l<!
! “lqgk<!kch<Hl<!lqgk<!OkxZl<!-e<oxeqz<!
! Sgk<jkk<!kVl<!olb<Shiu!fQI!fe<Ox”!
. Okve<!fQIg<Gxq!ofb<g<Gxq< Q < < << Q < < << Q < < < !
  According to theriyar, urine should be of low density and with discoloration.  
In cegana vatham, urine is yellow colour with low density. 
!
ofb<g<Gxq< << << < !
! “fqxg<Gxqg<!Gjvk<k!fqVlie!fQiqx<!
! sqxg<g!ou{<o{b<ohiI!sqXKtq!fMuqMk<!
! oke<Xxk<!kqxk<okizq!Obgikjlk<kkq!
! eqe<x!kqujz!Ohil<!ofxquqpqbxqUl<!
! ose<xK!HgZf<!osb<kqjb!B{Ov”!
. Ofib<fimz<!Ofib<Lkz<fimz<!hGkq!< < < < << < < < << < < < < –!I!
!! fQIfqxg<! Gxqbiz<! Ofijbg<! g{<M! hqck<kx<ohiVm<Ms<! osiz<zqbqVg<gqe<x!
uqkq! ohiVf<kqb! sqXfQiqz<! yV! sqxqbKtq! w{<o{b<! fMuqz<! jgbjsuqeiz<!
w{<o{b<Ktq!sqkxilz<!uqm<M!oub<bqzieK!nf<fQiqz<!hMl<hc!kqxf<K!gix<xieK!
nkqz<! uQsq! nf<k! w{<o{b<k<! Ktq! Nmikhc! juk<K! ns<sqXfQiqz<!
uqmh<hm<cVg<gqe<x! w{<o{b<k<!KtqbieK!osz<Zgqe<x!upqbqz<! g{<{xqjuBl<!
dbqvxqjuBl<! osZk<kq?! nk<Ktq! okiquqg<Gl<! Ofib<! uqtg<gk<jk! fQ! okiqf<K!
ogit<tzil</!
! “nvoue!fQ{<ce0Ok!uikl<”!
! Npq!Ohix<hvuqe<!n0Ok!hqk<kl<”!
! Lk<okik<K!fqx<gqe<!olipquoke<!ghOl”!
. Ofib<fimz<!Ofib<!Lkz<fimz<!hGkq< < < < << < < < << < < < < .I!
  In pakkavatham patients during neikuri examination the oil spreads like snake 
and sometimes like ring and pearl. 
UYIR THATHUKKAL 
Vatham 
 Pranan: 
  Physiological function: Inspiration and expiration responsible for sneezing 
coughing   and belching 
  Features in Pakkavatham: Not affected 
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 Abanan:  
   Physiological function: Act with downward movement 
  Features in Pakkavatham: Affected (constipation present). 
 Viyanan: 
  Physiological function: Helps in various movements of body, responsible for 
 sensation 
  Features in Pakkavatham: Affected difficulty to use right or left upper limb or  
lower limb. 
 Udhanan: 
Physiological function: Regulates the higher functions of brain.  Responsible  
for physiological reactions like hiccough and vomiting 
  Features in Pakkavatham: Not affected 
 Samanan: 
   Physiological function: Regulates all other vayus 
   Features in Pakkavatham: Affected (Difficulty to control other vayus). 
 Nagan: 
Physiological function: Responsible for intelligence helps in opening and  
closing of eyes 
Features in Pakkavatham: Affected in aged patients.  Acuity of vision is 
diminished. 
 Koorman: 
Physiological function: Responsible for lacrimation.  Helps to visualization of 
all  things in the world. 
Features in Pakkavatham: Affected in aged patients.  Acuity of vision is 
diminished. 
 Kirugaran: 
   Physiological function: Yawning, Drippling of Saliva. 
  Features in Pakkavatham: Affected (Drippling of Saliva). 
 Thevathathan: 
  Physiological function: Responsible for laziness. Rotation of eyeballs 
  Features in Pakkavatham: Affected (Sleeplessness, fatigue). 
 Thananjeyan: 
   Physiological function: Responsible for tinnitus oedema. 
  Features in Pakkavatham: Not affected 
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Pitham 
 Anar pitham: 
  Physiological function: Digests all the ingested particles. 
  Features in Pakkavatham: Affected (Anorexia present in some patients) 
 Ranjaga pitham: 
  Physiological function: Increases the blood and gives blood colour 
  Features in Pakkavatham: Affected (Reduced haemoglobin level). 
 Saathaga pitham: 
  Physiological function: Makes the work to complete what mind thinks 
  to do 
  Features in Pakkavatham: Affected (Difficulty to use upper limb and  
lower limb   
 Aalosaga pitham: 
  Physiological function: Responsible for clear vision. 
  Features in Pakkavatham: Affected in old age peoples. 
 Prasaga pitham: 
  Physiological function: Gives colours to skin 
Features in Pakkavatham: Not affected 
Kabam 
 Avalambagam: 
  Physiological function: Controls other 4 types of kabam 
  Features in Pakkavatham: Affected (santhigam affected) 
 Klethagam: 
  Physiological function: Moistens the food 
  Features in Pakkavatham: Not affected 
 Pothagam: 
  Physiological function: Helps to know the taste 
  Features in Pakkavatham: Not affected 
 Tharpagam: 
  Physiological function: Gives cooling effect to the eyes 
  Features in Pakkavatham: Not Affected.  
 Santhigam: 
  Physiological function: Gives lubrication to joints 
  Features in Pakkavatham: Affected (pain in cervical region) 
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SEVEN PHYSICAL CONSTITUENTS OF BODY 
 Saaram: 
 Physiological function: Strengthens the body and mind  
 Features in Pakkavatham: Tiredness and mental depression 
 Senneer: 
 Physiological function: Preserves brightness, boldness, power&   
 knowledge 
 Features in Pakkavatham: weakness of the nerve 
 Oon: 
Physiological function: Gives structure and shape to the body. 
 Features in Pakkavatham:  Acute stage - There is hypotonicity 
Later stage  - There is hypertonicity 
 Kozhuppu: 
 Physiological function: Responsible for movement lubricants   
 the joint 
 Features in Pakkavatham: pain in affected side 
 Enbu: 
Physiological function: Responsible to joint movements 
 Features in Pakkavatham: weak bones 
 Moolai 
Physiological function: Present inside the bones and gives    
 strength to  the  bones 
 Features in Pakkavatham: Weakness of nerves 
 Sukkilamor suronitham: 
 Physiological function: _ 
 Features in Pakkavatham: due to above 6 udalkattugal affected 
 
GNANTHRIYAM 
 Mei: 
 Physiological function: Feels the sensation of touch 
 Features in Pakkavatham: Affected (Parasthesia may present in   
  upper limb and lower limb) 
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 Naa: 
 Physiological function: Analyses taste 
 Features in Pakkavatham: Not affected 
 Kan: 
 Physiological function: For vision 
 Features in Pakkavatham: Not affected  
 Mooku: 
 Physiological function: For smell 
 Features in Pakkavatham: Not affected 
 Sevi : 
 Physiological function: For hearing 
 Features in Pakkavatham: Not affected 
 
Kanmenthiriyam 
 Kai 
 Physiological function: Handling the objects. 
 Features in Pakkavatham: there is loss of function of one side  
            of upper limb 
 Kal 
  Physiological function:  Walking 
 Features in Pakkavatham: loss of function of one side of  
lower  limb 
 Vaai 
 Physiological function: For speaking 
 Features in Pakkavatham: Loss of function of speech  
 Eruvaai 
 Physiological function: For defaecation and maturation 
Features in Pakkavatham: There is loss of bladder control 
 Karuvaai 
 Physiological function: For reproduction 
 Features in Pakkavatham: May not have loss of libido 
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THINAIGAL  
 Kurinji: 
 Place: Mountain and its surroundings 
 Common diseases : Kabanoi liver disease are common 
 Mullai : 
 Place: Forest and its surroundings 
 Common diseases: Pitha and vatha disease liver    
 disease and common 
 Marutham: 
 Place: Field and its surroundings 
 Common diseases: Safest place to maintain good    
 health 
 Neithal: 
 Place: Sea and its surroundings  
 Common diseases: Vatha disease and liver     
 enlargement are common 
 Paalai: 
 Place: Desert and its surroundings 
 Common diseases: Vatha pitha and kabha disease and common 
 Most of the patients came from Marutha nilam.  Patients were   
 also reported from neithal nilam. 
 
Paruva Kaalangal 
 Kaarkaalam  
  Aavani and Purattasi(August 16 – October 15)  
 Kuttram- Vatham ↑ ↑Pitham  ↑ 
 Koothirkaalam            
 Ayppasi and karthigai(October16 – December15) 
 Kuttram - Vatham (-)Pitham  ↑ ↑ 
 Munpanikaalam         
 Maargali and Thai(December 16 – February 15*       
 Kuttram- Pitham  (-) 
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 Pinpanikaalam          
 Maasi and Panguni(February 16 – April 15* 
 Kuttram- Kabam  ↑ 
 Elavenilkaalam        
 Aani and Aadi(April 16 – June 15)  
 Kuttram- Kabam ↑↑ 
 Muduvenilkaalam      
 Aani and Aadi(June 16  - August 15*!
! Kuttram- Vatham ↑Kabam (-) 
 
NOI KANIPPU VIVATHAM: 
  Pakkavatham should not be confused with other types of vatham which have 
more or less similar symptoms. 
 
Dvgk!uikl<;< << !
nx<Hklib<!Ofiuigqh<!HVur<!giK!
!! nr<gk<kqx<!hikqkie<!uzqk<okh<!OhiKf<!
kx<Hklib<!Ogi{qOb!kjzBl<!uiBf<!
kiuOu!lqgfMr<gqg<!Gtqv<f<K!%Sl<!
uqx<Hklib<!uqpqgTf<kie<!lqjlh<H!xiK!!
olzquigqs<!svQvolzil<!uqbv<ju!biGl<!
Hx<Hklib<!uib<fQV!lqgOu!B,Xl<!
HgZOli!Vvgui!kf<kqe<!OhOv/!
!
The clinical features are: 
 Eyebrow,ear and half of the body are painfull 
 Paralysis occurs rarely in one half of the body 
 Involuntary movement of head and mouth 
 Chillness, tingling sensation of the body 
 Excess salaivation 
 
nx<Hk!uikl<;< << << < !
kQi<g<glib<!^<kqvQsr<gl<!h{<[l<!OhiKf<!
kqMg<ogeOu!uiv<k<jkOgi!hqk<k!OhiKl<!
Dv<g<gli!Bxk<Kkie<!hiMl<!OhiKl<!
d{<[luz<!gs<sibl<!hig<Gk<!kiEl<!
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Nv<g<glib<k<!km<cOb!gck<k!OhiK!
Lpgie!Lgf<ke<eqz<!uiB!Ogihqk<!
kiv<g<glib<!lqgs<sqkxq!uiBr<!Ogi[R<!
sir<gli!bx<Hkui!kf<ki!eiOl/!
The clinical features are: 
 vatham habitually exaggerated during intercourse, getting angry, singing loudly, 
chewing betal nut, threatening and scolding others 
 exaggerated vatham leads to the paralysis and deviation of mouth 
 
TREATMENT OF PAKKAVATHAM: 
  In siddha system of medicine the main aim of the treatment is exclusion of 
udalpinigal( due to alteration of udalthathukkal and uyir thathukkal) and ulappinigal. 
Treatment is not only for removal of disease but for the prevention and improving the 
body condition also. 
This said as follows 
 Kaapu 
 Neekam 
 Niraippu 
 
“Study the disease emissary the cause 
Seek subsiding ways and do what is proper and effective” 
 
“The man well versed in medical lore, would measure the patient, 
 Disease and time before the healing work begins” 
                   Thirukkural   
  So, it is essential to know the cause of the disease nature of the patient severity 
of illness, the seasons and time of occurrence. 
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TREATMENT: 
LINE OF TREATMENT: 
The line of treatment consist of 
1. The purgative drugs must be given first to compensate the vitiated vadham. 
2. Medicines – internal and externals are to be given for affected uyir thathukkal 
and udal thathukkal  
3. The sirappu maruthuvam 
Thokkanam must be done after application of oil for the strengthening  
the affected part 
Varmam are also applied as supportive therapy for quick recovery 
4. The food and habits, which are avoiding and adding, are also determined 
clearly 
5. Kanma neekam apart of treatment and it must also be done properly before the 
treatment 
 
PURGATIVE: 
  uqOvsek<kiz<!uikf<!kiPl<!////////////////////!
 Vellai ennai- 15 ml at early morning is given one day before starting the main  
treatment given for patients. 
 
MEDICINES: 
Pakkavatham treated with internal as well as external medicines 
       Internal medicine:         Vishnu chakra mathirai- 130 mg twice a day with 
                                               Thirikadugu  choornam + Inji juice + Honey 
  External medicine:        kodiveli thylam  
 
COMPLIMENTARY THERAPIES: 
   Aparts from other departments, Sirappu maruthuvam department gives equal 
importance to complimentary therapies along with internal and external treatments. 
Many complimentary therapies used to treat the diseases in siddha like varmam., ect 
The Following two complimentary therapies used for this study 
1. Thokkanam 
2. Varmam 
 
23 
 
VARMAM: 
  Varmam  is a branch of siddha medicine. It is one of the ancient south indian 
priceless living heritage. Varma is a point where prana exists. An equilibrium of this 
points contributes to good health. If any varma points are derive insane or affected the 
related limbs or part of the body get afflicted, causing particular problem. 
  The varma points are distributed all over the body. It is mainly classified as 
 Padu varmam - 12 
 Thoduvarmam – 96 
Varma points to be manipulated for hemiplegia are as follows: 
 Vilangu varmam 
 Kai Kavali  
 Kondaikolli varmam 
 Ullangai vellai 
 Kuthirai muga varmam 
 Aamai kalam 
 Kaal kavali 
 
MASSAGE THERAPHY: 
 Thattal 
 Pidithal 
 Izhuthal 
 Asithal 
 
uikl<!Lkzqb!Lg<Gx<x! hq{qgt<!d{<mig<Gl<! uzqjb!ouXr<jgbiOzi! )n*!
jkzl<!kmuqObi!hqch<hK/!
! ! okig<g{k<kq!eizqvk<kf<!Okiz<D!{qjugm<G!
! ! lqg<G!sUg<gqbR<s!lQv[l<ohi!–!olb<g<gkqg!
! ! Hm<cBxg<gl<!H{i<s<sq!bqju!gkqg<Gl<!
! ! hm<m!njzs<szXl<!hiI”!
.!Okve<<<<!
! !
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hqck<kz<< << << <! !
! ! “hqck<kzq!br<Gl<!jlkqbq!Ef<kGl<!hqf<kiOk!–!w{<o{!
! ! BMk<kK!osb<bqx<!xsutq!B,Em!Zf<kiOk!
!
! ! Oux<xK!osb<bqER<!$sqjg!hiiqjs!uqm<OmiMl<!.!Hzq!
! ! Ohix<xK!uiBU!lx<XK!Olezqh<!ohim<OmiMl<”!
! ! okig<g{l<!osb<bg<%cb!6!fqjzgtqZl<!osb<bzil</!!!
!! jkzl<! kmuqObi?! kmuilOzi! hqck<Kuqm! uik! Ofib<gTg<G! sqxh<hig!
ohiVf<Kl</!
!
-Pk<kz<< << << <!
-Pk<kz<!gqmk<k!zqVk<k!zqv{<cx<G!OlviOl!–!we<hqz<!
! ! LPk<kK!u{<[gr<!gielf<!kg<gkq!sQviOl!
! ! dVUk!oze<hK!lqk<Okipq!OzOfvl<!H,xigq!–!lel<!
! ! ouVUX!&e!uqjegjt!olb<bM!Ouxigq!
! ! utg<GX!ol{<o{b<!OzbqK!osb<uK!uz<zi{<jl!–!dmx<!
! ! gtg<gRI!Ohig<gs<!STg<oge!uiukqk<!okiz<zi{<jl”!
!! -jk! jkzk<jk! H,sqOb! osb<bOu{<Ml</! wZl<Hgt<! fe<xib<k<!
okiqBlqmr<gtqZl<?! kjzbqZl<! dVUl<OhiK! lf<klig! osb<bOu{<Ml</-keiz<!
fvl<hqz<!Dxq!uXk<Kgqe<x!uiBg<gt<?!hqch<Hgt<?!STg<Ggt<!G{liGl</!
 
  
25 
 
MODERN ASPECT 
  The human brain is the command center for the human nervous system. It 
receives input from the sensory organs and sends output to the muscles. The human 
brain has the same basic structure as other mammal brains, but is larger in relation to 
body size than any other brains. 
 
FACTS ABOUT THE HUMAN BRAIN 
 The human brain is the largest brain of all vertebrates relative to body size 
 It weighs about 3.3 lbs. (1.5 kilograms) 
 The brain makes up about 2 percent of a human's body weight 
 The cerebrum makes up 85 percent of the brain's weight 
 It contains about 86 billion nerve cells (neurons) — the "gray matter" 
 It contains billions of nerve fibers (axons and dendrites) — the "white 
matter" 
 These neurons are connected by trillions of connections, or synapses 
 
ANATOMY OF THE BRAIN 
  There are different ways of dividing the brain anatomically into regions. Let’s 
use a common method and divide the brain into three main regions based on 
embryonic development: the forebrain, midbrain and hindbrain. Under these 
divisions: 
 The forebrain (or prosencephalon) is made up of our incredible cerebrum, thalamus, 
hypothalamus and pineal gland among other features. Neuroanatomists call the 
cerebral area the telencephalon and use the term diencephalon (or interbrain) to refer 
to the area where our thalamus, hypothalamus and pineal gland reside. 
 The midbrain (or mesencephalon), located near the very center of the brain between 
the interbrain and the hindbrain, is composed of a portion of the brainstem. 
 The hindbrain (or rhombencephalon) consists of the remaining brainstem as well as 
our cerebellum and pons. Neuroanatomists have a word to describe the brainstem sub-
region of our hindbrain, calling it the myelencephalon, while they use the 
word metencephalon in reference to our cerebellum and pons collectively. 
Before exploring these different regions of the brain, first let’s define the important 
types of cells and tissues that are the building blocks of them all. 
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HISTOLOGY 
  Brain cells can be broken into two groups: neurons and neuroglia. 
  Neurons, or nerve cells, are the cells that perform all of the communication 
and processing within the brain. Sensory neurons entering the brain from the 
peripheral nervous system deliver information about the condition of the body and its 
surroundings. Most of the neurons in the brain’s gray matter are interneurons, which 
are responsible for integrating and processing information delivered to the brain by 
sensory neurons. Interneurons send signals to motor neurons, which carry signals to 
muscles and glands. 
  Neuroglia, or glial cells, act as the helper cells of the brain; they support and 
protect the neurons. In the brain there are four types of glial cells: astrocytes, 
oligodendrocytes, microglia, and ependymal cells. 
 
 Astrocytes protect neurons by filtering nutrients out of the blood and preventing 
chemicals and pathogens from leaving the capillaries of the brain. 
 Oligodendrocytes wrap the axons of neurons in the brain to produce the insulation 
known as myelin. Myelinated axons transmit nerve signals much faster than 
unmyelinated axons, so oligodendrocytes accelerate the communication speed of the 
brain. 
 Microglia act much like white blood cells by attacking and destroying pathogens that 
invade the brain. 
 Ependymal cells line the capillaries of the choroid plexuses and filter blood plasma to 
produce cerebrospinal fluid. 
The tissue of the brain can be broken down into two major classes: gray matter and 
white matter. 
 Gray matter is made of mostly unmyelinated neurons, most of which are interneurons. 
The gray matter regions are the areas of nerve connections and processing. 
 White matter is made of mostly myelinated neurons that connect the regions of gray 
matter to each other and to the rest of the body. Myelinated neurons transmit nerve 
signals much faster than unmyelinated axons do. The white matter acts as the 
information highway of the brain to speed the connections between distant parts of the 
brain and body. 
Now let’s begin exploring the main structures of our awesome human brain. 
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HINDBRAIN (RHOMBENCEPHALON) 
BRAINSTEM 
  Connecting the brain to the spinal cord, the brainstem is the most inferior 
portion of our brain. Many of the most basic survival functions of the brain are 
controlled by the brainstem. 
  The brainstem is made of three regions: the medulla oblongata, the pons, and 
the midbrain. A net-like structure of mixed gray and white matter known as the 
reticular formation is found in all three regions of the brainstem. The reticular 
formation controls muscle tone in the body and acts as the switch between 
consciousness and sleep in the brain. 
  The medulla oblongata is a roughly cylindrical mass of nervous tissue that 
connects to the spinal cord on its inferior border and to the pons on its superior 
border. The medulla contains mostly white matter that carries nerve signals ascending 
into the brain and descending into the spinal cord. Within the medulla are several 
regions of gray matter that process involuntary body functions related to homeostasis. 
The cardiovascular center of the medulla monitors blood pressure and oxygen levels 
and regulates heart rate to provide sufficient oxygen supplies to the body’s tissues. 
The medullary rhythmicity center controls the rate of breathing to provide oxygen to 
the body. Vomiting, sneezing, coughing, and swallowing reflexes are coordinated in 
this region of the brain as well. 
  The pons is the region of the brainstem found superior to the medulla 
oblongata, inferior to the midbrain, and anterior to the cerebellum. Together with the 
cerebellum, it forms what is called the metencephalon. About an inch long and 
somewhat larger and wider than the medulla, the pons acts as the bridge for nerve 
signals traveling to and from the cerebellum and carries signals between the superior 
regions of the brain and the medulla and spinal cord. 
 
CEREBELLUM 
  The cerebellum is a wrinkled, hemispherical region of the brain located 
posterior to the brainstem and inferior to the cerebrum. The outer layer of the 
cerebellum, known as the cerebellar cortex, is made of tightly folded gray matter that 
provides the processing power of the cerebellum. Deep to the cerebellar cortex is a 
tree-shaped layer of white matter called the arbor vitae, which means ‘tree of life’. 
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The arbor vitae connects the processing regions of cerebellar cortex to the rest of the 
brain and body. 
  The cerebellum helps to control motor functions such as balance, posture, and 
coordination of complex muscle activities. The cerebellum receives sensory inputs 
from the muscles and joints of the body and uses this information to keep the body 
balanced and to maintain posture. The cerebellum also controls the timing and finesse 
of complex motor actions such as walking, writing, and speech. 
 
MIDBRAIN (MESENCEPHALON) 
  The midbrain, also known as the mesencephalon, is the most superior region 
of the brainstem. Found between the pons and the diencephalon, the midbrain can be 
further subdivided into 2 main regions: the tectum and the cerebral peduncles. 
 The tectum is the posterior region of the midbrain, containing relays for 
reflexes that involve auditory and visual information. The pupillary reflex 
(adjustment for light intensity), accommodation reflex (focus on near or far 
away objects), and startle reflexes are among the many reflexes relayed 
through this region. 
 Forming the anterior region of the midbrain, the cerebral peduncles contain 
many nerve tracts and the substantia nigra. Nerve tracts passing through the 
cerebral peduncles connect regions of the cerebrum and thalamus to the spinal 
cord and lower regions of the brainstem. The substantia nigra is a region of 
dark melanin-containing neurons that is involved in the inhibition of 
movement. Degeneration of the substantia nigra leads to a loss of motor 
control known as Parkinson’s disease. 
 
FOREBRAIN (PROSENCEPHALON) 
DIENCEPHALON 
  Superior and anterior to the midbrain is the region known as the interbrain, or 
diencephalon. The thalamus, hypothalamus, and pineal glands make up the major 
regions of the diencephalon. 
 The thalamus consists of a pair of oval masses of gray matter inferior to the 
lateral ventricles and surrounding the third ventricle. Sensory neurons entering 
the brain from the peripheral nervous system form relays with neurons in the 
thalamus that continue on to the cerebral cortex. In this way the thalamus acts 
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like the switchboard operator of the brain by routing sensory inputs to the 
correct regions of the cerebral cortex. The thalamus has an important role in 
learning by routing sensory information into processing and memory centers 
of the cerebrum. 
 The hypothalamus is a region of the brain located inferior to the thalamus and 
superior to the pituitary gland. The hypothalamus acts as the brain’s control 
center for body temperature, hunger, thirst, blood pressure, heart rate, and the 
production of hormones. In response to changes in the condition of the body 
detected by sensory receptors, the hypothalamus sends signals to glands, 
smooth muscles, and the heart to counteract these changes. For example, in 
response to increases in body temperature, the hypothalamus stimulates the 
secretion of sweat by sweat glands in the skin. The hypothalamus also sends 
signals to the cerebral cortex to produce the feelings of hunger and thirst when 
the body is lacking food or water. These signals stimulate the conscious mind 
to seek out food or water to correct this situation. The hypothalamus also 
directly controls the pituitary gland by producing hormones. Some of these 
hormones, such as oxytocin and antidiuretic hormone, are produced in the 
hypothalamus and stored in the posterior pituitary gland. Other hormones, 
such as releasing and inhibiting hormones, are secreted into the blood to 
stimulate or inhibit hormone production in the anterior pituitary gland. 
 The pineal gland is a small gland located posterior to the thalamus in a sub-
region called the epithalamus. The pineal gland produces the hormone 
melatonin. Light striking the retina of the eyes sends signals to inhibit the 
function of the pineal gland. In the dark, the pineal gland secretes melatonin, 
which has a sedative effect on the brain and helps to induce sleep. This 
function of the pineal gland helps to explain why darkness is sleep-inducing 
and light tends to disturb sleep. Babies produce large amounts of melatonin, 
allowing them to sleep as long as 16 hours per day. The pineal gland produces 
less melatonin as people age, resulting in difficulty sleeping during adulthood. 
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CEREBRUM 
  The largest region of the human brain, our cerebrum controls higher brain 
functions such as language, logic, reasoning, and creativity. The cerebrum surrounds 
the diencephalon and is located superior to the cerebellum and brainstem. A deep 
furrow known as the longitudinal fissure runs midsagittally down the center of the 
cerebrum, dividing the cerebrum into the left and right hemispheres. Each hemisphere 
can be further divided into 4 lobes: frontal, parietal, temporal, and occipital. The 
lobes are named for the skull bones that cover them. Frighteningly, these lobes are 
some of the areas of the brain attacked by Alzheimer’s disease. If you want to find out 
your own genetic risk for late-onset Alzheimer’s, learn more about DNA health 
testing and how you can discuss the results of this testing together with your 
healthcare provider. 
  The surface of the cerebrum is a convoluted layer of gray matter known as 
the cerebral cortex. Most of the processing of the cerebrum takes place within the 
cerebral cortex. The bulges of cortex are called gyri (singular: gyrus) while the 
indentations are called sulci (singular: sulcus). 
  Deep to the cerebral cortex is a layer of cerebral white matter. White matter 
contains the connections between the regions of the cerebrum as well as between the 
cerebrum and the rest of the body. A band of white matter called the corpus callosum 
connects the left and right hemispheres of the cerebrum and allows the hemispheres to 
communicate with each other. 
  Deep within the cerebral white matter are several regions of gray matter that 
make up the basal nuclei and the limbic system. The basal nuclei, including the globus 
pallidus, striatum, and subthalamic nucleus, work together with the substantia nigra of 
the midbrain to regulate and control muscle movements. Specifically, these regions 
help to control muscle tone, posture, and subconscious skeletal muscle. The limbic 
system is another group of deep gray matter regions, including the hippocampus and 
amygdala, which are involved in memory, survival, and emotions. The limbic system 
helps the body to react to emergency and highly emotional situations with fast, almost 
involuntary actions. 
  With so many vital functions under the control of a single incredible organ - 
and so many important functions carried out in its outer layers - how does our body 
protect the brain from damage? Our skull clearly offers quite a bit of protection, but 
what protects the brain from the skull itself? Read on! 
31 
 
MENINGES 
  Three layers of tissue, collectively known as the meninges, surround and 
protect the brain and spinal cord. 
 The dura mater forms the leathery, outermost layer of the meninges. Dense 
irregular connective tissue made of tough collagen fibers gives the dura mater 
its strength. The dura mater forms a pocket around the brain and spinal cord to 
hold the cerebrospinal fluid and prevent mechanical damage to the soft 
nervous tissue. The name dura mater comes from the Latin for “tough 
mother,” due to its protective nature. 
 The arachnoid mater is found lining the inside of the dura mater. Much 
thinner and more delicate than the dura mater, it contains many thin fibers that 
connect the dura mater and pia mater. The name arachnoid mater comes from 
the Latin for “spider-like mother”, as its fibers resemble a spider web. Beneath 
the arachnoid mater is a fluid-filled region known as the subarachnoid space. 
 As the innermost of the meningeal layers, the pia mater rests directly on the 
surface of the brain and spinal cord. The pia mater’s many blood vessels 
provide nutrients and oxygen to the nervous tissue of the brain. The pia mater 
also helps to regulate the flow of materials from the bloodstream and 
cerebrospinal fluid into nervous tissue. 
 
CEREBROSPINAL FLUID 
  Cerebrospinal fluid (CSF) — a clear fluid that surrounds the brain and spinal 
cord — provides many important functions to the central nervous system. Rather than 
being firmly anchored to their surrounding bones, the brain and spinal cord float 
within the CSF. CSF fills the subarachnoid space and exerts pressure on the outside of 
the brain and spinal cord. The pressure of the CSF acts as a stabilizer and shock 
absorber for the brain and spinal cord as they float within the hollow spaces of the 
skull and vertebrae. Inside of the brain, small CSF-filled cavities called ventricles 
expand under the pressure of CSF to lift and inflate the soft brain tissue. 
  Cerebrospinal fluid is produced in the brain by capillaries lined with 
ependymal cells known as choroid plexuses. Blood plasma passing through the 
capillaries is filtered by the ependymal cells and released into the subarachnoid space 
as CSF. The CSF contains glucose, oxygen, and ions, which it helps to distribute 
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throughout the nervous tissue. CSF also transports waste products away from nervous 
tissues. 
  After circulating around the brain and spinal cord, CSF enters small structures 
known as arachnoid villi where it is reabsorbed into the bloodstream. Arachnoid villi 
are finger-like extensions of the arachnoid mater that pass through the dura mater and 
into the superior sagittal sinus. The superior sagittal sinus is a vein that runs through 
the longitudinal fissure of the brain and carries blood and cerebrospinal fluid from the 
brain back to the heart. 
 
PHYSIOLOGY OF THE BRAIN 
METABOLISM 
  Despite weighing only about 3 pounds, the brain consumes as much as 20% of 
the oxygen and glucose taken in by the body. Nervous tissue in the brain has a very 
high metabolic rate due to the sheer number of decisions and processes taking place 
within the brain at any given time. Large volumes of blood must be constantly 
delivered to the brain in order to maintain proper brain function. Any interruption in 
the delivery of blood to the brain leads very quickly to dizziness, disorientation, and 
eventually unconsciousness. 
 
SENSORY 
  The brain receives information about the body’s condition and surroundings 
from all of the sensory receptors in the body. All of this information is fed into 
sensory areas of the brain, which put this information together to create a perception 
of the body’s internal and external conditions. Some of this sensory information is 
autonomic sensory information that tells the brain subconsciously about the condition 
of the body. Body temperature, heart rate, and blood pressure are all autonomic senses 
that the body receives. Other information is somatic sensory information that the brain 
is consciously aware of. Touch, sight, sound, and hearing are all examples of somatic 
senses. 
 
MOTOR CONTROL 
  Our brain directly controls almost all movement in the body. A region of the 
cerebral cortex known as the motor area sends signals to the skeletal muscles to 
produce all voluntary movements. The basal nuclei of the cerebrum and gray matter in 
the brainstem help to control these movements subconsciously and prevent extraneous 
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motions that are undesired. The cerebellum helps with the timing and coordination of 
these movements during complex motions. Finally, smooth muscle tissue, cardiac 
muscle tissue, and glands are stimulated by motor outputs of the autonomic regions of 
the brain. 
 
PROCESSING 
  Once sensory information has entered the brain, the association areas of the 
brain go to work processing and analyzing this information. Sensory information is 
combined, evaluated, and compared to prior experiences, providing the brain with an 
accurate picture of its conditions. The association areas also work to develop plans of 
action that are sent to the brain’s motor regions in order to produce a change in the 
body through muscles or glands. Association areas also work to create our thoughts, 
plans, and personality. 
 
LEARNING AND MEMORY 
  The brain needs to store many different types of information that it receives 
from the senses and that it develops through thinking in the association areas. 
Information in the brain is stored in a few different ways depending on its source and 
how long it is needed. Our brain maintains short-term memory to keep track of the 
tasks in which the brain is currently engaged. Short-term memory is believed to 
consist of a group of neurons that stimulate each other in a loop to keep data in the 
brain’s memory. New information replaces the old information in short-term memory 
within a few seconds or minutes, unless the information gets moved to long-term 
memory. 
  Long-term memory is stored in the brain by the hippocampus. The 
hippocampus transfers information from short-term memory to memory-storage 
regions of the brain, particularly in the cerebral cortex of the temporal lobes. Memory 
related to motor skills (known as procedural memory) is stored by the cerebellum and 
basal nuclei. 
 
HOMEOSTASIS 
  The brain acts as the body’s control center by maintaining the homeostasis of 
many diverse functions such as breathing, heart rate, body temperature, and hunger. 
The brainstem and the hypothalamus are the brain structures most concerned with 
homeostasis. 
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  In the brainstem, the medulla oblongata contains the cardiovascular center that 
monitors the levels of dissolved carbon dioxide and oxygen in the blood, along with 
blood pressure. The cardiovascular center adjusts the heart rate and blood vessel 
dilation to maintain healthy levels of dissolved gases in the blood and to maintain a 
healthy blood pressure. The medullary rhythmicity center of the medulla monitors 
oxygen and carbon dioxide levels in the blood and adjusts the rate of breathing to 
keep these levels in balance. 
  The hypothalamus controls the homeostasis of body temperature, blood 
pressure, sleep, thirst, and hunger. Many autonomic sensory receptors for 
temperature, pressure, and chemicals feed into the hypothalamus. The hypothalamus 
processes the sensory information that it receives and sends the output to autonomic 
effectors in the body such as sweat glands, the heart, and the kidneys. 
 
SLEEP 
  While sleep may seem to be a time of rest for the brain, this organ is actually 
extremely active during sleep. The hypothalamus maintains the body’s 24 hour 
biological clock, known as the circadian clock. When the circadian clock indicates 
that the time for sleep has arrived, it sends signals to the reticular activating system of 
the brainstem to reduce its stimulation of the cerebral cortex. Reduction in the 
stimulation of the cerebral cortex leads to a sense of sleepiness and eventually leads to 
sleep. 
  In a state of sleep, the brain stops maintaining consciousness, reduces some of 
its sensitivity to sensory input, relaxes skeletal muscles, and completes many 
administrative functions. These administrative functions include the consolidation and 
storage of memory, dreaming, and development of nervous tissue. 
  There are two main stages of sleep: rapid eye movement (REM) and non-rapid 
eye movement (NREM). During REM sleep, the body becomes paralyzed while the 
eyes move back and forth quickly. Dreaming is common during REM sleep and it is 
believed that some memories are stored during this phase. NREM sleep is a period of 
slow eye movement or no eye movement, culminating in a deep sleep of low brain 
electrical activity. Dreaming during NREM sleep is rare, but memories are still 
processed and stored during this time. 
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REFLEXES 
  A reflex is a fast, involuntary reaction to a form of internal or external 
stimulus. Many reflexes in the body are integrated in the brain, including the pupillary 
light reflex, coughing, and sneezing. Many reflexes protect the body from harm. For 
instance, coughing and sneezing clear the airways of the lungs. Other reflexes help the 
body respond to stimuli, such as adjusting the pupils to bright or dim light. All 
reflexes happen quickly by bypassing the control centres of the cerebral cortex and 
integrating in the lower regions of the brain such as the midbrain or limbic system. 
Prepared by Tim Taylor, Anatomy and Physiology Instructor 
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HEMIPLEGIA 
  The most common cause of hemiplegia is a stroke. During a stroke 
(cerebrovascular accident), an area of tissue in the brain dies because of either an 
interrupted blood supply or increased brain swelling. The left brain controls the right 
arm and leg, so a stroke on one side of the brain may cause hemiplegia on the 
opposite side. 
  Hemiplegia can also temporarily result from migraine headaches, seizures, and 
many other conditions affecting the nerves. Unexplained new weakness on one side of 
the body should be considered an emergency and prompt immediate medical 
attention. 
  After a stroke, hemiplegia may be permanent. Hemiplegia may be very mild 
and almost unnoticeable, but get temporarily worse during periods of sleep 
deprivation, illness, or stress. 
 
CAUSES: 
  Though the arms, legs, and possibly torso are the regions of the body most 
obviously affected by hemiplegia, in most cases of hemiplegia these body regions are 
actually perfectly healthy. Instead, the problem resides in the brain, which is unable to 
produce, send, or interpret signals due to disease or trauma-related damage. Less 
frequently, hemiplegia results from damage to one side of the spinal cord, but these 
sorts of injuries more typically produce global problems, not just paralysis on one side 
of the body. 
Some common causes of hemiplegia include: 
 Traumatic brain injuries to one side of the brain only. These may be 
caused by car accidents, falls, acts of violence, and other factors. 
 Cardiovascular problems, particularly aneurysms and haemorrhages in the 
brain. 
 Strokes and transient ischemic attacks (better known as TIA or mini-
strokes). 
 Infections, particularly encephalitis and meningitis. Some serious 
infections, particularly sepsis and abscesses in the neck, may spread to the 
brain if left untreated. 
 Conditions that cause demyelination of the brain, including multiple 
sclerosis and some other autoimmune diseases. 
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 Reactions to surgery, medication, or anesthesia. 
 Loss of oxygen to the brain due to choking or anaphylactic shock. 
 Brain cancers. 
 Lesions in the brain, even if non-cancerous, since these lesions can impede 
function on one side of the brain. 
 Congenital abnormalities, including cerebral palsy and neonatal-onset 
multi-inflammatory disease. 
 Rarely, psychological causes; some states of catatonia can cause 
hemiplegia, and people with parasomnia—a sleep disorder leading to 
unusual night time behavior—may experience night time episodes of 
hemiplegia. 
 
MECHANISM: 
  Movement of the body is primarily controlled by the pyramidal (or 
corticospinal) tract, a pathway of neurons that begins in the motor areas of the brain, 
projects down through the internal capsule, continues through the brainstem, 
decussates (or cross midline) at the LOWER medulla, then travels down the spinal 
cord into the motor neurons that control each muscle. In addition to this main 
pathway, there are smaller contributing pathways (including the anterior corticospinal 
tract), some portions of which do not cross the midline. 
  Because of this anatomy, injuries to the pyramidal tract above the medulla 
generally cause contralateral hemiparesis (weakness on the opposite side as the 
injury). Injuries at the lower medulla, spinal cord, and peripheral nerves result 
in ipsilateral hemiparesis. 
  In a few cases, lesions above the medulla have resulted in ipsilateral 
hemiparesis: 
 In several reported cases, patients with hemiparesis from an 
old contralateral brain injury subsequently experienced worsening of their 
hemiparesis when hit with a second stroke in the ipsilateral brain.[14][15][16] The 
authors hypothesize that brain reorganization after the initial injury led to 
more reliance on uncrossed motor pathways, and when these compensatory 
pathways were damaged by a second stroke, motor function worsened further. 
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 A case report describes a patient with a congenitally uncrossed pyramidal 
tract, who developed right-sided hemiparesis after a hemorrhage in the right 
brain 
 
HEMIPLEGIA SIGN: 
  Hemiplegia caused by a lesion of the pyramidal tract. This is the main neural 
pathway that carries the motor orders. It is therefore a set of neurons involved in 
voluntary movement. 
  The pyramidal pathway begins in the brain at an area of nerve cells of 
pyramidal shape and joined with other nerve cells of the spinal cord. Pyramidal tract 
neurons then transmit their orders to l mn which carry them to the muscles. Before 
reaching the spinal cord, brain stem, the pyramidal tract changes sides. This explains 
that a lesion is localized on the side opposite the affected limb: left brain injury causes 
a right hemiplegia and vice versa. 
  Observed  with different depending on the location of the injury. 
 When the lesion in the brain cortex, this causes a disproportionate hemiplegia: 
the face and arms are predominantly affected. 
 When the lesion is located in the white matter of the brain, this causes a 
proportional hemiplegia: arm and leg are affected similarly deficient. 
 A brainstem lesion, it causes a paralysis of one side of the body and 
involvement of the face on the other side. 
 
HEMIPLEGIA SYMPTOMS 
  In some cases the lesions, arm and leg are affected, in others only the arm or 
only the face. 
  When hemiplegia is partial and that movements are still possible, there is a 
decrease in muscle strength and mobility impaired, as manifested by clumsiness, 
trouble walking accompanied by a great tiredness and falls of one side. 
  When hemiplegia is total, even lesreflexes are abolished. However, the 
babinski sign is present: when you touch the outside of the foot, it causes an extension 
of the big toe. In a healthy person, this stimulation leads to a bending of the big toe. 
Hemiplegia is accompanied by changes in muscle tone: the muscles are stiff and 
overly contracted any (spastic hemiplegia) or conversely soft and flabby (flaccid 
hemiplegia). 
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  On the face, the damage to the muscles can result in a drooping eyelid or an 
asymmetric smile. 
 
HEMIPLEGIA OTHER SYMPTOMS 
  In addition to motor disturbances, hemiplegia is characterized by the 
appearance of other symptoms. 
 Pain. There is pain associated with brain injury and localized pain in the 
affected limbs. 
 Aphasia. People, who suffer from hemiplegia, even though the process of 
thinking and developing ideas is held, are struggling to find words and 
articulate. In addition, they may have difficulty understanding the meaning of 
words they hear or read them. 
 Disorders of the sphincters. A quarter of people with hemiplegia have 
sphincter disturbances resulting in either urinary incontinence or urinary 
retention, fecal incontinence is still. 
 Sexual dysfunction: erection, ejaculation is compromised in many men with 
hemiplegia. Moreover, a decreased libido, especially at the beginning of the 
disability, is often found. 
 
INVESTIGATION 
Routine investigations: 
BLOOD 
TC 
DC 
ESR  
HB 
BIOCHEMISTRY 
  SUGAR: F/ PP/ R 
Cholesterol 
KIDNEY FUNCTION TEST 
  UREA 
CREATININE 
  URIC ACID 
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LIVER FUNCTION TEST 
   Bilirubin total Direct /indirect 
SGOT 
SGPT 
ALKALINE PHOSPHATASE 
PROTINE TOTAL ALB/GLO 
 
URINE ROUTINE TEST 
              Albumin  
              Sugar  
              Deposit  
 
NON-ROUTINE INVESTIGATIONS: 
Electrolytes 
Thyroid function 
Chest X-Ray 
Cranial CT/MRI 
Cardiac ultrasound 
Echocardiography 
ECG 
EEG 
Antithrombin 
Temporal artery biopsy 
Blood culture 
Cardiac culture 
 
EXAMINATION OF CENTRAL NERVOUS SYSTEM: 
HIGHER FUNCTIONS:   
Higher brain function such as thought and actions are examined 
Conscious level     
Sleep rhythm         
Handedness           
Speech                  
Memory                
Intelligence            
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ORIENTATION  : 
  In  orientation a person's basic attitude, beliefs, or feelings in relation to a 
particular subject or issue are examined.  
Ex. 
Place                     
Time                     
Person                   
 
EXAMINATION OF CRANIAL NERVES: 
There is 12 pair of cranial nerves in the body. Cranial nerve examination is 
used to examine the functionality of the cranial nerves. This is a highly formalized 
series of tests that assess the status of each nerve. 
 Olfactory nerve                     
 Optic nerve                          
 Occulomotor nerve             
 Trochlear nerve                     
 Trigeminal nerve                    
 Abducent  nerve                    
 Facial nerve                          
 Vestibule cochlear nerve         
 Glosso pharyngeal nerve          
 Vagus nerve                        
 Accessory nerve                     
 Hypoglossal  nerve                 
 
EXAMINATION OF MOTOR SYSTEM 
NUTRITION:    
  Nutrition of the patient is examined for ascessing if any atrophy of muscles 
present 
 Shoulder girdle 
 Upper limp 
 Hip girdle 
 Lower limp 
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TONE:    
   Muscle tone is the continuous partial contraction in a muscle. Muscle tone 
determines how well the muscle works when the brain signals the body to hold a 
position or perform a movement. For example, it affects sitting, standing, reaching 
and walking.  
  Strength and muscle tone are not the same thing, but they are related. Normal 
muscle tone makes it easier to strengthen muscles.  
  The type of muscle tone a person has is present at birth. 
  Good (average) muscle tone allows muscles and joints to move easily.  
  “Low” muscle tone, or hypotonia, means that the muscle is soft and flabby. It 
makes movement difficult because the muscle is not held together well.  
  “High” muscle tone, or hypertonia, means that the muscle is stiff, so it is 
difficult to relax the muscle and move the joint freely.  
                                                                        
POWER: 
Power of the muscle is examined by using grade 
Grading of muscle power:  
Grade 0- complete paralysis. 
Grade 1 -flicker of contraction present. 
Grade 2- active movement with gravity eliminated.  
Grade 3-Active movement against gravity.  
Grade 4-Active movement against gravity and some resistance 
Grade 5-Active movement against gravity and fulle resistance 
 
EXAMINATION OF SENSORY SYSTEM: 
The following sensory functions are examined 
Touch                      
Pain                        
Temperature              
Position sence           
Vibration sence          
Joint sence              
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CORTICAL SENSES: 
           Tactile localisation            
2 point discrimination       
Stereognosis                   
Graphesthesia                  
Sensory inattention           
 
REFLEXES 
A reflex is an involuntary and nearly instantaneous movement in response to a 
stimulus. A reflex is made possible by neural pathways called reflex arcs which can 
act on an impulse before that impulse reaches the brain. The reflex is then an 
automatic response to a stimulus that does not receive or need conscious thought. It is 
used to differentiate the upper motor lesion from the lower motor lesion.  
 
Superficial reflexes: 
Corneal 
Conjuctival 
Abdominal 
Cremasteric 
Plantar 
 
Deep tendon reflexes: 
Biceps 
Triceps 
Supinator 
Knee 
Ankle 
 
Grading of the reflexes: 
Grade 0: Absence 
Grade 1: Diminished 
Grade 2: Normal 
Grade 3: Exaggerated 
Grade 4: Clonus 
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CEREBRAL COORDINATION: 
  The cerebellum is the part of the brain most involved in coordinating 
sequences of movements. It also controls balance and posture. Anything that damages 
the cerebellum can lead to loss of coordination. The following test are used to assess 
the cerebral co ordination function is affected / normal. 
 
Upper limb: 
Finger nose test                             
Finger to finger nose test            
Tapping in a circle test                
Disdokokinesia                            
Pest pointing test                          
Rigid hand tapping                       
Spiral drawing                                
Dysmetria                                        
Rebound phenomenon      
           
Lower limb:       
Heel knee test                                
Drawing a circle in air                 
Walking in straight line              
Foot pat test                                   
 
INVOLENTORY MOVEMENTS 
  The following  involuntary movements of the body are examined to asses the 
involvement of cerebellum. 
Epilepsy                                                         
Choreas & dystonias                                   
Inv.movements of face and neck              
Tremors                                                    
Movements limited to the muscles         
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GAIT: 
A person's manner of walking is examined 
 
HEMIPLEGIA COMPLICATION 
  The immobility of paralysis arising member is responsible for complications 
that specialists in physical medicine and rehabilitation at trying to prevent the initial 
management. 
  The main complication remains on the loss of autonomy: everything must be 
done to try to recover mobility as complete as possible. 
Among the complications that can occur after hemiplegia 
 Pain in joints of immobilized different: the shoulder is often affected with a stiffening 
of the muscles (spasticity) and local inflammation. 
 Moreover, the bones of people with hemiplegia are weakened and lose bone density 
(osteopenia) as the brain give rise to abnormal vascularisation of bone. 
 Finally, sitting in a wheelchair or bedridden status may promote pressure sores (skin 
necrosis at the points of support) and problems such as venous disorders of venous 
circulation, the risk of phlebitis and oedema.The sphincter disturbances can cause 
infectious complications.  
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MATERIALS AND METHODS 
 
 The clinical study on pakkavatham was carried out in the post graduate 
sirappu maruthuvam department of Government siddha medical college and 
Palayamkottai In this study 38 patients (who are selected by inclusion and exclusion 
criteria) were treated as OP and IP patients. 
 
Selection of the patients: 
  All cases were carefully and thoroughly examined at the time of admission. 
Beside an individual case sheet was maintained for each patient in the in-patient ward. 
All patients were advised to come to the outpatient ward for further follow up. During 
admission the patients were subjected to careful history taking 
 
INCLUSION CRITERIA: 
 Age: between 20 – 65 years 
 Sex: Both male and female 
 Willing for admission and study in IPD for 40 Days or willing to attend OPD 
 Inability/difficulty to use upper and lower limb of one side 
 Willing to sign in the informed consent form. 
 
EXCLUSION CRITERIA: 
 Age:  below 15 and above 65 
 Pregnant and lactating women 
 Known hypersensitivity or allergy to drug ingredients 
 Renal failure 
 Cirrhosis of liver 
 Cardiac diseases 
 
Diagnosis of the cases: 
  Diagnosis was made by conducting all the nessary investigations in siddha and 
by through clinical examination and laboratory findings as per modern medicine 
methodology. 
  In siddha system the following aspect were taken into consideration 
 Pori arithal 
 Pulan arithal 
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 Vinathal 
 Examination of uyir thathukkal 
 Envagai thervugal 
 Udal thathukkal 
 Nilangal 
 Neerkuri and neikuri 
 
  The following investigations were done in modern medicine methodology 
Hematological Investigation: 
 Total WBC 
 Differential wbc count 
 Erythrocyte sedimentation rate 
 Haemoglobin percentage 
 Blood sugar 
 Blood urea 
 Serum cholesterol 
 Bleeding time 
 Clotting time 
Urine analysis: 
 Albumin 
 Sugar 
 Deposit 
Special investigations: 
 X-Ray chest PA view 
 Computerized tomography – brain(contrast) 
 Computerized tomography – brain(plain) 
 Magnetic resonance imaging 
 Electro encephalo gram 
Selection of drug: 
  The selected trail drug are 
INTERNAL MEDICINE : VISHNU CHAKRA MATHIRAI   
                         Ref : Siddha vaithiya thirattu 
EXTERNAL MEDICINE:  KODIVELI THYLAM  
                        Ref : Gunapadam mooligai vaguppu 
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LINE OF TREATMENT: 
  The day before the internal medicine started, vellai ennai-15 ml wa given at 
early morning for purgation to correct the deranged vatham to all the patients 
From the second day  - the trail drug were administrated 
 
VISHNU CHAKRA MATHIRAI  as a internal medicine – 130 mg twice a day after 
food with thirikadugu choornam + inji juice + honey 
 
KODIVELI THLAM as external medicine used for external application only 
All the patients were adviced to maintain diatary regimen (or) pathiyam to avoid 
interaction with drug.  Complimentary therapy like massage and varmam were 
manipulated. 
 
TEST AND ASSESSMENT: 
A.CLINICAL ASSESSMENT: 
 Difficulty to use upper and lower limb of one side of the body 
 Deviation of the mouth 
 Drippling of saliva 
 Difficulty in speech 
 Difficulty to close the eyelids 
 
B.ASSESMENT SCALE OF HEMIPLEGIA 
 Examination of cranial nerves 
 Examination of spino motor system 
 Nutrion 
 Tone 
 Power 
Grade 0- complete paralysis. 
Grade 1 -flicker of contraction present. 
Grade 2- active movement with gravity eliminated.  
Grade 3-Active movement against gravity.  
Grade 4-Active movement against gravity and some resistance 
Grade 5-Active movement against gravity and fulle resistance 
  
54 
 
 Coordination 
 Involuntary movements 
 Gait 
 Reflexes: 
Extensor plantar response 
Superficial reflexes 
Deep tendon reflexes 
Grade 0: Absence 
Grade 1: Diminished 
Grade 2: Normal 
Grade 3: Exaggerated 
Grade 4: Clonus 
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RESULTS AND OBSERVATION 
For the clinical study 40 patients were selected and treated in PG-III Sirappu 
Maruthuvam Department, Government Siddha Medical College and Hospital, 
Palayamkottai.  Results were observed with respect to the following criteria. 
1. Sex distribution 
2. Age distribution 
3. Occupation 
4. Socio-economic status 
5. Gunam 
6. Diet 
7. Pathological history 
8. Mukkutra Kaalam 
9. Thinai and land incidence 
10. Paruva kaalam 
11. Affected side 
12. Interest to siddha treatment after stroke 
13. Duration of illness In patients 
14. Duration of illness Out patients 
15. Precipitating factor 
16. Clinical presentation 
17. Disturbance in vadha 
18. Disturbance in pitha 
19. Disturbance in kabha 
20. Udal Thathukkal 
21. Patients treated only with trial drugs 
22. Patients treated only trial drugs along with Massage therapy 
23. Patients treated only  trial drugs with along with varmam 
24. Patients treated with trial drugs with varmam and massage therapy 
25. Comparison between effective of trial drug and trial drug with complementary 
therapies 
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1. INCIDENCE OF PAKKAVATHAM (INPATIENTS AND OUT PATIENTS) 
  Among the thirty eight patients of varied etiology who were treated for study 
in the inpatient and outpatient ward the incidence is  30 patients in Males, 78.94% and  
8  patients  in female , 21.05%  
 
S.no Sex 
No. of patients in IN and OUT 
patients ward 
Percentage(%) 
1 Male 30 78.94 
2 Female 8 21.05 
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2. AGE INCIDENCE 
  Among the thirty four patients the highest incidence was in the age group of  
51 – 60 years (31.5%), 1 patient belonged to the age group of 30 years , 2.63% 
9patients belong to Age group of 31 – 40, 26.3%, 6 patients to the age group of  60 
and above, 15.78% 
 
S.no Age No. of patients Percentage(%) 
1 16 – 20 0 0 
2 21 – 30 1 2.63 
3 31 – 40 9 23.6 
4 41 – 50 10 26.3 
5 51 – 60 12 31.5 
6 Above  60 6 15.78 
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3. OCCUPATION 
  Among  38 Patients ,17patients were agricultural labour 44.73%,5 patients 
were house wife 13.15%,3 patients were office employee 7.89%,  2 patients were 
factory workers and beedi workers 5.26%,1 patient was driver  and rest were others.] 
 
S.no Occupation No. of patients Percentage(%) 
1 Agricultural labours 17 44.73 
2 House wife 5 13.15 
3 Office employee 3 7.89 
4 Factory worker 2 5.26 
5 Beedi worker 2 5.26 
6 Un employee 0 0 
7 Drivers 1 2.63 
8 Others 8 21.05 
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4. SOCIO ECONOMICAL STATUS 
  Among 38 patients, 33 patients were belong to middle class 86.84%and 5 
patients belong to low class 13.15%. 
 
S.no Socio - Economical status No. of patients Percentage(%) 
1 Low class 5 13.15 
2 Middle class 33 86.84 
3 High class 0 0 
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5. REFERENCE TO GUNAM 
  Among 38 patients, 26 patients were raso gunam 68.42% and 12 patients 
belong to thamo gunam 31.57% 
 
S.no Gunam No. Of patients Percentage(%) 
1 Sathuva gunam 0 0 
2 Raso  gunam 26 68.42 
3 Thamo gunam 12 31.57 
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6. REFERENCE TO DIET 
 
  Among 38 patients , 35 patients were belong to mixed diet 92.10%,  2 patient 
vegetarian diet 5.26% and 1 patient  Non vegetarian diet 2.63% 
 
S.no Diet No. Of patients Percentage(%) 
1 Vegetarian diet 2 5.26 
2 Non vegetarian diet 1 2.63 
3 Mixed diet 35 92.10 
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7.  PATHOLOGICAL  HISTORY REFERENCE 
 
  Among  38 patients  all have negative pathological history 
 
S.no Pathological history No. Of patients Percentage(%) 
1 Positive 0 0 
2 Negative 38 100 
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8. DISTRIBUTION ACCORDING TO MUKKUTRA KAALAM 
 
  Among 38 patients 33 patients belong to pitha kalam 86.84%, 3 patients 
belongs to vatha kalam 7.89% and 2 patients belongs to Kaba kalam 5.26% 
 
S.no Kaalam No. Of patients Percentage(%) 
1 Vatha kaalam(1-33yrs) 3 7.89 
2 Pitha kaalam(34-66yrs) 33 86.84 
3 Kaba kaalam(67-100yrs) 2 5.26 
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9. THINAI OR LAND INCIDENCE 
 
   Among 38 patients 33 belongs to marutham thinai 92.10 % and 3 patient 
belongs to neithal thinai 7.89% 
 
S.no Thinai or Land No. of patients Percentage(%) 
1 Kurinji 0 0 
2 Mullai 0 0 
3 Marutham 33 92.10 
4 Neithal 5 7.89 
5 Paalai 0 0 
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10. SENSATIONAL(PARUVAKALAM)  INCIDENCE 
   
  Among 38 patients 14 patients belongs to munpani kalam, 36.84%, 10 patients 
belongs to koothirkaalam 26.31%, 5 patients belongs to elavenil kalam 13.15 %, 4 
patients belongs to pinpani kalam 10.52%, 3 patients belongs to Kaar kalam. 7.89%, 2 
patients belongs to  muthuvenirkaalam 5.26%. 
 
S.no Paruvakalam Month No. Of patients Percentage(%) 
1 Kaarkalam 
Avani-puratasi 
(15 aug – 14 oct) 3 7.89 
2 Koothirkaalam 
Ippasi-karthigai 
(15 oct – 14 dec) 
10 26.31 
3 Munpanikaalam 
Margazhi-thai 
(15 dec – 14 feb) 
14 36.84 
4 Pinpanikaalam 
Maasi-panguni 
(15 feb – 14 apr) 
4 10.52 
5 Elaveenirkaalam 
Chitthirai-vaigasi 
(15 april– 14 jun) 5 13.15 
6 muthuvenirkaalam 
Aani-aadi 
(15 jun– 14 aug) 2 5.26 
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11. INCIDENCE OF PAKKAVATHAM ACCORDING TO THE SIDE EXISTS 
 
  Among 38 patients 20 patients were affected right side 52.63% and 18 patients 
were affected  left side 47.36%. 
 
S.no Affected side No. of patients Percentage(%) 
1 Right 20 52.63 
2 Left 18 47.36 
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12. INTEREST TO THE SIDDHA TREATMENT AFTER STROKE 
  Among 38 patients  8 patients were interested in siddha treatment  below 1 
year  21.05%, 10 patients were interested about 1 – 2 years  26.31%, 16 patients were 
interested about 2 – 5 years  42.10%, and 4 patients were interested about 5-10 years 
10.52%. 
 
S.No Affected side No. of patients Percentage(%) 
1 Below 1 year 8 21.05 
2 1 – 2 years 10 26.31 
3 2 – 5 years 16 42.10 
4 5 – 10 years 4 10.52 
5 Above 10 years 0 0 
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13. DURATION OF ILLNESS AT THE TIME OF ADMISSION 
IN PATIENTS 
  At a time of admission among the 25 patients in the Inpatient ward All the 25 
patients had been suffered below 2 years. 
 
S.no 
Duration of illness 
(in months) No. Of patients Percentage(%) 
1 1 – 3 2 5.26 
2 3 – 6 3 7.89 
3 6 – 12 7 18.42 
4 12 – 24 8 21.05 
5 Above 24 months 5 13.15 
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OUT PATIENTS 
  Among 13 patients  of the outpatient ward 4 patients suffered below 1 year  
and four patients suffered above 2 years and 5 patients between 12  and   24 months. 
 
S.no 
Duration of illness 
(in months) No. of patients Percentage(%) 
1 1 – 3 1 2.63 
2 3 – 6 2 5.26 
3 6 – 12 1 2.63 
4 12 – 24 5 13.15 
5 Above 24 months 4 10.52 
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14. PRECIPITATING FACTOR 
 
  Among 38 patients  Hypertension was precipitating factor in 10 patients 
26.31%, 15 diabetic 39.47% and 1 having other complaints 2.63%. 
 
S.no precipitating factor No. of patients Percentage(%) 
1 Hypertension 10 26.31 
2 Diabetes mellitus 15 39.47 
3 Trauma 0 0 
4 Cerebral tumour 0 0 
5 Syphilis 0 0 
6 Miscellaneous 1 2.63 
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15. CLINICAL PRESENTATION 
  Among 38 Patients  clinical presentation of the patients are noted as follows 
S.no Clinical symptoms 
No. Of 
patients 
Percentage(%) 
1.  Difficulty to use left upper limb and 
lower limb 
20 52.63 
2.  Difficulty to use right upper limb and 
lower limb 
18 47.36 
3.  Deviation of angle of mouth 24 63.15 
4.  Dripping of saliva 0 0 
5.  Difficulty in speech 24 63.15 
6.  Difficulty in closing eyes 0 0 
7.  Difficulty in swallowing 0 0 
8.  Breathlessness 0 0 
9.  Excessive thrust 0 0 
10.  Frequency of micturition 0 0 
11.  Head ache 4 10.52 
12.  Past history of similar episode 1 2.63 
13.  Circumduction gait 38 100 
14.  Giddiness 0 0 
15.  Epilepsy 1 2.63 
16.  Clubbing 0 0 
17.  Anaemia 3 7.89 
18.  Pedal oedema 1 2.63 
19.  Normal higher interLectual function 0 0 
20.  Muscle wasting 8 21.05 
21.  Constipation 5 13.5 
22.  Consciousness defect 0 0 
23.  Orientation defect 0 0 
24.  Lymphadenopathy 0 0 
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16. CLINICAL PRESENTATION 
VATHAM 
  Among 38 patients Viyanan and Samanan are affected in all patients 100%, 
Abanan were affected in 6 patients 15.78%,  Devadathan were affected in 25 patients. 
65.78% 
 
S.no Vatham No. Of patients Percentage(%) 
1 Piranan 0 0 
2 Abanan 6 15.78 
3 Vudhanan 0 0 
4 Viyanan 38 100 
5 Samanan 38 100 
6 Naagan 0 0 
7 Koorman 0 0 
8 Kirukaran 0 0 
9 Thevathathan 25 65.78 
10 Thananjayan 0 0 
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PITHAM 
  Among 38 patients Sathaga pitham was affected in all patients 100%, 
Anarpitham was affected in 4 patients, 10.52% and Ranjagapitham were affected in 3 
patients 7.89% 
S.no Pitham No. of patients Percentage(%) 
1 Anarpitham 4 10.52 
2 Ranjagapitham 3 7.89 
3 Sathagapitham 38 100 
4 Aalosagapitham 0 0 
5 pirasagapitham 0 0 
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KABAM 
  Among 38 patients  Santhigam was affected in all patients 100%. 
 
S.no Kabam No. Of patients Percentage(%) 
1 Avalambagam 0 0 
2 Kilethagam 0 0 
3 Pothagam 0 0 
4 Tharpagam 0 0 
5 Santhigam 38 100 
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17.CONDITION OF UDAL THATHUKKAL 
 
  Among 38 patients  all Udal thathukkal were affected in all patients 100% 
 
S.no Udal thathukkal No. Of patients Percentage(%) 
1 Saaram 38 100 
2 Senneer 38 100 
3 Oon 38 100 
4 Kozhuppu 38 100 
5 Enbu 38 100 
6 Moolai 38 100 
7 Sukkilam / suronitham 38 100 
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18.  EFFECT OF TRAIL DRUG  
 By treating with trial drug only 30.76% patients had good improvement, 46.15% of 
patients had moderate improvement and 23.07% of patients had mild effect. 
S.no Effect of therapy No. Of patients  Percentage(%) 
1 Marked effect 4 30.76 
2 Moderate effect 6 46.15 
3 Mild effect 3 23.07 
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TABLE 19.  EFFECT OF COMPLEMENTORY THERAPY ALONG WITH 
TRAIL DRUG(VARMAM) 
By treating trail drug along with complementary therapy (Varmam) 30 % 
patients had good improvement, 40 % of patients had Moderate improvement, 30 % 
of patients had Mild Improvement. 
S.no Effect of therapy No. Of patients  Percentage(%) 
1 Good 3 30 
2 Moderate effect 4 40 
3 Mild effect 3 30 
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TABLE 20. EFFECT OF THERAPY ALONG WITH TRAIL DRUG 
(MASSAGE) 
By treating trail drug along with complementary therapy (Massage) 20 % 
patients had good improvement, 50 % of patients had Moderate improvement, 30  % 
of patients had Mild Improvement. 
S.no Effect of therapy No. Of patients  Percentage(%) 
1 Marked effect 2 20 
2 Moderate effect 5 50 
3 Mild effect 3 30 
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TABLE 21. EFFECT OF THERAPY ALONG WITH TRAIL DRUG 
(MASSAGE & VARMAM) 
By treating trail drug along with complementary therapy (Massage & 
Varmam) 60 % patients had good improvement, 20 % of patients had Moderate 
improvement,20 % of patients had Mild Improvement. 
S.no Effect of therapy No. Of patients  Percentage(%) 
1 Marked effect 3 60 
2 Moderate effect 1 20 
3 Mild effect 1 20 
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22.  EFFECT OF THERAPY 
 By treating with compliment therapy 32% patients had good improvement, 
44% of patients had moderate improvement and 24% of patients had mild effect. 
S.no Effect of therapy No. Of patients  Percentage(%) 
1 Marked effect 8 32 
2 Moderate effect 11 44 
3 Mild effect 6 24 
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20.COMPARISON BETWEEN EFFECTIVE OF TRAIL DRUG WITH 
COMPLEMENTARY THERAPIES 
By treating trial drug with compliment therapy 31.57% patients had good 
improvement, 44.73% of patients had moderate improvement and 23.68% of patients 
had mild effect. 
 
S.no 
 
 
Effect of therapy 
Trail drug alone Trail drug with 
external therapy 
No.Of 
cases 
percentage No.Of 
cases 
Percentage 
1 Good 4 30.76 8 32 
2 Moderate 6 46.15 11 44 
3 Mild 3 23.07 6 24 
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LIST OF OUT  PATIENTS OF PG III SIRAPPU MARUTHUVAM DEPARTMENT GIVEN  
1.VISHNU CHAKRA MATHIRAI – INTERNAL    2.KODIVELI THYLAM – EXTERNAL 
 
S.no Op.no Name Age/sex Occupation Diagnosis Date of 
registration 
Date of 
completion of 
treatment 
No. Of days 
treated 
Result 
1 65222 KANNAN 43/M AGRICULTURAL PV(L) 31-07-2017 16-09-2017 48 MODERATE 
2 71413 KRISHNAN 60/M AGRICULTURAL PV(R) 20-08-2017 06-10-2017 48 MILD 
3 77381 CHELLA DURAI 50/M AGRICULTURAL PV(R) 08-09-2017 25-10-2017 48 MODERATE 
4 99459 MARIAPPAN 32/M AGRICULTURAL PV(R) 11-11-2017 25-12-2017 48 GOOD 
5 104148 SUBRAMANIYAN 39/M AGRICULTURAL PV(R) 24-11-2017 10-12-2017 48 MODERATE 
6 104514 SHAM 31/M AGRICULTURAL PV(L) 25-11-2017 11-12-2017 48 GOOD 
7 105078 NIJAM 50/M SHOPKEEPER PV(L) 27-11-2017 13-12-2017 48 MODERATE 
8 107775 KANAGARAJ 47/M AGRICULTURAL PV(R) 06-12-2017 22-01-2018 48 MILD 
9 108670 LAKSHMI 34/F HOUSE WIFE PV(R) 08-12-2017 24-01-2018 48 GOOD 
10 110436 SENTHIL KUMAR 35/M AGRICULTURAL PV(L) 14-12-2017 30-01-2018 48 MODERATE 
11 4981 YESUVADIYAN 59/M AGRICULTURAL PV(R) 13-01-2018 29-02-2018 48 MILD 
12 6480 CHELLAMAL 65/F HOUSE WIFE PV(L) 19-01-2018 05-03-2018 48 MILD 
13 8145 MUTHAIYA 52/M AGRICULTURAL PV(L) 24-01-2018 10-03-2018 48 MILD 
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LIST OF IN PATIENTS OF PG III SIRAPPU MARUTHUVAM DEPARTMENT GIVEN  
1.VISHNU CHAKRA MATHIRAI – INTERNAL    2.KODIVELI THYLAM – EXTERNAL 
S.NO IP.NO NAME AGE/SEX OCCUPATION DATE OF ADMISSION 
DATE OF 
DISCHARGE 
TOTAL NO. OF DAYS 
TREATED TOTAL NO. OF 
DAYS RESULT IP OP 
 
1 2345 SELVI 45/F HOUSE WIFE 22-08-2017 29-09-2017 38 10      48 DAYS MODERATE 
2 2559 PITCHAMMAL 60/F    HOUSE WIFE 15-09-2017 24-10-2017 41 7 48 DAYS MODERATE 
3 2999 PITCHAIYA 59/M COOLI 08-11-2017 31-12-2017 54 - 48 DAYS MODERATE 
4 3000 MUTHAIYA 59/M COOLI 08-11-2017 29-12-2017 52 - 48 DAYS GOOD 
5 3013 SUBRAMANIYAN 39/M AGRICULTURAL 10-11-2017 04-12-2017 25 23 48 DAYS GOOD 
6 3014 SAKTHIVEL 28/M FACTORY WORK 10-11-2017 02-12-2017 23 25 48 DAYS MILD 
7 3023 THANGA PAUNDI 37/M CLERK 13-11-2017 04-12-2018 22 26 48 DAYS GOOD 
8 3090 RAJASEKAR 59/M AGRICULTURAL 20-11-2017 08-01-2018 49 - 48 DAYS GOOD 
9 3096 THANGA NADATHI 70/F AGRICULTURAL 20-11-2017 07-12-2017 18 30 48 DAYS MILD 
10 3109 CITTU 57/F AGRICULTURAL 23-11-2017 07-12-2017 15 23      48 DAYS MODERATE 
11 3185 SAKTHIVEL 57/M BEEDI WORKER 05-12-2017 07-01-2018 34 14 48 DAYS MODERATE 
12 3224 JOHN PETER 50/M AGRICULTURAL 10-12-2017 27-01-2018 48 - 48 DAYS MODERATE 
13 3228 AASIRVATHAM 45/M OFFICE WORK 10-12-2017 27-01-2018 49 - 48 DAYS GOOD 
14 3263 MARIYADOSS 60/M COOLI 13-12-2017 12-01-2018 31 17 48 DAYS MILD 
15 3309 RAJANARAYANAN 45/M AGRICULTURAL 18-12-2017 04-02-2018 49 - 48 DAYS MILD 
16 3335 RAJARATHINAM 58/M FACTORY WORK 22-12-2017 25-01-2018 35 13 48 DAYS GOOD 
17 12 JEYALAKSHMI 55/F BEEDI WORKER 02-01-2018 10-01-2018 9 39 48 DAYS MILD 
18 75 ESSAKKI 65/M COOLI 17-01-2018 28-02-2018 43 5 48 DAYS MODERATE 
19 146 SARASWATI AMMAL 82/F HOUSE WIFE 22-01-2018 05-02-2018 15 33 48 DAYS MILD 
20 171 MURUGAN 37/M DRIVER 24-01-2018 13-03-2018 51 - 48 DAYS MODERATE 
21 186 DURAI PAUNDI 38/M OFFICE WORK 25-01-2018 06-03-2018 43 5 48 DAYS MODERATE 
22 235 THIRAVIYA KANI 50/M COOLI 30-01-2018 16-03-2018 48 - 48 DAYS GOOD 
23 241 SUBBURAJ 45/M AGRICULTURAL 30-01-2018 11-03-2018 43 5 48 DAYS MODERATE 
24 369 VEMBAN 65/M AGRICULTURAL 12-02-2018 13-03-2018 32 15 48 DAYS GOOD 
25 378 SANTHIYAPPAN 42M COOLI 12-02-2018 11-03-18 30 18 48 DAYS MILD 
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EXAMINATION OF POWER 
S.No Ip.No Before And After Treatment 
Shoulder 
 
Elbow Wrist Hip Knee Ankle Result 
Abd Add Flx Ext Flx Ext Abd Add Flx Ext Flx Ext  
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S.No Ip.No Before And After Treatment 
Shoulder 
 
Elbow Wrist Hip Knee Ankle Result 
Abd Add Flx Ext Flx Ext Abd Add Flx Ext Flx Ext  
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S.No Ip.No 
Before And 
After 
Treatment 
Shoulder 
 
Elbow Wrist Hip Knee Ankle Result 
Abd Add Flx Ext Flx Ext Abd Add Flx Ext Flx Ext  
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S.No Ip.No Before And 
After 
Treatment 
Shoulder 
 
Elbow Wrist Hip Knee Ankle Result 
Abd Add Flx Ext Flx Ext Abd Add Flx Ext Flx Ext  
16 3335 BT 
AT 
0/5 
3/5 
0/5 
3/5 
0/5 
3/5 
0/5 
3/5 
0/5 
1/5 
2/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
0/5 
2/5 
0/5 
2/5 
GOOD 
17 12 BT 
AT 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
0/5 
0/5 
2/5 
2/5 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
1/5 
2/5 
1/5 
2/5 
MILD 
18 75 BT 
AT 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
MODERATE 
19 146 BT 
AT 
0/5 
2/5 
0/5 
2/5 
0/5 
2/5 
0/5 
2/5 
0/5 
0/5 
0/5 
0/5 
0/5 
2/5 
0/5 
2/5 
0/5 
2/5 
0/5 
2/5 
0/5 
2/5 
0/5 
2/5 
MILD 
20 171 BT 
AT 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
2/5 
2/5 
2/5 
2/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
MODERATE 
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S.No Ip.No Before And 
After 
Treatment 
Shoulder 
 
Elbow Wrist Hip Knee Ankle Result 
Abd Add Flx Ext Flx Ext Abd Add Flx Ext Flx Ext  
21 186 BT 
AT 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
2/5 
3/5 
2/5 
3/5 
3/5 
4/5 
3/5 
4/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
3/5 
MODERATE 
22 235 BT 
AT 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
GOOD 
23 241 BT 
AT 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
1/5 
2/5 
1/5 
2/5 
3/5 
3/5 
3/5 
3/5 
3/5 
4/5 
3/5 
4/5 
3/5 
3/5 
3/5 
3/5 
MODERATE 
24 369 BT 
AT 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
2/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
3/5 
4/5 
GOOD 
25 378 BT 
AT 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
0/5 
0/5 
2/5 
2/5 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
2/5 
3/5 
1/5 
2/5 
1/5 
2/5 
MILD 
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EXAMINATION OF CRANIAL NERVES 
S.no Ip. No Olfactory 
nerve 
Optic 
nerve 
Occulomotor 
nerve 
Trochlear 
nerve 
Trigeminal 
nerve 
Abducent 
nerve 
Facial nerve Auditory 
nerve 
Glosso 
pharyngeal 
nerve 
Vagus 
nerve 
Accessory 
nerve 
Hypoglossal 
nerve 
1 2345 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
2 2559 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
3 2999 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
4 3000 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
5 3013 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
6 3014 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
7 3023 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
8 3090 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
9 3096 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
10 3109 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
11 3185 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
12 3224 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
13 3228 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
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14 3263 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
15 3309 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
16 3335 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
17 12 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
18 75 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
19 146 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
20 171 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
21 186 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
22 235 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
23 241 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
24 369 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
25 378 NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL AFFECTED NORMAL NORMAL NORMAL NORMAL NORMAL 
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BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT – OP PATIENT 
 
S.NO OP.NO TC DC HB ESR BLOOD SUGAR BLOOD  SERUM 
        N L E B M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 65222 8400 7900 64 63 32 34 4 3 0 0 0 0 9.5 9.9 34 28 89 85 149 140 34 29 179 165 
2 71413 7400 7600 72 69 25 28 3 3 0 0 0 0 13.1 13 22 19 124 118 168 155 40 31 208 201 
3 77381 6900 6700 64 62 33 36 3 2 0 0 0 0 11.8 11.9 25 20 96 92 176 168 29 22 199 187 
4 99459 7800 7400 65 64 31 32 4 4 0 0 0 0 9.6 10.1 34 25 108 102 189 172 36 22 221 201 
5 104148 7200 7500 59 61 36 34 5 5 0 0 0 0 12.5 12.7 25 19 136 127 167 156 29 25 196 185 
6 104514 7700 7300 62 64 32 34 6 2 0 0 0 0 13.5 13.6 31 23 122 108 154 146 37 31 167 157 
7 105078 7500 8100 64 67 29 29 7 4 0 0 0 0 12.1 12.4 15 10 97 92 149 135 28 27 185 176 
8 107775 8200 7900 69 69 28 29 3 2 0 0 0 0 12.8 12.9 32 21 142 128 165 148 35 32 139 127 
9 108670 9200 9000 70 70 26 25 4 5 0 0 0 0 10.9 11.1 30 19 136 128 159 139 42 37 165 157 
10 110436 7300 7100 66 67 33 31 1 2 0 0 0 0 13.5 13.7 28 19 99 90 149 132 29 22 159 149 
11 4981 7800 7700 59 61 37 36 4 3 0 0 0 0 12.2 12.4 27 20 106 97 167 165 37 34 186 172 
12 6480 6700 6900 61 62 34 34 5 4 0 0 0 0 11.8 12.2 26 18 121 118 172 159 19 15 194 188 
13 8145 8800 8400 63 65 35 34 2 1 0 0 0 0 12.2 12.4 19 11 129 117 179 161 22 19 186 174 
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BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT – IP PATIENT 
S.NO IP.NO TC DC HB ESR BLOOD SUGAR BLOOD  SERUM 
        N L E B M   F PP UREA CHOLESTEROL 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 2345 7300 7100 62 64 33 32 5 4 0 0 0 0 12.2 12.2 32 24 80 78 115 102 8 12 172 119 
2 2559 7200 7600 65 67 32 31 3 2 0 0 0 0 13 12.4 12 10 91 88 121 110 20 18 190 182 
3 2999 7800 7300 61 63 37 36 2 1 0 0 0 0 11 13.3 8 6 86 74 110 100 16 15 216 195 
4 3000 9300 9000 59 58 41 40 0 2 0 0 0 0 13.1 13.3 15 12 110 96 142 120 24 12 126 115 
5 3013 8800 8600 70 74 26 26 4 0 0 0 0 0 11.6 11.8 40 30 81 74 112 100 23 25 187 165 
6 3014 7400 7800 66 65 29 32 5 3 0 0 0 0 12.0 12.3 12 10 135 120 155 134 16 15 175 168 
7 3023 8100 8600 57 58 37 42 6 0 0 0 0 0 12.0 12.6 15 10 99 96 118 103 31 18 166 152 
8 3090 7800 8200 64 68 32 30 4 2 0 0 0 0 9.5 9.8 20 15 92 89 120 99 27 21 150 135 
9 3096 6900 7200 73 75 23 25 4 0 0 0 0 0 13.1 13.2 18 13 143 120 180 164 25 22 175 162 
10 3109 8800 8900 76 78 21 20 3 2 0 0 0 0 12.6 12.8 4 3 98 90 122 102 20 22 210 186 
11 3185 8400 8300 65 68 31 30 4 2 0 0 0 0 11.4 11.9 22 11 88 83 115 104 27 21 147 126 
12 3224 7300 7200 61 66 38 31 1 3 0 0 0 0 11.8 11.9 26 12 90 88 118 99 18 20 245 223 
13 3228 9100 9400 58 66 37 34 5 0 0 0 0 0 9 9.2 24 12 86 84 110 95 16 22 135 121 
14 3263 7000 7400 64 68 30 30 6 2 0 0 0 0 12 12 7 6 180 99 366 175 34 21 197 172 
15 3309 7600 7700 61 59 31 38 6 3 0 0 0 0 12.1 12.2 40 20 106 79 131 96 26 22 140 122 
16 3335 6400 6600 65 69 32 27 3 4 0 0 0 0 9.6 12.2 21 11 86 99 117 98 34 31 185 173 
17 12 8200 8400 66 68 31 32 3 0 0 0 0 0 11.1 9.9 12 8 111 96 132 111 16 12 220 196 
18 75 7700 7600 69 70 29 28 7 2 0 0 0 0 12.2 11.3 16 9 108 86 146 102 41 17 165 142 
19 146 7300 7800 65 73 31 24 4 3 0 0 0 0 10.5 13.6 10 7 92 84 116 97 8 22 210 185 
20 171 7400 7600 55 65 27 32 5 3 0 0 0 0 13.5 11 22 11 95 84 110 92 36 21 170 176 
21 186 7900 8200 71 74 27 26 2 0 0 0 0 0 12.8 13.6 4 3 90 70 121 90 22 24 195 157 
22 235 9000 9300 66 70 31 27 3 3 0 0 0 0 11 12.9 20 13 89 80 106 88 24 26 175 176 
23 241 7600 7300 76 78 20 17 4 5 0 0 0 0 10.5 11.3 11 9 84 70 108 84 22 25 150 147 
24 369 8300 8300 64 76 28 22 5 2 0 0 0 0 12.4 11 33 20 73 84 99 80 18 22 126 132 
25 378 6000 6200 60 78 35 21 5 1 0 0 0 0 13.5 12.5 26 14 92 95 124 100 27 30 164 148 
  
93 
 
URINE EXAMINATION BEFORE & AFTER TREATMENT – OUT  PATIENTS 
 
S.no 
 
Op.no Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 65222 NIL NIL NAD NIL NIL NAD 
2 71413 NIL NIL NAD NIL NIL NAD 
3 77381 NIL NIL NAD NIL NIL NAD 
4 99459 TRACE             + 1-2 PUS CELLS NIL NIL NAD 
5 104148 NIL NIL NAD NIL NIL NAD 
6 104514 NIL NIL NAD NIL NIL NAD 
7 105078 NIL NIL NAD NIL NIL NAD 
8 107775 NIL NIL NAD NIL NIL NAD 
9 108670 TRACE NIL NAD Trace  NIL NAD 
10 110436 NIL NIL NAD NIL NIL NAD 
11 4981 NIL + NAD NIL NIL NAD 
12 6480 NIL NIL NAD NIL NIL NAD 
13 8145 NIL NIL NAD NIL NIL NAD 
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URINE EXAMINATION BEFORE & AFTER TREATMENT – IN PATIENTS 
S.no 
 
Ip.no Before treatment After treatment 
Albumin  Sugar Deposit Albumin  Sugar Deposit 
1 2345 NIL NIL NAD NIL NIL NAD 
2 2559 NIL NIL NAD NIL NIL NAD 
3 2999 NIL NIL NAD NIL NIL NAD 
4 3000 NIL NIL NAD NIL NIL NAD 
5 3013 NIL NIL NAD NIL NIL NAD 
6 3014 Trace  + NAD Trace  NIL NAD 
7 3023 NIL NIL NAD NIL NIL NAD 
8 3090 NIL NIL NAD NIL NIL NAD 
9 3096 Trace NIL NAD NIL NIL NAD 
10 3109 NIL NIL NAD NIL NIL NAD 
11 3185 NIL NIL 2-3 pus cells NIL NIL NAD 
12 3224 NIL NIL NAD NIL NIL NAD 
13 3228 NIL NIL NAD NIL NIL NAD 
14 3263 Trace ++ NAD Trace  NIL NAD 
15 3309 NIL NIL NAD NIL NIL NAD 
16 3335 NIL NIL NAD NIL NIL NAD 
17 12 NIL NIL NAD NIL NIL NAD 
18 75 Trace NIL NAD NIL NIL NAD 
19 146 NIL NIL NAD NIL NIL NAD 
20 171 NIL NIL NAD NIL NIL NAD 
21 186 NIL NIL NAD NIL NIL NAD 
22 235 NIL NIL NAD NIL NIL NAD 
23 241 NIL NIL NAD NIL NIL NAD 
24 369 NIL NIL NAD NIL NIL NAD 
25 378 NIL NIL NAD NIL NIL NAD 
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DISCUSSION 
Hemiplegia in the modern medicine charecterised by paralysis of one half of 
the body which can be more or less correlated with pakkavatham which is one of the 
vatha disease affecting one half of the body and interfering function of upper and 
lower limbs of one side and may associate with cranial nerve or not. The only literal 
evidence of this disease is found in the classification of vatha disease in yugi vaithiya 
chinthamani perunool-800 which gives the etiology and the clinical feature also 
This dissertation works includes literary collections of observations both 
siddha and modern aspect of this disease. As per the symptamatology and the envagai 
thervugal and other siddha methods were selected and admitted 25 patients in IN-
patient ward and 13 patients were selected in outpatient ward 
On the dat of admission routine lab investigations (blood and urine test), 
radiological investigations, general and systemic examinations, neer kuri and nei kuri 
were done in all 25 ip patients. An individual case sheet was prepared and maintained 
to all the patients. 
To fulfil the primary endeavours of the study, the trail drug given below was 
used in treating the disease pakkavatham. 
Vishnu Chakra Mathirai (Internal)- 130 mg BD with Thirikadugu 
chooranam+ Inji juice+ Honey 
Kodiveli Thylam (External) 
Among the 25 IPD patients for 10 patients Massage and 10 patients Varmam 
and 5 patients treated with Varmam and Massage theraphy were given. All the 
patients were advised to follow the pathiyam. Another 13 patients were also treated 
with only the trial drug In the Outpatient ward 
In order to execute the primary objectives of this study, an inclusive open 
clinical trial was done with the drugs in treating the disease pakkavatham 
The clinical evaluation was done as per the protocol and the data were 
collected by using approved form. The disease pakkavatham was considered under 
various criteria to gather the secondary objectives of the study and the results were 
observed and tabulated. A variety of criteria and the results were discussed here under 
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Gender distribution: 
  From the above mentioned tabulation, among the 38 patients, 78.94% were 
male and 21.05% were female.. 
Age distribution: 
  This study shows high incidence of pakkavatham in 51-60 (31.5%) years of 
age. And the second largest incidence in 41-50 (26.3%) years. pakkavatham which is 
compared with hemiplegia which is a neurological disease, so the above inference 
explained the age is not much more significant in this disorder. 
Kaalam distribution: 
  From the above mentioned tabulation, the highest incidence of pakkavatham 
to be in pitha kaalam 
Occupational status: 
  In the study, among the 38 patients 17 patients were agricultural labours 
(44.73%), house wives(13.15%), office employee(7.89%), factory worker(5.26%), 
beedi worker(5.26%), driver(2.63%), others(21.05%). 
  In this study agricultural labours(44.73%) had high incidence of pakkavatham. 
Seasonal variation: 
From the above mentioned data 3 patients (7.89%)were admitted in kaar 
kaalam , 10 patients(26.31%) was admitted in koothir kaalam and 14 patients 
(36.84%) were admitted in munpani kaalam, 5 patients(13.15%) was admitted in 
elavenir kaalam. Most of the patients were admitted in munpani kaalam and koothir 
kaalam. 
Our study period for this study was short and moreover the patients obtained 
from this study were participating in same area. So the above obtained result may not 
have a scientific value. 
Thinai 
From the above mentioned data, 33 (92.10%) cases were from marutham and 
5(7.89%) cases were from neithal thinai 
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Hence the disease was studied in single area not globally, so it’s difficult to 
come to conclusion by this above data to evaluate the thinai distribution scientifically. 
Socio- economical status: 
From the above data, the majority of the patient 33 (86.84%) were from 
middle class, 5 (13.15%)were low class. 
Dietary habits: 
Among the 38 patients, 1 patients were non- vegetarian (2.63%) and 2 patients 
was vegetarian(5.26%) and Mixed diet 35 (92.10%) .Mixed diet hapid patients were 
reported to be high incidence. 
Precipitating factors: 
Inferred result proves that the hypertention 10 (26.31%) and diabetes 15 
(39.47%) were the most important precipitating factors 
Gradation of results on pakkavatham 
According to the prognosis of the pakkavatham, among the 25 in patient, good 
clinical result was seen in 8(32%). Moderate clinical result was seen in patients 
10(40%). 7 patients (28%) had mild improvement. 
Among  13 outpatient good clinical results was seen in 3 patients(7.89%). 
Moderate clinical result was seen in 5 patients (13.15%). Mild was seen in 5 patients 
(13.15%) 
Interest to siddha treatment after stroke: 
Among the 38 patients only 2 patients (5.26% )were treated in siddha system 
immediately after stroke with in 3 month, 3 patients (7.89%)were treated in siddha 
system within six months.  
Clinical features: 
According to this study, 100% of them had circumduction gait, deviation of 
mouth and difficulty in speech 24 patients (63.15%) of them had difficulty to use left 
upper and lower limbs 20 (52.63%) of them had difficulty to use right upper and 
lower limbs and 18 (47.36%) had past history of similar episodes 1(2.63%)of them 
had normal higher intellectual function. 
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Incidence of pakkavatham according to the side exists: 
Among the 38 patients right side was affected in 20 patients (52.63%) left side 
was affected in 18 patients (47.36%) right side was affected  
Reference to gunam: 
Among the 38 patients, majority of them had raso gunam 26 patients (68.42%) 
and remaining 12 patients (31.57%) were thamo gunam 
Distribution of three Thosam: 
Vatham 
From the above tabulation, samanan and viyanan were affected in 38 
(100%)of cases, abanan were affected in 6 (15.78%) of cases, Devathathan were 
affected in 25(65.7%) of cases. 
Pitham 
Saathaga pitham affected in all the cases and ranjaga pitham was affected in 3 
cases(7.89%) and anarpitham affected in 4 cases (10.52%) 
Kabam 
Santhigam were pretentious in all cases(100%) 
Udal kattugal 
Among the seven udal kattugal, saaram, senneer, oon, kozhuppu, enbu, 
moolai, sukkilam were found affected in all the cases(100%) 
Investigations: 
Laboratory investigations were done in all the cases before and after treatment. 
The significant variations occur in parameters like ESR and HB, while other 
parameters have significant variation. 
Pre clinical studies: 
The Biochemical study of had revealed the presence of calcium, iron(ferrous), 
unsaturated compounds and amino acid. 
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Pharmacological studies: 
The pharmacological studies done in Vishnu chakra mathirai revealed the 
presence of actions such as 
 Anti-inflammatory action 
The pharmacological studies done in vishamushti thylam revealed that it has 
an anti- inflammatory action 
 Haemolytic activity 
The pharmacological studies done in vishamushti thylam revealed that it has a 
haemolytic activity action 
Toxicity study: 
Acute toxicity and subacute studies have done for Vishnu chakra mathirai in 
rats and it is analyzed that they have no toxicity. 
Treatment: 
In our siddha system the line of treatment is chiefly intended to retain the 
deranged thoshas and thus relieved the symptoms of disease. 
Before started treatment each patient was advised to take purgation by giving 
vellai ennai 15 ml with hot water in the morning time for first day. 
From the second day onward internal medicine Vishnu chakra mathirai two 
times a day with honey after food and external medicine kodiveli thylam were given. 
At the time of treatment the patient were advised to follow pathiyam and 
specifically advised to avoid foods which increase vadha. 
Along with the course of treatment the complimentary therapies like massage 
and varmam theraphy were given additionally 
The outcome of the disease mainly assessed by the ability to perform the day 
to day activities well, increased range of movements and improvement in quality of 
life. 
Assessment scale was also used to detect proper outcome. No adverse effect 
was noted for both internal and external medicine along with the course of treatment. 
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Out of 38 patients good relief was seen in 11(28.94%) patients, they were 
marked with normal blood pressure, no giddiness and improvement in using the 
affected side. Moderate relief was seen in 15(39.47%) patients, they were marked 
with normal blood pressure, and some improvement in using the affected side. Mild 
relief was seen in 12(31.57%) patients, they were marked with normal blood pressure 
and mild improvement in affected limbs. 
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SUMMARY 
  The research work on pakkavatham was chosen with an intention to give 
solance to the patients who are suffering from the disease. The disease hemiplegia 
was comparatively studied with the disease pakkavatham with reference to its 
etiology, clinical featurea and pathogenesis. The author had a chance of referring 
many siddha literature and collected more information. 
  Vishnu chakramathirai is a internal drug and kodiveli thylam is a external 
medicine was chosen and a clinical trial in Govt, siddha medical college, 
palayamkottai was conducted with these drugs. For this 38 cases were selected in 
which 13 were treated in out patient ward and remaining 25 were in in patient ward. 
The preclinical studies of the trial drug were initiating to be encouraging. 
  Pharmacological analysis of vishnuchakra mathirai shows  
 Anti inflammatory action and 
 Haemolytic activity 
  Since, complimentary therapies or manual therapies like massage and varmam 
plays a significant role in treatment of hemiplegia. Some of the complimentary 
therapy from siddha system are manipulated along with trial drugs depending upon 
the severity of the disease. 
  Daily improvement was observed to assess the efficacy. The results obtained 
were found to be propitious. Particularly results by complimentary therapies were 
found to be very auspicious. 
  No adverse reactions were found. Hence the trial drug was found to be safe 
and effective. 
  From the clinical study it could be inferred that treatment with trail drugs 
considerably improves the functions of  
Viyanan – responsiple for sensory and motor activities and body movement 
Abanan – responsible for defaecation, micturation, menstruation and 
ejaculation 
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Nagan: responsible for higher intellectual functions and eye ball movement 
Dhevathathan – responsible for movements of eye ball, laziness, arguing, 
begging 
Samanan – responsible for normal digestion and correction of other vayus 
  It could be also inferred that the trial drugs inhibit the further vascular 
disorders and regulate the other physiological process of the body 
  Available investigations in modern medicine were also considered for 
diagnosis and follow the prognosis of the patients.  
  The efficacy of the trial drugs were studied by bio-chemical analysis and 
pharmacological analysis. 
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CONCLUSION 
In this clinical study Vishnu chakra mathirai – 130 mg twice a day with 
honey was taken as internal medicine administered to the pakkavatham along with 
kodiveli thylam was taken for external application have good relief. 
  In the pre clinical study pharmacological evaluation of the trial drug shows  
 Thrombolytic activity and 
 Anti inflammatory activity 
In the preclinical study toxicity study of Vishnu chakra mathirai shows that the 
trial drug had no acute toxicity. 
The overall results of efficacy of the trial drugs along with external therapies 
by declining the clinical signs and symptoms like difficulty in using upper and lower 
limbs of one side of the body, difficulty in walking 
Good clinical improvement was observed in 11(28.94%) patients. Moderate 
clinical improvement  was  observed  in  15(39.47%) patients.    Mild clinical 
improvement was observed in 12(31.57%) patients. 
The trial drug Vishnu chakra mathirai and kodiveli thylam have no adverse 
effects durin thr treatment period. So the trial medicines are safe and effective 
Patients who had undergone massage and varma therapies got good reliefe 
than the others 
  Because of engorging result clinically, the study may undertake with a large 
number of patients with same drug will creat a new era in the field of siddha medicine 
especially in the treatment of pakkavatham. It may through light on relieving the 
patient from the clutches of clippling by this disease. 
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INGREDIENTS  OF THE TRIAL DRUG 
VISHNU CHAKRA MATHIRAI (INTERNAL MEDICINE) 
  
Lingam 
 
Rasam 
 
Thalagam 
 
Ganthakam 
 
Manosilai 
 
Kantham 
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Thutham 
 
Naabi 
 
Palagarai 
 
Veppampalam 
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INGREDIENTS  OF THE TRIAL DRUG 
KODIVELI THYLAM  (EXTERNAL MEDICINE) 
 
 
  
Kodiveli 
 
Karunjeeragam 
 
Thandrikai 
 
Thalisapathiri 
 
Pasuvennai 
 
Pasumpal 
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VISHNU CHAKRA MATHIRAI  
(INTERNAL DRUG) 
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KODIVELI THYLAM 
(EXTERNAL DRUG) 
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ANNEXURES 
PREPARATION AND PROPERTIES OF THE TRIAL DRUG 
STANDARD OPERATING PROCEDURE  FOR PREPARATION OF VISHNU 
CHAKRA MATHIRAI  (Internal)  AND KODIVELI THYLAM (External) 
 
TRIAL DRUG  : 
         INTERNAL MEDICINE     : “VISHNU CHAKRA MATHIRAI ” 
                            Ref:  siddha vaithiya thirattu 
SOURCE OF TRIAL MEDICINE: 
            The required raw drugs for preparation of “VISHNU CHAKRA 
MATHIRAI” (internal) will be purchased from a well reputed country shop and the 
purchased drugs will be authenticated by the faculty members in charge of 
Gunapadam laboratory at Government Siddha medical college palayamkottai. 
 
INGREDIENTS:                      
1. PURIFIED RASAM  (MERCURY)  
2. PURIFIED LINGAM  (CINNABAR) 
3. PURIFIED GANTHAGAM (SULPHUR) 
4. PURIFIED THUTHTHAM  (ZINC SULPHAS) 
5. PURIFIED THALAGAM (TRISULPHURET OF ARSENIC) 
6. PURIFIED KANTHAM  (MAGNETIC OXIDE OF IRON) 
7. PURIFIED MANOSILAI  (RED ORPIMENT) 
8. PURIFIED NAABI  (ACONITUM NAPELLUS.LINN) 
9. PURIFIED  PALAGARAI (COWRY) 
10. NEEM FRUIT JUICE   (AZADIRACTA INDICA) 
11. CHUKKU (ZINGIBER OFFICINALE) 
12. MILAGU (PIPER NIGRUM.LINN) 
13. THIPPILI  (PIPER LONGUM) 
14. INJI JUICE  (ZINGIBER OFFICINALE )  
15. THEAN  (HONEY) 
  All the ingredients completely purified under the methoid of sarakku suththi 
muraigal literature. 
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METHOD OF PREPARATION: 
  The purified ingredients one to nine taken as equal amounts and gently grind 
with juice of Neem fruit. After the sufficient amount of time to mixture it is prepare as 
a kuntri (130 mg) size mathirai and dried in dark place. 
 
PROPERTIES OF DRUG – INGREDIENTS: 
Internal drug - Vishnu chakara mathirai 
 
1. -zqr<gl<< << << <!
Tamil name : -zqr<gl<!
English name: Cinnabar (or) virmilion 
Chemical name: Red sulphide of mercury (natural) 
OuX!ohbv<gt<;< << << < !N{<Gxq,-visl<,gjmue<eq,gv<h<hl,<n{<mgl, <slvsl/<!!!!!!
ke<jl;<<< !ouh<hl<!
!
ohiKG{l<;!<<< !
!!! ! ‘‘OhkqSvR<!sf<fq!!ohVuqv{!!fQoviMk!
!!!!!!!!!!!gikgc!gisr<!gvh<hie<H{<.O{ik!
!!!!!!!!!!!UVuqzqr<g!sr<gkli!B,Xgm<c!Bl<Ohir<!
!!!!!!!!!!!GVuqzqr<g!sr<glk<jkg<!ogit</’’!!!!!
!!!!!!!!!!!!!!!
!!!!!!!!!!!‘‘Nkq!bqvkUVg<!gikzix<!sikqzqr<g!
!!!!!!!!!!!!Olikq!zqvkG{!Lx<Xmzqx<.xQKHvq!
!!!!!!!!!!!!Gm<mr<!gqvf<kq!ogiMr<S,jz!uikLk!
!!!!!!!!!!!!Zm<mr<G!Ofib<gjtObim<!Ml</’’!!
!
osb<jg;!<<< dmx<Okx<xq!
kQVl<! Ofib<gt<;!Q < < <Q < < <Q < < < Ke<hk<jk!d{<Mh{<[gqe<x! Ohkq,Svl<,sf<fqhikl,<kQvih<H{<gt<,!
nkq&k<kqvl<,gi{ig<gcuqml<,gisl< ,gvh<hie< ,sqvr<G,osiz<ukx<Gl<! hiv<h<hkx<Gl,<!
ouXh<Hk<!Okie<Xl<!hvU!F{ig<gib<g<!gqvf<kq,Gm<ml<,!gqvf<kq, ogiMjl!osb<gqe<x!
$jz,! uik! Ofib<! LkzqbjugjtBl<! dmzqz<! ljxf<K! -Vg<Gl<!
hq{qgjtBl<!fQg<Gl</!
Sk<kq! Ljx;!<<< hps<siX,! hSl<hiz<,! Oleqs<siX! -l<&e<jxBl<! sloujm! %m<c!
-zqr<gk<kqx<Gs<!SVg<gqm<M!wMg<g!Sk<kqbiGl</!
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!
!
3/-vsl<<<<!
Tamil name: -vsl< 
English name: Hydrargyrum 
Chemical name: Mercury, Quick silver. 
OuX!ohbv<gt<;< << << < !givl< ,!$kl< ,!H{<{qbl< ,!uq{<lVf<K,!hivkl< ,!Nkq,!lgilvl, <!
-eqjl,!siX/!
Sju;!nXSju!
ke<jl;<<< !ouh<h!sQk!uQvqbr<gtqv{<jmBLjmbK/!
hqvqU;! wh<ohiVjt! Kj{lVf<kig<gq! ogiMg<gqe<OxiOli! nh<ohiVtqe<! hqvqju!
njmBl</!
fqxl<;< << !outqh<Hxk<K..$vqb!ytq!fqxl<!
!!!!!dm<Hxk<K.sqxqK!fQzfqxl<!
ohiKg<G{l<;!< << << < !
!! ! ‘‘uqpqOfib<!gqvf<kqGe<ll<!olb<s<$jz!H{<Gm<!
!!!!!!!!!!!mpqgizqz<!uqf<Kuqeiz<!nk<jk.upqbib<!
!!!!!!!!!!!HvqB!uqkq!biK!HvqbqOei!obz<zil<!
!!!!!!!!!!!-vqBuqkq!biK!lqz<jz’’!!!
!
kQVl<Ofib<gt<;Q < < <Q < < <Q < < < ! g{<Ofib<,! gqvf<kq,! w{<ujgg<! Ge<ll, <! $jz,! ohVl<! H{, <!
okiPOfib< ,!utqg<GjxU!Ofib<gt<!fQr<Gl</!
!
osb<jg;<<< ! lzOhig<gq,! dvlig<gq,! dmx<Oxx<xq,! uQg<gLVg<gq,! dlqp<fQv<! ohVg<gq,!
sqXfQv<ohVg<gq,!Olgfisqeq,!hqk<kfQv<!ohVg<gq/!
!
Sk<kq! Ljx;<<< ! -zqr<gk<kqzqVf<K! wMg<ghMgqe<x! uijzvsl<! K~b<jlbigUl<!
sqxf<kkigUl<!gVkh<hMgqe<xK/!
! !
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4/gf<kgl<< << << <!
Tamil name:!gf<kgl< 
English name: Sulphur 
Chemical name: Sulphur 
OuX! ohbv<gt<;< << << < ! givqjpbqe<! fikl<,! hjvuQvqbl<,! hQ\l<,kel<,ohie<ui<{q,!
-vsSOvi{qkl</!
Sju;!jgh<H,!Kuv<h<H/!
ohiKG{l<;<<< !!
!! ! ‘‘ofz<zqg<gib<g<!gf<kqg<G!fQt<hkqoe{<!Gm<mlf<kl<!
!!!!!!!!!!!uz<jz!guqjsGe<l!uiBg{<O{ib<!.ohiz<zi!
!!!!!!!!!!!uqmg<gcue<!OlgOfib<!uQXSvl<!Ohkq!
!!!!!!!!!!!kqmg<gqvS!{Qghl<Ohif<!Okv<’’ 
 
kQVl<Ofib<gt<;Q < < <Q < < <Q < < < ! hkqoe{<Gm<ml<, lf<kl<, gz<zQvz< uQg<gl<, ohVubqX! ujggTt<!
ye<xigqb! guqjs,! Ge<luiB,! g{<O{ib<gt< ,ogiMjljbs<! osb<gqe<x!
uqmg<gcgt<! fim<hm<m!Olg!Ofib<gt, <! uik!Svl, <! Ohkq,!fim<hm<m!gqvg{q,!ghl<!
Lkzqbe!fQr<Gl</!
!
osb<jg;<<< ! hqk<kfQjv! nkqghMk<Kl<, dmx<Oxx<xq,! uqbv<juohVg<gq,! gqVlqfisqeq,!
lzlqtg<gq/!ngr<gtqe<!stqs<su<U!Svh<jh!nkqghMk<Kl</!
!
outqh<hMkz<!< << << < : uqbv<ju,!hiz< ,!sqXfQv</!
!
Sk<kq! Ljx;<<< ! uijpg<gm<jm! fQvqz<! ogf<kqjb! 21! Ljx! dVg<gq! dVg<gq!
sib<okMg<gs<!Sk<kqbiGl</!
!
5/kitgl<<<<!
Tamil name:!kitgl< 
English name: Orpiment/yellow arsenic Trisulphide  
Chemical name: Trisulphide of arsenic!!
OuX!ohbv<gt<;!< << << < hQkgq,!hqR<sel< ,!Nzl<hq,!lizl< ,!giz<Hk<kq/!
ohiKg<G{l<;< << << < !!
! ! ‘‘kitgk<kqe<!OhVjvg<gk<!kiZgUt<!Ofib<G]<ml<!
!!!!!!!!!!!fQtg<!Gtqv<gib<s<sz<!fQMghl<!.fitgr<ogit<!
!!!!!!!!!!!K]<mh<!hxr<gqh<H{<!$pPg{<!l{<jmOfib<!
!!!!!!!!!!!gqm<mh<!hMhli!gqtk<K/’’!!
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kQVl<Ofib<gt<;Q < < <Q < < <Q < < < !fig<G,!gOhizl, <!-jugjth<!hx<xqb!Ofib< ,!Gm<ml< ,!Gtqv<Svl< ,!
ghl<! &k<kqv! fitk<jkh<! hx<xqb! hxr<gqh<H{< ,! nPg{< ,! l{<jmOfib<!
Lkzqbju!fQr<Gl</!
osb<jg;<<< ! Ogijpbgx<xq, dvlig<gq,! dmx<Oxx<xq,! uif<kqB{<mig<gq,! fs<svq,!
Svlgx<xq.!!
Sk<kq! Ljx<<< ;! S{<{il<Hg<! gz<zqe<! -jmbqz<! juk<Kh<! her<gt<tqeiz<! 21!
kvk<Kg<G!Gjxbilz<!kitqk<K!wMk<K,!gPuq!dzv<k<kqg<!ogit<t!Sk<kqbiGl</!
!
6/lOeisqjz!
Tamil name:!lOeisqjz 
English name: Red orpiment (or) Realgar 
Chemical name:Arsenic Disulphidum 
OuX!ohbv<gt<;< << << < fie<Lge<,!Okeq,!svOsikq,!kiljvuisqeq,!ui{qout<ts<sq/!
juh<H;!6%!out<jth<himi{Ll<+4%!gf<kgLl<!
!
ohiKg<G{l<;< << << < !!
!! ! ‘‘ogicb!G]<ml<!gib<s<sz<!fMg<gz\ gz<zqjvh<!
!!!!!!!!!!!!Hs<sqzf<kqh<!OhsXl!Oeisqjzg<Gh<!OhS/’’ 
!
kQVl<Ofib<gt<;Q < < <Q < < <Q < < < ! sVl!Gm<ml<?! ftqv<! Svl<?! n\gz<zqgiOvigl<?! -jvh<H! )Suisl<*,!
sqzf<kquqml<!Lkzqbe!Ohil</!
Sk<kq! Ljx;<<< ! -R<sqs<six<xqz<! yVsill<! ye<xib<! njvk<K,! dzv<k<kq! wMg<gs<!
Sk<kqbiGl</!
!
7/gif<kl<< << << <!
Tamil name:!gif<kl< 
English name: Magnet. 
Chemical name: Magnetic oxide of iron. 
OuX! ohbv<gt<;< << << < ! squOzigs<! Osuge<,! $k! nr<Gsl< ,fuOzig! Kvm<c,! LVge<!
Hvi{l<!
ohiKg<G{l<;< << << < !!
!! gif<kk<kix<!OsijhGe<lr<!gilqzOl!gl<hi{<M!
!!!!!Osv<f<kkqvq!Okimoum<jm!sQkr<giz<.Yb<f<khsq!
!! OhVkvr<!g{<O{ib<!hqvlqbfQ!vijlBl<Ohil<!
!! Yvqeqjx!biBTXl<!de<!
!
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osb<jg;<<< !dmx<Oxx<xq!
Sk<kq! Ljx;<<< ! wZlqs<jshps<siX,! Htqk<k! gic,! Htqk<k! Oliv, <! -jugtqz<!
LjxOb! Ll<Le<X! fit<! Dxjuk<K! oubqzqz<! juk<Kg<! gPuq! wMg<gs<!
Sk<kqbiGl</!
!
8/Kk<kl<< << << <!
Tamil name: hiz<!Kk<kl<!
English name: Zinc sulphas 
Chemical name:Sulphate of zinc 
OuX!ohbv<gt<;< << << < !out<jtkKk<kl< ,lmz<!Kk<kl,<!fig!dh<H,!out<tqb!dh<H/!
ohiKg<G{l<;< << << < ! 
  ‘‘ Lx<xqb!Gxqh<H{<!Ljxuqv{R<!ose<eqkjjh<!
!!!!!!hx<xqfqe<x!uikl<!hmv<gvh<hie<!.Sk<kuqpqg<!
!!!!!!gisr<!g{l<hqz<zr<!g{<O{ib<Gf<!kf<okijzBl<!
!!!!!!uislqG!Kk<kk<kiz<!uip<k<K/’’ 
!
kQVl<Ofib<gt<;Q < < <Q < < <Q < < < ! GxqgtqZ{<mil<! H{<?! &jtgtqZt<t! H{<gt< ,! kjzjbh<!!
hx<xqb! uikOfib<?! hmv<gqe<x! gvh<hie<?! g{<! gisl<?! Gpf<jkgTg<Gg<gi[l<!
g{l<?! -jlbqZ{<mil<! hqz<zl<?! g{<O{ib<?! Gf<kl<! Lkzqb! hq{qgt<!
Kk<kk<kqeiz<!fQr<Gl</ 
osb<jg;<<< !dvlig<gq,!-squgx<xq,!uif<kqB{<mig<gq/! 
Sk<kq!Ljx;<<< ! hSuqe<! fQvqz<!juk<okvqk<Kg<! gPuqobMk<K! oub<bqzqz<!dzv<k<kq!
ogit<ts<!Sk<kqbiGl</!!
!
9/fihq!
Tamil name:!fihq 
English name: Aconitum napellus 
Family name: Ranunculaceae 
OuX!ohbv<gt<;< << << < !fihl< ,!uqml< ,lVkl</!
hbe<hMl<!dXh<H!;< < << < << < < ! Rhizome 
Sju;!jgh<H!
ke<jl;<<< !ouh<hl<!
hqvqU;giv<h<H!
!
!
!
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ohiKg<G{l<;< << << < !!
uikuzq!lf<klxz<!lixig<!ghh<hq{qgt<!!
!! YKGm<M!Ge<lf<Okt<!yMr<gi{<!.!gikzi<kl<!
!! Hk<kqObi!miVbqVl<!!H,Ul<!ujeGpOz"!
!! Sk<kqosb<k!fiuqbqe<Ohi<!osiz</!
!
kQVl<!Ofib<gt<;Q < < <Q < < <Q < < < !gQp<uib<g<!gMh<H?!osvqbijl?!!Jbh<hq{qgt<?!ohVOfib<?!Ge<ll<?!
Okt<!fR<S!Ohil</!
osb<jg;<<< ! uqbv<juohVg<g<gq,! sqXfQv<ohVg<gq,! Ljxouh<hgx<xq,! kiKouh<hgx<xq,!
&v<s<jsB{<mig<gq,!Kbvmg<gq/!
Sk<kq!Ljx;<<< !wZlqs<sl<!hps<siX,!Htqk<kgic,!Htqk<kOliv<!-jugtqz<!LjxOb!
Ll<&e<X! fit<! gf<kgk<jk! Dxjuk<K! oubqzqz<! juk<Kg<! gPuq! wMg<gs<!
Sk<kqbiGl</!
Chemical Constituents:  Aconitine, mesaconitine, hypaconitine and jesaconitine. 
 
:/hzgjx!
Tamil name:!hzgjx!
English name: Marine shell, Cowry 
Zoological name: Cypraea moneta linn. 
OuX!ohbv<gt<;< << << < !guc,!Osigq,!uvic/!
Sju;!jgh<H!
ohiKg<G{l<;< << << < ! 
‘‘lf<kf<ki!gr<gqvg{q!liuqms<!Svr<g{<O{ib<!
!! okif<kl<!hvqfils<!$jzgb!–lqf<k!
Uzgjxjb!giozicju!ObiM!fjvk<k!
!!! hzgjxjb!gi{qeqbl<!hii<’’/!
kQVl<Ofib<gt<;Q < < <Q < < <Q < < < ! o<u{<! hzgjxbqeiz<! nzsl<?! kigl<?! gqvg{q?! uqms<Svr<gt<?!
uqpqOfib<?! uik! okif<kl<?! hzuqkg<! Gk<kz<?! gbl<?! ghuikl<?! n\Qv{l<?!
gilijz?!gz<zQvz<?!l{<{Qvz<!uQg<gl<?!Suisgisl<?!gisl<!kQVl</!
osb<jg;<<< ! ouh<hL{<mig<gq,! Ogijpbgx<xq,! kiKouh<hgx<xq,! outqh<hqvObigk<kqz<!
kch<H{<mig<gq/!
Sk<kq! Ljx;<<< ! hSuqe<! fQvqz<! juk<Kg<! gPuqobMk<K,! oub<bqzqz<! dzv<k<kqg<!
ogit<ts<!Sk<kqbiGl</!
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EXTERNAL MEDICINE: 
 
  KODIVELI THYLAM 
. Ref: Gunapadam mooligai 
INGREDIENTS: 
1. KODIVELI  ROOT (PLUMBAGO INDICA) – 35 grms 
2. KARUNJEERAGAM (NIGELLA SATIVA) - 35 grms 
3. THALISAPATHIRI  (ABIES SPECTABILIS) - 35 grms 
4. THANTRIKKAI  (TERMINALIA BELLIRICA)- 35 grms 
5. GINGLY OIL  (SESAMUM INDICUM)– ½ padi 
6. PASU VEENNAI – punnai kai alavu 
7. COW MILK 
 
METHOD OF PREPARATION: 
Add Kodiveli root with four times of water and boiled until the water reduced 
to half padi decoction. Then second to fourth ingredients grind with cow milk and 
added into the above decoction. gingly oil and pasu vennai added with above 
combination and boiled by thylam preparation method.  
 
1.!ogicOuzq!
OuXohbv<gt<;< << << < !ou{<sqk<kqv&zl<?!ou{<ogic&zl/<!
Botanical name: Plumbago zeylanica. 
Family name: plumbaginaceae. 
English name: Ceylon lead- wort 
Part used: Root <?!Root bark. 
Sju;!gii<h<H?!uqXuqXh<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!gii<h<H!
ohiKg<G{l<;!< << << < !
!!! gm<cuqv!{r<gqvf<kq!giz<gt<!njvbih<Hg<!
!!!!!gm<cs<$!jzuQg<gr<!gip<&zl<!.Lm<cvk<kg<!
!!!!!gm<MfQ!Ovx<xr<!gek<k!ohVubqXl<!
!!!!!nm<Mr<!ogicOuzq!bil</!
kQVl<Ofib<gt<;Q < < <Q < < <Q < < < gm<c?! H{<?! gpjz?! utqOfib<?! njvbh<Hg<gm<c?! Gk<kz<?! Osijh?!
&zOvigl<?!dkqvgm<M?!fQOvx<xl<?!ohVubqX!Ohil</!!
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!
osb<jg;<<< !Ljxouh<hgx<xq?!uqbi<juB{<mig<gq/!
!
Chemical Constituents: plumbagin, isoshinanolone , plumbagic acid, beta-sitosterol, 
4-hydroxybenzaldehyde, trans-cinnamic acid, vanillic acid, 2, 5-dimethyl-7-
hydroxychromone, indole-3-carboxaldehyde . 
 
2. gVR<sQvgl<< Q << Q << Q <!
OuXohbv<gt<;< << << < !nv{l< ,!dhGR<sqjg/!
Botanical name:Nigella sativa. 
Family name: Ranunculaceae 
English name: Black cumin 
Part used: Seed!!
Sju;!jgh<H!
ke<jl;<<< !ouh<hl<!
hqvqU;!giv<h<H!
ohiKg<G{l<;< << << < !
gVR<sQ!vgf<kie<!gvh<hoeiM!H{<[l<!
uVR<sqvib<h<!hQfsL!lix<Xl<.nVf<kqeiz<!
gib<s<sz<!kjzuzqBr<!g{<uzqBl<!OhiLzgqz<!
uib<s<s!lVf<okeOu!ju/!
kQVl<! Ofib<gt<;Q < < <Q < < <Q < < < ! l{<jm! gvh<hie< ,! H{<! ,dm<$M,! kjz! Ofib<! ,g{<O{ib, <!
sqvr<G,! ubqx<Xh<! ohiVlz< ,! Ge<ll< ,! liv<Huzq,! -Vlz< ,! uif<kq,! Yg<gitl< ,!
gilijz!Ngqbju!kQVl</!
osb<jg;<<< ! sqXfQv<ohVg<gq, VKU{<mig<gq, hix<ohVg<gq, hsqk<kQk<K~{<c,!
K~g<G{qHPg<ogiz<zq,!uxm<sqbgx<xq/ 
Chemical Constituents: Cuminaldehyde, cymene, terpenoids, essential oil. 
 
! !
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4/!kitqshk<kqvq< << !
Botanical name:Abies spectabilis 
Family name:Pinaceae 
English name: Flaurtia calapharacta 
Part used:!Leaf 
Sju;!giv<h<H!
ke<jl;<<< !ouh<hl!
hqvqU;!giv<h<H!
ohiKg<G{l<;< << << < !!
fisq!gth<hq{qgt<!fim<hm<m!-gisR<S!
!! uisl<!nVsq!uelr<giz<!.uQsquV!
!! Olglf<kl<!nk<kqSvl<!uqm<OmGf<!kitqs<sk<kiz<!
!! NGR<!Sgh<hqvs!ul</!
kQVl<! Ofib<gt<;Q < < <Q < < <Q < < < ! gpqs<sz< ,! Svl< ,! fim<hm<m! -Vlz< ,! -jvh<H,! uif<kq,! uib<U,!
nsQi{l< ,!nk<kqSvl<!kQVl</!-keiz<!Sgh<hqvsul<!d{<miGl</!
osb<jg;<<< !hsqk<kQk<K~{<c, ngm<Muib<ugx<xq, Ogijpbgx<xq, dvlig<gq/ 
 
4. kie<xqg<gib<< < << < << < <!
OuXohbv<gt<;< << << < !ng]l<,!nLkl, <!wvqgm<hzl<,!gf<Kge<,!sgkl<,!uqhQkgl< .!
Botanical name: Terminalia bellirica 
Family name: Combretaceae 
English name: Beleric myrobalans 
Part used:!Seed 
Sju;!Kuv<h<H!!
ke<jl;<<< !ouh<hl<!
hqvqU;!-eqh<H 
ohiKg<G{l<;< << << < !
sqzf<kquqml<!gilqbh<H{<!sQpie!Olgr<!
gzf<KuVl<!uikhk<kr<!giOzi.mzv<f<Kmzqz<!
De<xqg<gib<!ouh<h!Lkqvhqk<!Kr<gvg<Gf<!
kie<xqg<gib<!jgbqozMk<!kiz<!
N{qh<ohie<!Oleqg<!gpGl<!ytqBlqGl<!
Ogi{qg<ogit<!uikhqk<kg<!ogit<jgOhil<.kieqg<gib<!
ogi{<muv<g<G!OlglXl<!%xi!nex<xq{Bl<!
!!!!!g{<muv<g<G!uikl<Ohil<!gi{<!
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kQVl<!Ofib<gt<;Q < < <Q < < <Q < < < !sqzf<kqfR<S,!N{<Gxqh<H{< ,!out<jt,!GVkqbpz<Ofib< , utq!kQ!
Gx<xr<gtiz<! uVl<! Ofib<gt<! Ohil</dmx<G! npjgBl<! ytqjbBl<! ogiMk<K!
Lg<Gx<xr<gjtBl<!ke<eqjzh<hMk<Kl</!
osb<jg;<<< !Kuv<h<hq,!Ogijpbgx<xq,!lzlqtg<gq, dvlig<gq! 
Chemical Constituents: Beta-sitosterol, gallic acid, ellagic acid, ethyl gallate, galloyl 
glucose, chebulagic acid,Tanin. 
 
DRUG STORAGE:  
The trial drug “VISHNU CHAKRA MATHIRAI” is stored in clean and dry 
glass bottles. “KODIVELI THYLUM” is stored in dry, clean and narrow mouthed 
bottles.  
 
DISPENSING: 
The “MATHIRAI” is to be dispensed in dry, plastic container and the “OIL” is 
to be given in disposable pet bottles. 
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ANNEXURES -II 
QUALITATIVE AND QUANTITATIVE ANALYSIS 
BIO-CHEMICAL ANALYSIS OF VISHNU CHAKRA MATHIRAI                                      
(IN POWDER FORM) 
Preparation of the extract:   
 
  5gms of the drug was weighed accurately and placed in a 250ml clean beaker.  
Then 50ml of distilled water is added and dissolved well.  Then it is boiled well for 
about 10 minutes.  It is cooled and filtered in a 100ml volumetric flask and then it is 
made to 100ml with distilled water.  This fluid is taken for analysis. 
 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  
TEST FOR CALCIUM 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution. 
A white precipitate is 
formed. 
Indicates the 
presence of 
calcium. 
2. 
TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 
No white precipitate 
is formed. 
Absence of 
sulphate. 
3.  
TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution. 
No white precipitate 
is formed. 
Absence of 
chloride. 
4. 
TEST FOR CARBONATE 
The substance is treated with 
concentrated HCL. 
No Brisk 
effervescence is 
formed 
Absence of 
carbonate 
5. 
 
TEST FOR STARCH 
The extract is added with weak iodine 
solution. 
No Blue colour is 
formed. 
Absence of 
starch. 
6.  
TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
No blue colour is 
formed. 
Absence of ferric 
iron. 
7. 
TEST OF FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thio cyanide 
solution. 
Blood red colour is 
formed. 
Indicates the 
presence of 
ferrous iron. 
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8.  
TEST FOR PHOSPHATE 
The extract is treated with Ammonium 
Molybdate and concentrated nitric acid. 
No yellow 
precipitate is formed. 
Absence of 
phosphate. 
9.  
TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent. 
No Yellow 
precipitate is formed. 
Absence of 
Albumin. 
10.  
TEST FOR TANNIC ACID 
The extract is treated with ferric chloride. 
No Blue black 
precipitate is formed. 
Absence of 
tannic acid. 
11.  
TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract. 
It gets decolourised. 
 
Indicates the 
presence of 
unsaturated 
compound. 
12.  
TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 mts and add 8-10 drops of the extract 
and again boil it for 2 minutes. 
No colour change 
occurs. 
Absence of 
reducing sugars 
13.  
TEST FOR AMINO ACID; 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over the 
same and dried it well. 
Violet colour is 
formed. 
Indicates the 
presence of 
Amino acid. 
14. 
TEST FOR ZINC; 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc. 
15. 
TEST FOR MERCURY; 
The extract is treated with Ammonia and 
boil(till the ammonia caeses off) then add 
potassium Iodide 
No scarlet 
precepetate is formed 
Absence of 
Mercury 
 
Inference: 
  The given sample of “VISHNU CHAKRA MATHIRAI” contains Calcium, 
Chloride, Ferrous iron, Unsaturated compound, Amino acid. 
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ANNEXURE  - III 
PHARMACOLOGICAL ANALYSIS 
EFFECT OF  VISHNU CHAKRA MATHIRAI   WITH INJI JUICE AND HONEY ON 
CARRAGEENAN-INDUCED LOCALISED INFLAMMATORY PAIN IN RATS 
SUMMARY 
  The study plan was developed based on the guidelines of Vogel1 and also it has reference 
to Chao Ma and Jun-Ming Zhang2 and Walker et al. 3, Winter CA, Risley EA, Nuss GW. 
Carrageenin induced edema in hind paw of the rat as an assay for anti-inflammatory 
drugs. Proc Soc Exp Biol Med. 1962;111:544–7. 
Objective 
  To study the anti-inflammatory effect of   VISHNU CHAKRA MATHIRAI   were 
prepared WITH INJI JUICE AND HONEY in the rat model of Carrageenan-induced 
localized inflammation.  
Methods: 
Test System 
Species : Rat   
Strain : Albino Wister 
Age : 6-8 weeks at the time of dosing 
Total no. of Rats : 24 
Sex : Male 
Weight                   :    150 gm 
 
 The animals were housed in polypropylene cages with stainless steel top grills having 
facilities for holding pellet food and drinking water in bottle with stainless steel sipper tube. 
Each cage contained 6 rats. All rats had free access to potable water and standard pelleted 
laboratory animal diet ad libitum. Paddy husk was used as bedding material. The animals 
were divided into 5 groups (6 rats/group). Localized inflammatory pain was induced in all 
groups of animals by intraplantar injection of carrageenan (50 µl of 3% suspension).  
 One day before the experiment, three basal readings of hind paw in each rat were 
recorded. Group 1 received vehicle orally, Group 2 received a standard drug Diclofenac 
sodium (10 mg/kg i.p), whereas groups 3,4and 5 received VISHNU CHAKRA MATHIRAI. 
The doses of VISHNU CHAKRA MATHIRAI were prepared WITH INJI JUICE AND 
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HONEY, whereas Diclofenac sodium was dissolved in normal saline. After 30 min, the rats 
were challenged with subcutaneous injection of 0.1 ml of 1% w/v solution of carrageenan into 
the sub plantar region of left paw. The paw was marked with ink at the level of lateral 
malleolus and immersed in mercury up to the mark. The paw volume was measured at 0, 1, 2, 
3, 4, 5 and 6th hr after carrageenin injection using Digital Plethysmometer. The difference 
between initial and subsequent reading gave the actual edema volume.  
 
CONVERSION FORMULA: 
Human dose is 130 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
130 mg x 2(a) x 0.018 (b) = 2.34 (c) /150 gm of Rat 
2.34/1000x150 = 0.351 mg /kg/rat 
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of 
administration 
1 Vehicle Control INJI JUICE AND HONEY 1 ml 
 
2 Therapeutic Dose 0.351 mg /kg 
 
1 ml 
3 Middle  Dose 1.755mg/kg 1 ml 
 
4 High Dose 8.775mg/kg 1 ml 
 
EXPERIMENTAL DESIGN: 
Group-I:   Served as a negative control (0.1ml of 1% carrageenin) 
Group-II: Served as standard received Diclofenac sodium (10mg/kg, i.p) + 
                  (0.1ml of 1% carrageenin) 
Group-III: Received VISHNU CHAKRA MATHIRAI   were prepared WITH INJI 
JUICE AND HONEY 
                 (0.351 mg /kg) + (0.1ml of 1% carrageenin) 
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Group IV: Received  VISHNU CHAKRA MATHIRAI   were prepared WITH INJI 
JUICE AND HONEY 
                   (1.755mg/kg) + (0.1ml of 1% carrageenin) 
Group V: Received  VISHNU CHAKRA MATHIRAI   were prepared WITH INJI JUICE 
AND HONEY 
                   (8.755mg/kg) + (0.1ml of 1% carrageenin) 
TABLE: EFFECT OF VISHNU CHAKRA MATHIRAI   WITH INJI JUICE AND 
HONEY ON Carrageenin -INDUCED PAW EDEMA IN RATS 
 (BODY WEIGHT in gms) 
 
Group 
Control 
carrageenan 
+ Standard 
carrageenan 
+ VCM LD 
carrageenan 
+ VCM M D 
carrageenan 
+ VCM H D 
 
INITIAL BODY 
WEIGHT 
144.3±1.453 142.3±3.18 147.3±4.372 141.3±2.667 141.3±2.728 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one 
way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by comparing 
treated group with control group. 
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EFFECT OF VISHNU CHAKRA MATHIRAI WITH INJI JUICE AND HONEY ON 
Carrageenin -INDUCED PAW EDEMA IN RATS  
 
 
Group 
Mean paw 
volume before 
carrageenan 
injection 
Paw Volume after induction with carrageenin 
 
Increase in paw volume (ml) after carrageenan injection (mean ± SEM)/Percent 
inhibition of edema 
0 min 30 min 1h 2h 3h 4h 5h 6h 
 
Control 
2.967± 
0.2437 
7.24± 
0.4997 
8.11± 
0.2775 
8.087± 
0.1683 
8.147± 
0.2439 
8.26± 
0.2212 
8.347± 
0.1162 
7.963± 
0.1978 
 
Standard 
3.223± 
0.1934 
7.227± 
0.4068 
7.71± 
0.1253 
7.44± 
0.2274 
7.343± 
0.09207* 
6.893± 
0.04667** 
6.607± 
0.1397** 
6.013± 
0.4917** 
carrageenan  
+VCM  LD 
3.123± 
0.2739 
7.707± 
0.6244 
7.603± 
0.1586 
8.687± 
0.2285 
8.683± 
0.1641 
7.873± 
0.2367 
7.973± 
0.07424 
7.22± 
0.1692 
carrageenan  
+VCM M D 
3.163± 
0.0928 
7.153± 
0.2743 
7.353± 
0.07055 
7.577± 
0.2843 
7.187± 
0.03333** 
7.3± 
0.1908* 
6.893± 
0.4939* 
6.09± 
0.3256** 
carrageenan  
+ VCM H D 
3.423± 
0.277 
7.027± 
0.1179 
7.453± 
0.2544 
7.52± 
0.1804 
6.807± 
0.1298*** 
7.16± 
0.2013** 
33.23± 
27.05** 
5.833± 
0.2987** 
 
 Values are expressed as the mean ± S.D. Statistical significance (p) calculated by 
one way ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by 
comparing treated group with control group. 
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EFFECT OF VISHNU CHAKRA MATHIRAI WITH INJI JUICE AND HONEY ON 
Carrageenin -INDUCED PAW EDEMA IN RATS  
 
         
                  Only Carrageenin                                        Carrageenin+  STD 
     
          
               Carrageenin + L.D                                                       Carrageenin + M.D 
 
Carrageenin + M.D 
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EVALUATION OF THROMBOLYTIC EFFECTS OF VISHNU CHAKRA MATHIRAI 
WITH INJI JUICE AND HONEY IN THE CARRAGEENAN-INDUCED RAT TAIL 
THROMBOSIS MODEL 
EXPERIMENTAL ANIMALS: 
 Male Albino rats were procured from Bangalore and were housed in microloan boxes in a 
controlled hygienic environment at temperature 25 ± 2°C and 12 hr dark/light cycle. The study 
was conducted after obtaining institutional animal ethical committee’s clearance (IAEC No: ----
---). As per the standard practice, the rats were segregated and quarantined for 15 days before 
the commencement of the experiment. They were fed on standard healthy diet and water ad 
libitium. The acute toxicity studies carried out confirmed that the VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY are not toxic even at the concentration of 
6000 mg/kg. 
 
Grouping of animals: 
  The rats were divided into five groups with six rats in each. The groupings are as follows: 
Groups Description Drug Dose 
I Control - 
II κ – carrageenan only - 
III κ – carrageenan +Streptokinase inj 30,000 IU 
IV κ – carrageenan + VCM 0.35 mg/kg 
V κ – carrageenan + VCM 1.75 mg/kg 
VI κ – carrageenan + VCM 8.77 mg/kg 
 
THROMBUS INDUCTION: 
 Rats with tail length more than 15 cm were chosen for the study. Experimental rats were 
anaesthetized with i.p injection of ketamine hydrochloride (100 mg/kg). To attain effective clot 
formation κ – carrageenan (1 mg/kg) dissolved in saline was injected into the rat tail vein at a 
site 12 cm from the tip of the tail with a ligation. After a period of 10 minutes, the ligature was 
removed. The length of the infarct was monitored for thrombus formation. Once thrombus was 
formed, the animals were treated with respective extracts and monitored for the reduction in the 
length of the thrombus in rat tail for 10 days.1 
1. Kishore K: In vitro and in vivo screening methods for antithrombotic agents. American Journal 
of Phytomedicine and Clinical Therapeutics 2013; 1(5): 497-506. 
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  At the end of the study, the rats were sacrificed after an overnight fasting. The blood of the 
animals was collected by heart puncture and the serum separated was used for the estimation of 
haematological parameters associated with thrombolysis. 
 
Estimation of bleeding time and clotting time: 
 At the end of the period, bleeding time was determined for each animal using Duke’s 
method while clotting time was determined by Ivy’s method as reported by Ibu and Adeniyi 2. 
For bleeding time, the tip of the tail of each rat was cut to cause bleeding. A stopwatch was 
started as soon as animal began to bleed. A blotting paper was used to wipe off blood every 15 
seconds. As soon as bleeding ceased the stopwatch was stopped and the time recorded as 
bleeding time for that particular animal. For the clotting time, a drop of blood from the tail of 
each rat was placed on a clean glass slide and a stopwatch was started at the same time. A pin 
was passed across the drop of blood once every 15 seconds. As soon as threads of fibrin were 
noticed, the stopwatch was stopped and the time recorded as the clotting time for that particular 
rat. 
2. Ibu JO and Adeniyi KO: A Manual of Practical Physiology, Published by Jos University 
Press, Jos. 1989; 126. 
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TABLE 1: INFARCT LENGTH FORMED AND LYSED BY VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY  
Group Treatments 
Tail length 
(cm) 
Infarct tail length 
(cm) 
Before 
lysis 
Before 
lysis 
I Control 15.0 NA NA 
II κ – Carrageenan 15.6 15.4 NA 
III κ - Carrageenan + Streptokinase 15.2 14.8 4.6 
IV κ – Carrageenan + VCM 15.5 15.1 12.7 
V κ – Carrageenan + VCM 15.0 14.2 8.9 
VI κ – Carrageenan + VCM 15.1 14.5 6.5 
 
 
 
FIG. 1: PERCENT CLOT LYSIS BY IN EXPERIMENTAL RATS 
Group III – Streptokinase treated   Group IV – VCM L.D   Group V – VCM M.D 
Group VI – VCM H.D 
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TABLE 2: COAGULATION TIME PARAMETERS IN EXPERIMENTAL RATS 
Group Treatments Bleeding time Clotting time 
I Control 9 min 35 s 5 min 20 s 
II κ – Carrageenan 6 min 50 s 3 min 35 s 
III 
κ - Carrageenan + 
Streptokinase 
19 min 25 s 8 min 30 s 
IV κ – Carrageenan + VCM L.D 10 min 30 s 4 min 45 s 
V κ – Carrageenan + VCM  M.D 12 min 25 s 5 min 55 s 
VI 
κ – Carrageenan + VCM    
H.D 
15 min 35 s 7 min 36 s 
 Normal values 3 to 10 min 2 to 5 min 
 
 
 
FIG. 2: COAGULATION TIME PARAMETERS IN EXPERIMENTAL RATS 
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VISUAL MANIFESTATION OF THROMBUS 
 
      
CONTROL                                          ONLY CARRAGEENAN 
 
CARRAGEENAN + STD                                CARRAGEENAN + VCM L.D    
  
CARRAGEENAN + VCM M.D              CARRAGEENAN + VCM H.D 
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ANNEXURE – IV 
 
ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF CHAKRA MATHIRAI WITH INJI JUICE                       
AND HONEY 
 
Table 1. Test substance details 
Name of the test substance 
 
CHAKRA MATHIRAI WITH INJI 
JUICE AND HONEY 
 
 
Colour of the test substance BLACK 
Nature of the test substance Powder 
 
Table 2. Experimental protocol 
Name of the study Acute toxicity 
Guideline followed OECD 423 method-acute toxic class 
method 
Animals Healthy young adult female wister rats, 
nulliparous, non-pregnant 
Body weight 150-200 g 
Sex                       female 
Administration of dose and volume 2000 mg/kg in 200g body weight, single dose in 1 ml 
Number of groups and animals 
5 groups and 3 animals in each group 
100mg,250mg,500mg,1000mgand 
2000mg/kg 
Route of administration Oral Cavage (po) 
Vehicle INJI JUICE AND HONEY 
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Table3. Housing and feeding conditions 
Room temperature 22°C  ±  3°C 
Humidity 40-60% 
Light 12 h : 12h (light : dark cycle) 
Feed 
Standard laboratory animal food pellets 
with water ad libitum 
 
Table 4. Study period and observation parameters 
Initial once observation First 30 minutes and periodically 24 h 
Special attention First 1-4 h after drug administration 
Long term observation Upto 14 days 
Direct observation parameters 
Tremors, convulsions, salivation, 
diarrhea, lethargy, sleep and coma. 
Additional observation parameters 
Skin and fur, eyes and mucous 
membrane, respiratory, circulatory, 
autonomic and central nervous systems, 
somato motor activity and behavior 
pattern etc. 
  
The time of death, if any, is recorded. (Complete observations: annexure I). After 
administration of the drug, food is withheld for a further 1-2 hours. 
 
Study procedure 
  Acute oral toxicity was performed as per organization for economic co-
operation for development (OECD) guideline 423 method. The CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY was administered in a single dose 
by tuberculin syringe. Animals are fasted 3 h prior to dosing (food was withheld for 3 
h but not water). Following the period of fasting animals was weighed and test 
substance was administered orally at a dose of 100mg,250mg,500mg,1000mgand 
2000mg/kg. After the CHAKRA MATHIRAI WITH INJI JUICE AND HONEY 
administration, food was withheld 2 h in mice. Animals are observed individually 
after at least once during the first 30 minutes, periodically during the first 24 hrs, with 
special attention given during the first 4 hrs, and daily thereafter, for a total of 14 
days.  
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REPORT 
Toxicological evaluation of CHAKRA MATHIRAI WITH                                             
INJI JUICE AND HONEY 
 
Table:5 Effect of CHAKRA MATHIRAI WITH INJI JUICE AND HONEY on 
acute toxicity test in female rats. 
 
 
RESULT: 
  From acute toxicity study it was observed that the administration of 
CHAKRA MATHIRAI WITH INJI JUICE AND HONEY to Female Wister rats 
did not induce drug-related toxicity and mortality in the animals up to 2000mg/kg in 
200g female Wister rats. So No-Observed-Adverse-Effect- Level (NOAEL) of 
CHAKRA MATHIRAI WITH INJI JUICE AND HONEY is 2000 mg/kg equal to 
human dose 
S.N 
 
 
Response 
Head Body Tail 
Before After Before After Before After 
1 Alertness Normal Normal Normal Normal Normal Normal 
2 Grooming Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response Normal Normal Normal Normal Normal Normal 
5 Pain response Normal Normal Normal Normal Normal Normal 
6 Tremors Absent Absent Absent Absent Absent Absent 
7 Convulsion Absent Absent Absent Absent Absent Absent 
8 Righting reflux Normal Normal Normal Normal Normal Normal 
9 Gripping strength Normal Normal Normal Normal Normal Normal 
10 Pinna reflux Present Present Present Present Present Present 
11 Corneal reflux Present Present Present Present Present Present 
12 Writhing Absent Absent Absent Absent Absent Absent 
13 Pupils Normal Normal Normal Normal Normal Normal 
14 Urination Normal Normal Normal Normal Normal Normal 
15 Salivation Normal Normal Normal Normal Normal Normal 
16 Skin colour Normal Normal Normal Normal Normal Normal 
17 Lacrimation Normal Normal Normal Normal Normal Normal 
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DISCUSSION 
 
CHAKRA MATHIRAI WITH INJI JUICE AND HONEY was 
administered single time at the doses of 100mg, 250mg, 500mg, 1000mg and 
2000mg/kg to female Wister rats and observed for consecutive 14 days after 
administration. Doses were selected based on the pilot study and literature review. All 
animals were observed daily once for any abnormal clinical signs. Weekly body 
weight and food consumption were recorded. No mortality was observed during the 
entire period of the study. Data obtained in this study indicated no significance 
physical and behavioral signs of any toxicity due to administration of CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY at the doses of 100 mg, 250mg 
,500mg, 1000mg and 2000mg/kg to female Wister rats. 
 
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand held 
activity were observed. Home cage activities like Body position, Respiration, Clonic 
involuntary movement, Tonic involuntary movement, Palpebral closure, Approach 
response, Touch response, Pinna reflex, Sound responses, Tail pinch response were 
observed. Handheld activities like Reactivity, Handling, Palpebral closure, 
Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominal tone, Limb tone 
were observed. Functional and behavioral examination was normal in all treated 
groups. Food consumption of all treated animals was found normal as compared to 
normal group. 
 
SUMMARY & CONCLUSION: 
Summary: 
The present study was conducted to know single dose toxicity of CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY on female Wister rats. The study 
was conducted using 15 female Wister rats. The female animals were selected for 
study of 8- 12 weeks old with weight range of within ± 20 % of mean body weight at 
the time of randomization. The groups were numbered as group I, II, III, IV and V 
and dose with 100mg, 250mg, 500mg, 1000mg and 2000mg/kg of CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY. The drug was administered by 
oral route single time and observed for 14 days. Daily the animals were observed for 
clinical signs and mortality.  
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There were no physical and behavioral changes observed in Female Wister 
rats during 14 days. Mortality was not observed in any treatment groups. 
 
CONCLUSION: 
The study shows that CHAKRA MATHIRAI WITH INJI JUICE AND 
HONEY did not produce any toxic effect at dose of 100mg, 250mg, 500mg, 1000mg 
and 2000mg/kg to rats. So No-Observed-Adverse-Effect-Level (NOAEL) of 
CHAKRA MATHIRAI WITH INJI JUICE AND HONEY is 2000 mg/kg. 
 
7.0 ABBREVIATIONS 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o  peros 
ML  Milliliter 
%   percentage 
R&D   Research and Development 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of 
Experiments on Animals 
 
 
8.0 REFERENCES: 
 
1. OECD. Guideline for Testing of Chemicals 423, Acute oral toxicity (acute 
toxic class method). December 2001. 
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SUB-ACUTE TOXICITY STUDY IN WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF   VISHNU CHAKRA MATHIRAI WITH INJI 
JUICE AND HONEY  
Objective 
 The objective of this study is to evaluate the toxic effects, if any, as a result of 
the repeated once daily oral administration of   VISHNU CHAKRA MATHIRAI 
WITH INJI JUICE AND HONEY to Wister Albino rats for a minimum period of 
28 consecutive days. This study will provide information on any major toxic effects, 
target organs and a rationale for concluding the No-Observed-Adverse-Effect-Level 
(NOAEL) and/or No Observed Effect Level (NOEL) / LOEL (Low Observed Effect 
Level) and risk assessment in humans. 
1. Test Guidelines  
This study plan is prepared as per the following guidelines: 
Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
OECD – 407 – Repeated dose 28-day Oral Toxicity Study in Rodents, Adopted 3 
October, 2008. 
1.1. Test System Details 
Species : Rat 
Strain  : Wister Albino  
Source    : Sree Venkateshwara Enterprises Pvt Ltd, Bangalore  
Age : 6-8 weeks  
Sex : Male / Female (nulliparous and non-pregnant) 
Body weight   : 0to 180.0 g 
1.2.  Acclimatization 
Animals will be allowed to acclimatize to the experimental room conditions for five 
days prior to the commencement of dosing. During the acclimatization period, the 
animals will be observed daily for any apparent adverse clinical signs. Prior to 
assignment to the study and commencement of treatment, a detailed physical health 
examination will be performed on all animals by a veterinarian and animals with any 
evidence of ill health or poor physical condition will not selected for the study. 
1.3. Randomization and Grouping 
On the starting day of dosing, the animals will be weighed and health examination 
will be performed by veterinarian. Animals will be randomly allocated to different 
groups according to their body weight by using MS-Excel sheet as described in the 
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randomization SOP. Animals will be divided into four groups (vehicle control, low, 
intermediate, and high dose). At the initiation of the treatment, the body weight 
variation between the groups did not exceed ±20% of the mean weight of each sex. 
1.4. Animal Identification 
In each cage, animals will be identified with numbers by marking at the base of the 
ear. The cages will be identified with an attached colored cage label showing study 
number, study code, group number, sex, dose, strain, species, cage number, route of 
administration and animal number. 
2. Animal Husbandry 
2.1. Animal Welfare and approval 
The study was approved by the IAEC (SLS) and Committee for the Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA registration number: 
Abc14).Their recommendations regarding animal care and handling will be followed. 
2.2. Environmental Conditions 
The temperature of the experimental room will be maintained at 22±30C and the 
relative humidity between 30-70 %. The photoperiod will be 12 hours light and 12 
hours dark cycles  
2.3. Housing Conditions 
Two animals will be housed in autoclaved polypropylene rat cages (Size in mm=L x 
W x H: 430 x 290 x 160) using paddy husk as the bedding material. Each cage will be 
fitted with a top grill having provision for keeping rodent pellet feed and an 
autoclaved polypropylene water bottle with stainless steel drinking nozzle. Cages will 
be placed on 3-tier racks and cage rotation will be performed every week. Cages will 
be changed at least twice a week. The cages and water bottles will be cleaned and 
autoclave sterilized. 
2.4. Sanitation 
Each day, the floor of the animal room will be swept and mopped. Cages and bedding 
material will be changed once in three days and water bottles will be changed daily. 
All the experimental procedures will be done in a clean environment. 
2.5. Feed 
The experimental animals will be provided with irradiated rodent pellet feed ad 
libitum supplied from Sai feeds Pvt ltd, Chennai . Feed will be withheld for four hours 
prior to blood collection and necropsy. 
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2.6. Drinking Water 
Animals will be provided with filtered drinking water ad libitum  passed through 
water filter system (Aquaguard™) in autoclaved polypropylene bottles. Water bottles 
will be changed daily. Microbial analysis of water will be carried out once monthly 
and the report is maintained in the study file. 
3. Personnel Safety 
All personnel handling animals undergo regular medical examination. Protective 
clothing like apron, face mask, head cap, and gloves will be used to maintain hygienic 
conditions. 
4. Materials and Methods  
4.1. Preparation of Dose formulation 
The dose formulation will be prepared under aseptic conditions as per SLS, SOP.  
4.2. Route of Administration and Justification 
Administration will be by oral gavage, as it is one of the possible routes of exposure. 
4.3. Frequency and Duration of Administration  
Once daily for 28 consecutive days 
4.4. Dosing Procedure 
The test item will be administered in once daily by oral gavage using a suitable 
intubation cannula fitted with a graduated syringe. The scheme of dosing and sacrifice 
time points are presented in the below below Table. 
4.5. Experimental Procedures 
All experimental procedures will be performed in accordance with the Study plan and 
Standard Operating Procedures (SOPs) of SLS. 
 
CONVERSION FORMULA: 
Human dose is 130 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
130 mg x 2(a) x 0.018 (b) = 2.34 (c) /150 gm of Rat 
2.34/1000x150 = 0.351 mg /kg/rat 
Experimental Doses Calculated as per the standard procedures are 
141 
 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
 
1 Vehicle Control INJI JUICE AND 
HONEY 
1 ml 
 
2 Therapeutic Dose 0.351 mg /kg 
 
1 ml 
3 Middle  Dose 1.755mg/kg 1 ml 
 
4 High Dose 8.775mg/kg 1 ml 
 
 
Experimental Design 
 
5. Observations 
Animals will be observed daily throughout the treatment period at regular intervals. 
During the treatment period, animals will be observed twice daily for any clinical 
signs of toxicity, morbidity and mortality. All the surviving animals will be sacrificed 
at the end of scheduled period and subjected to gross necropsy and histopathological 
evaluations. 
5.1. Clinical Signs 
All the animals will be subjected to cage-side (home-cage) observations twice a day 
for any clinical signs of toxicity, preferably at the same time each day and considering 
the peak period of anticipated effect. In addition to home cage observations, a detailed 
Group 
No. Group 
Dose                          
(mg/kg  
b.wt /day) 
No. of 
Animals 
Male Female 
G1 Vehicle control Inji Juice And Honey 5 
5 
G2 
Low dose of    VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE 
AND HONEY 
0.351 mg/kg 
   
5 5 
G3 
Intermediate dose   VISHNU 
CHAKRA MATHIRAI WITH 
INJI JUICE AND HONEY   
1.755mg/kg 5 5 
G4 
High dose    VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE 
AND HONEY   
8.775mg/kg 5 5 
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clinical examination will be performed once prior to dosing and weekly thereafter 
during treatment period.  
5.2. Morbidity/ Mortality 
All animals will be examined twice a day for mortality and signs of morbidity.  
5.3. Body Weights 
Body weights will be recorded at the beginning of acclimatization, before 
randomization,  there after at weekly intervals and at the time of necropsy. 
5.4. Feed Consumption 
Feed consumption will be calculated on a weekly basis throughout the study period. 
5.5. Haematology and Clinical Biochemistry  
Hematology and clinical biochemistry tests will be performed with terminally 
collected blood samples on day-29 from all animals. Animals will be deprived of feed 
overnight and blood samples will be collected by tapping the ear for visibility of the 
vein site and inserted the needle into the marginal ear vein and collected the blood 
into micro centrifuge tube. Approximately 0.5 ml of blood will be collected in vials 
containing 1% EDTA (20µl) as an anticoagulant for hematological analysis. 
Approximately 2 ml blood will be collected from each animal in micro centrifuge 
tubes containing 15µl of heparin (19 units) and the plasma will be separated by 
centrifugation at 4000 rpm for ten minutes at 4oC. The plasma will be stored at -20 oC 
± 2 and used for all clinical chemistry analysis. 
5.6. Hematology 
Erythrocyte count (RBC), Total Leucocyte count (WBC), Hemoglobin (Hb), 
Hematocrit (HCT), Mean Corpuscular Volume (MCV), Mean Corpuscular 
Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC) and 
Platelet (PLTC). 
5.7. Clinical Biochemistry  
Glucose, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), 
Alkaline phosphatase (ALP), Total protein, Albumin, Creatinine, Urea, Cholesterol, 
Triglycerides, Sodium, Potassium, Calcium, and  Chloride. 
5.8 Pathology 
All animals will be euthanized by CO2 asphyxiation and subjected to necropsy under 
the supervision of the veterinary pathologist. Different tissues/organs of thoracic, 
abdominal and cranial cavities will be examined for any gross pathological changes. 
Tissues from vehicle control and high dose groups will be subjected to detailed 
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histopathological analysis (Ovaries/ testes,  kidneys, liver, lungs). The organs will be 
fixed using Bouin’s (reproductive organs) and 10% neutral buffered formalin 
(kidneys, liver, spleen, lungs).Processing of tissue will be done by spin tissue 
processer, embedding of the tissue by tissue embedder. The tissues will be initially 
trimmed to 10-20µ thickness and later 3-6µ to obtain thinner tissue sections by using 
rotary microtome. Haematoxylin and Eosin staining will be performed for all tissues. 
5.8. Organ Weights 
Absolute weights of adrenal glands, brain, ovaries/testes, epididymis/uterus, heart, 
kidneys, liver, spleen and lungs will be recorded for all the animals after trimming 
adherent tissue immediately after dissection from the animal. Paired organs will be 
weighed together. Relative weights of these organs against fasting animal body 
weights will be calculated and reported. 
6. Data Compilation  
Data will be summarised in a tabular form showing the number of animals, 
experimental design, dose groups, dose volume and concentrations, test item and 
vehicle control details. All findings like clinical signs, mortality and morbidity data, 
time of death, body weights, feed consumption, clinical signs, and necropsy and 
pathology observations will be recorded and given in the final report. One original 
copy of the final report is issued to the sponsor.  
7. Statistical Analysis 
All the parameters of treated groups of both sex, viz. body weight, feed consumption, 
organ weights (absolute and relative), biochemical parameters, and hematology 
parameters will be analyzed using SPSS software, version 16.0 by using one-way 
ANOVA test with multiple comparison (vehicle controls treated groups) in the study 
report, and p value < 0.05 is considered as statistically significant.  
 
8. References 
1. Committee for the Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA) guidelines for Laboratory Animal Facility, The Gazette of India, 1998. 
2. Hayes AW, 2000. Principles and Methods of Toxicology, 4th ed., Taylor and Francis, 
London. 
3. Karl-Heinz Diehl, R. H. (2001). A Good Practice Guide to the Administration of 
Substances and Removal of Blood, Including Routes and Volumes. journal of applied 
toxicology , 15-23. 
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MATERIALS AND METHODS 
         ESTIMATION OF HEMATOLOGICAL PARAMETERS: 1 
Collection of blood for hematological studies 
After the treatment period the animals were anaesthetized by ketamine hydrochloride 
and the blood was collected from Retro-orbital sinus by using capillary into a 
centrifugation tube which contains EDTA for haematological parameters The 
haematological parameters like RBC, WBC and Hb percentage, Differential cell 
count, MCV, MCHC, Hematocrit, MCH, platelet count were estimated by the 
following procedures. 
1. ENUMERATION OF RED BLOOD CELLS: 1    Ramnic 2007) 
Reagents : RBC diluting fluid 
       Procedure: 
         Using a red blood cell pipette of haemocytometer, well mixed blood was drawn 
up to 0.5 mark and RBC diluting fluid was taken up to mark II. The fluid blood 
mixture was shaken and transferred onto the counting chamber. The cells were 
allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get 
dried. Using 45X or high power objective the RBC’s were counted uniformly in the 
larger corner squares.   
The cells were expressed as number of cells x1012/l 
2. ENUMERATION OF WBC: 2    John 1972) 
      Reagents: 
 Turk’s fluid: Turk’s fluid was prepared by mixing 2ml of acetic acid with 100 
ml of distilled water. To this 10 drop of aqueous methylene blue 3 %    w/v) was 
added. This solution haemolysis the red cells due to acidity so that counting of white 
cells becomes easy. 
Procedure:     
              Using a white blood cell pipette of haemocytometer, well mixed blood was 
drawn up to 0.5 mark and WBC diluting fluid was taken up to mark II. The fluid 
blood mixture was shaken and transferred onto the counting chamber. The cells were 
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allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get 
dried. 
 Using 10X or low power objective the WBC’s were counted uniformly in the 
larger corner squares.  
 The cells were expressed as number of cells/10mm. 
3. DIFFERENTIAL LEUCOCYTE COUNT: 3      John 1972) 
Reagent: 
              Leishmann’s stain: 150mg of powdered leishmann’s stain was dissolved in 
133ml of acetone free methanol. 
Procedure: 
 A blood film stained with leishmann’s stain was examined under oil 
immersion and the different types of WBCs were identified. The percentage 
distribution of these cells was then determined. Smears were made from anticoagulant 
blood specimens and stained with leishmann’s stain. The slides were preserved for 
counting the number of lymphocytes and neutrophils, per 100 cells were noted.  
 From the different Leukocyte count and WBC count, absolute lymphocyte and 
neutrophil count were calculated. 
                                 Number of neutrophils  
 Absolute neutrophil count =   _______________________________   x  TWBC 
                             100  
                                                                  Number of lymphocytes  
 Absolute lymphocyte count =   _______________________________ x TWBC 
                             100 
 
DETERMINATION OF BIOCHEMICAL PARAMETERS: 
For assessment of biochemical parameters, blood samples were collected from the 
animals by puncturing the retro-orbital plexus and centrifuged. The serum collected 
after centrifugation was analyzed for various biochemical parameters like SGOT, 
SGPT, ALP,TC.TG,HDL All of the above biochemical parameters were estimated 
using semi autoanalyzer (Photometer 5010 V5+, Germany) with enzymatic kits 
procured from Piramal Healthcare limited, Lab Diagnostic Division, Mumbai, India. 
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1. Total Cholesterol (TC)  
 Principle 
Determination of cholesterol is done after enzymatic hydrolysis and oxidation. 
The colorimetric indicator is quinoneimine, which is generated from 4-
aminoantipyrine and phenol by hydrogen peroxide under the catalytic action of 
peroxidase (trinder’s reaction). 
Cholesterol ester + H2O       CHE       Cholesterol + Fatty acid 
Cholesterol + O2          CHO      Cholesterol-3-one +H2O2 
2H2O2  + 4- Amino antipyrine + Phenol      POD          Quinonelimine + 4 H2O2 
Method  
 CHOD-PAP: Enzymatic photometric test 
Table 6: Reagents 
Goods buffer (pH 6.7) 50 mmol/ l 
Phenol 5 mmol/l 
4-aminoantipyrine 0.3 mmol/l 
Cholesterol estrase >  200 U/l 
Cholesterol oxidase >  100 U/l 
Peroxidase 3 KU/l 
Standard (5.2 mmol/l) 
 
Assay procedure 
a. 1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b.  Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C   for 5 min. 
d. Read the test sample. 
NORMAL RANGE: < 200 mg/dl in serum.      
1. Deeg R, Ziegenhorn J, Kinetic enzymatic method for automated determination of total 
cholesterol in serum, Clin. Chem., 1983, 29:1798-802. 
2. Triglycerides 
Principle 
Determination of triglycerides (TG) alters enzymatic splitting with lipoprotein 
lipase. Indicator is quinoneimine which is generated from 4-aminoantipyrine and 4- 
chlorophenol by hydrogen peroxidase under the catalytic action of peroxidase. 
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Triglycerides              LPL           Glycerol + fatty acid 
Glycerol + ATP              GK            Glycerol-3-phosphate+ ADP 
Glycerol-3-phosphate +O2         GPO         Dihydroxyaceton phosphate + H2O2 
2H2O2  + 4- Amino antipyrine + 4- chlorophenol         POD     Quinonelimine + HCL + 
4H2O2 
Method 
 Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO). 
Reagents 
Components and concentrations in the test Goods buffer pH 7.2, 50 mmol/ l 
Table 7: Reagents 
4-chloroPhenol 4 mmol/l 
ATP 2 mmol/l 
Mg2+ 15 mmol/l 
Glycerokinase > 0.4 Kµ/l 
Peroxidase > 2 Kµ/l 
Lipoprotein lipase > 4 Kµ/l 
4-aminoantipyrine 0.5 mmol/l 
Glcerol-3-phosphate- oxidase > 1.5Kµ/l 
Standard (2.3 mmol/l) 
 
Assay procedure 
a.  1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b. Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample. 
 Normal Range: < 200 mg/dl in serum. 
1. Cole T.G, Klotzsch S.G, Mcnarmara J, Measurement of triglyceride concentration, In 
Rifai N, Warnick G.R, Dominiczak M.H, Handbook of lipoprotein testing, 
Washington:AACC, Press, 1997, 115-26. 
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3. HDL Cholestrol 
 Principle  
Chylomicrons, VLDL and LDL are precipitated by adding phosphotungstic acid 
and magnesium ions to the sample. Centrifugation leaves only the HDL in the 
supernatant. The cholesterol content in it is determined enzymatically. 
Method 
Phosphotungstic acid precipitation method. 
Table 8: Reagents 
Phosphotungstic acid 0.55 mmol/l 
Magnesium chloride 25 mmol/l 
Assay procedure 
A.  Preparation of supernatant for the HDL-CHL estimation 
    Added 200 µl of serum to the 500 µl of HDL-Cholesterol precipitating reagent 
(from HDL kit) in 1.5 ml centrifuge tube and mixed well. Centrifuged the above 
solution at 4000 rpm for 10 min. 
B. Preparation of test sample for the estimation of HDL-Cholesterol 
a. Taken 1000 µl of reagent-1 (from cholesterol kit) in a 5 ml test tube. 
b. Added, 100 µl of supernatant from above centrifuged solution 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample.  
Normal Range: > 60 mg/dl in serum. 
1. Friedewald W.T, Levy R.T, Frederickson D.S, Estimation of VLDL and LDL 
cholesterol, Clin. Chem., 1972, 18:499-502. 
 
4. ESTIMATION OF SERUM GLUTAMATE PYRUVATE TRANSAMINASES 
(SGPT/ ALT) 
1. Determination of aspartate aminotransferase (AST) 
      Aspartate aminotransferase, also known as Glutamate Oxaloacetate 
Transaminase (GOT) catalyses the transamination of L-aspartate and α keto glutarate 
to form oxaloacetate and L- glutamate. Oxaloacetate formed is coupled with 2,4- 
Dinitrophenyl hydrazine to form hydrazone, a brown coloured complex in alkaline 
medium which can be measured colorimetrically. 
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Reagents  
Buffered aspartate  (pH 7.4); 2,4- DNPH reagent;  4N sodium hydroxide;  working 
pyruvate standard; solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with 
purified water). 
 
Procedure  
  Rietman and Frankle method was adopted for the estimation of SGOT. 
(Reitmann S, Frankel S, 1957. A colorimetric method for the determination of serum 
oxaloacetic and glutamic pyruvate transminases. American Journal of Clinical 
Pathology.28: 56-63.The reaction systems used for this study included blank, 
standard, test (for each serum sample) and control (for each serum sample). 0.25 ml of 
buffered aspartate was added into all the test tubes. Then 0.05 ml of serum was added 
to the test group tubes and 0.05 ml of working pyruvate standard into the standard 
tubes. After proper mixing, all the tubes were kept for incubation at 37oC for 60 min, 
after which 0.25 ml each of 2,4- DNPH reagent was added into all the tubes. Then, 
0.05 ml of distilled water and 0.05 ml of each serum sample was added to the blank 
and the serum control tubes respectively. The mixture was allowed to stand at room 
temperature for 20 min. After incubation, 2.5 ml of solution I was added to all test 
tubes. Mixed properly and optical density was measured in a spectrophotometer at 
505 nm within 15 min. 
The enzyme activity was calculated as:-  
AST (GOT) activity in IU/L) = [(Absorbance of test - Absorbance of control)/ 
(Absorbance of standard - Absorbance of blank)] x concentration of the standard         
 
2.  Determination of alanine aminotransferase (ALT) 
 Alanine aminotransferase, also known as Glutathione Peroxidase (GPT) 
catalyses the transamination of L-alanine and α keto glutarate to form pyruvate and L- 
Glutamate. Pyruvate so formed is coupled with 2,4 – Dinitrophenyl hydrazine to form 
a corresponding hydrazone, a brown coloured complex in alkaline medium which can 
be measured colorimetrically. 
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Reagents 
  Buffered alanine (pH 7.4), 2,4–DNPH, 4N sodium hydroxide, working 
pyruvate standard, solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with 
purified water). 
Procedure  
 Rietman and Frankle method was dopted for the estimation of SGPT. The 
reaction systems used for this study included blank, standard, test (for each serum 
sample) and control (for each serum sample). 0.25 ml of buffered alanine was added 
into all the test tubes. This was followed by the addition of 0.05 ml of serum into the 
test group tubes and 0.05 ml of working pyruvate standard into the standard tubes. 
After proper mixing, all the tubes were kept for incubation at 37oC for 60 minutes, 
after which 0.25 ml each of 2,4- DNPH reagent was added into all the tubes. Then, 
0.05 ml of distilled water and 0.05 ml of each serum sample was added to the blank 
and the serum control tubes respectively. The mixture was allowed to stand at room 
temperature for 20 min. After incubation, 2.5 ml of solution I was added to all test 
tubes. Mixed properly and optical density was read against purified water in a 
spectrophotometer at 505 nm within 15 min. 
The enzyme activity was calculated as:- ALT (GPT) activity in IU/L) = [(Absorbance 
of test - Absorbance of control)/ (Absorbance of standard - Absorbance of blank)] x 
concentration of the standard.        
            
3. Determination of alkaline phosphatase (ALP) 
  Alkaline phoshatase from serum converts phenyl phosphate to inorganic 
phosphate and phenol at pH 10.0. Phenol so formed reacts in alkaline medium with 4-
aminoantipyrine in presence of the oxidising agent potassium ferricyanide and forms 
an orange-red coloured complex, which can be measured spectrometrically. The color 
intensity is proportional to the enzyme activity. 
 
Reagents: 
Buffered substrate 
Chromogen Reagent 
Phenol Standard, 10 mg% 
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Procedure: 
  ALP was determined using the method of Kind (Kind PRM, King EJ, 1972. 
In-vitro determination of serum alkaline phosphatase. Journal of Clinical Pathology 7: 
321-22\). The working solution was prepared by reconstituting one vial of buffered 
substrate with 2.2 ml of water. 0.5 ml of working buffered substrate and 1.5 ml of 
purified water was dispensed to blank, standard, control and test. Mixed well and 
incubated at 370C for 3 min. 0.05 ml each of serum and phenol standard were added 
to test and standard test tubes respectively. Mixed well and incubated for 15 min at 
370C. Thereafter, 1 ml of chromogen reagent was added to all the test tubes. Then, 
added 0.05 ml of serum to control. Mixed well after addition of each reagent and the 
O.D of blank, standard, control and test were read against purified water at 510 nm. 
Serum alkaline phosphatase activity in KA units was calculated as follows  
[(O.D. Test-O.D. Control) / (O.D. Standard- O.D. Blank)] x 10 
 
4. Determination of bilirubin  
  In toxic liver, bilirubin levels are elevated. Hyperbilirubinemia can result from 
impaired hepatic uptake of unconjugated bilirubin, such a situation can occur in 
generalized liver cell injury, certain drugs (e.g Rifampin and probenecid) interfere 
with the rat uptake of bilirubin by the liver cell and may produce a mild unconjugated 
hyperbilirubinemia. Bilirubin level rises in diseases of hepatocytes, obstruction to 
bilirubin excretion into duodenum, in haemolysis and defects of hepatic uptake and 
conjugation of Bilirubin pigment such as Gilbert’s disease.  
Elevation of total serum bilirubin may occur due to:  
1. Excessive haemolysis or destruction of the red blood cells.Eg:Haemolytic 
disease of the new born. 
2. Liver diseases.Eg.Hepatitis and cirrhosis. 
3. Obstruction of the biliary tract.Eg.Gall stones. 
The method is based on the reaction of Sulfonilic acid with sodium nitrite to form 
azobilirubin which has maximum absorbance at 546nm in the aqueous solution. The 
intensity of the color Produced is directly proportional to the amount of direct or total 
bilurubin concentration present in the sample. 
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Reagents 
1. Diazo A-(Reagent-R1) :Ready to use 
2. Diazo B-(Reagent-R2):Ready to use 
3. Bilirubin Activater :Ready to use 
Procedure 
Kind & King’s method was followed for the estimation of Bilirubin. Five hundred µl 
of working reagent was added to 50 µl of rat serum & incubated for 5 min at 37°C. 
Absorbance was measured AT 546 NM in semi auto analyzer against the standard. 
The Bilirubin content was calculated using the following equation: 
Total bilirubin (mg/dt) = Abs of the sample blank x 15. 
Direct Bilirubin(mg/dt) = Abs of sample blank x 10. 
5. ESTIMATION OF UREA 
Urea is the nitrogen-containing end product of protein catabolism. States 
associated with elevated levels of urea in blood are referred to as hyper uremia or 
azotemia.  
Method 
Estimation of urea was done by Urease-GLDH: enzymatic UV test.  
Principle 
Urea + 2H2O     Urease       2NH4 + 2HCO3 
2- Oxoglutarate +NH4+ +NADH      GLDH      L- Glutamate +NAD+ + H2O                                        
Table 14. Reagents 
 
 
 
 
 
 
 
 
 
  
R 1 
TRIS pH 7.8 120  mmol/l 
2-Oxoglutarate 7 mmol/l 
ADP 0.6 mmol/l 
Urease ≥ 6 KU/l 
GLDH ≥ 1 KU/l 
R 2 NADH 0.25 mmol 
R 3 Standard 40 mg/dl 
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Procedure 
a. Take 1000 µl of reagent-1 and 250 µl of reagent-2 in 5 ml test tube. 
b. To this, add 10 µl of serum. 
c. Mix well and immediately read the test sample at 340 nm Hg 334 nm Hg 365 nm 
optical path 1 cm against reagent blank (2-point kinetic). 
d. And note down the value. 
Normal range: 10 – 50 mg/dl. 
 
6. ESTIMATION OF URIC ACID 
Uric acid and its salts are end products of the purine  metabolism. In gout the 
most common complication of  hyperuricemia, ie. Increased serum levels of uric acid 
lead to formation of  monosodium urate crystal around the joints. 
Method  
Enzymatic photometric test using  TOOS (N ethyl- N (hydroxyl -3- sulfopropyl)-m- 
toluidin) 
Principle  
Uric acid + H2O + O2       uricase         Allantoin +CO2 +H2O2 
TOOS + 4 aminoantipyrine + 2H2O2      POD       Indamine + 3H2O 
 
Table 15.reagents 
R1 Phosphate buffer pH 7.0 100mmol/l 
TOOS 1mmol/l 
Ascorbate oxidase ≥1 KU/l 
R2 Phosphate buffer pH 7.0 100mmol/l 
4- amino antipyrine 0.3mmol/l 
K4 (Fe( CN)6) 10µmol/l 
Peroxidase ≥1KU/l 
Uricase ≥50U/l 
Procedure 
a. Take 800µl of  reagents -1 in a2ml centrifuge tube. 
b. To this add 20µl of serum. 
c. Mix well and incubate at 30°c for 5 minutes. 
d. Then add 200µl of reagent2 
e. Mix well incubate for 5min at 37°c 
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f. Measure the not down the values. 
Normal range: 1.9-8.2mg/dl 
7. ESTIMATION OF CREATININE:  
 
Principle: 
Creatinine forms a coloured complex with picrate in alkaline medium.  
The rate of formation of the complex is measured.  
 
Reagents: 
Reagent 1    Standard Creatinine (2mg/100ml) 
Reagent 2    Picric acid solution. 
Reagent 3     sodium hydroxide solution  
 
Procedure: 
 Take 500 µl of reagent -2 and 500 µl of reagent -3 in a 5ml test tube. To this 
add 100 µl of serum. Mix well and immediately read the test sample at Hg 492 nm 
1cm light path and note down the values.  
Normal range is 0.6 -1.1 mg/dl. 
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TABLE: 1   EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU 
CHAKRA MATHIRAI WITH INJI JUICE AND HONEY ON BODY WEIGHT 
IN Gram (PHYSICAL PARAMETER) 
 
GROUP CONTROL LOW DOSE  MIDDLE 
DOSE  
HIGH DOSE  
 
1st wk 
 
132.7±1.43 
 
131±1.342 
 
132.7±1.961 
 
132.3±1.944 
 
 
2nd wk 
 
138.5±1.408 
 
137±0.9309 
 
140.7±2.362 
 
140.8±1.424 
 
 
3rd wk 
 
144.5±1.408 
 
144.8±0.7923 
 
150.5±2.79 
 
148.3±1.626 
 
 
4th wk 
 
150.3±1.52 
 
153.5±1.31 
 
159±3.347 
 
157±1.844 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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Table-2 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON Food Intake In Gram 
 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 32 42 36 28 62 40 72 32 
DAY2 46 30 48 35 36 58 40 53 
DAY3 34 28 66 49 42 30 66 47 
Day 4 44 68 42 36 30 18 44 72 
DAY5 26 42 38 80 25 36 52 80 
Day 6 36 28 56 52 50 42 35 44 
DAY7 48 32 72 66 35 36 26 80 
DAY8 60 40 56 32 39 54 38 34 
Day 9 35 28 30 40 35 66 60 32 
DAY10 27 55 18 20 60 32 66 56 
Day 11 48 62 26 44 57 18 72 20 
DAY12 51 36 44 36 69 44 30 32 
DAY13 53 44 44 33 69 58 60 66 
Day 14 52 56 26 42 38 26 26 22 
DAY15 52 66 30 54 39 34 38 36 
Day 16 42 36 30 18 44 32 42 36 
DAY17 38 80 25 36 52 46 30 48 
DAY18 56 52 50 42 35 34 28 66 
Day 19 72 66 35 36 26 44 68 42 
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DAY20 56 32 39 54 38 28 52 66 
DAY21 35 28 30 40 35 35 42 36 
Day 22 27 55 18 20 60 49 38 80 
DAY23 48 62 26 44 57 36 56 52 
DAY24 51 36 44 36 69 45 72 66 
Day 25 42 35 44 56 52 50 56 32 
DAY26 36 26 80 72 66 35 26 26 
DAY27 54 38 34 56 32 39 34 38 
DAY28 66 60 32 35 28 30 32 42 
 Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
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Table-3 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON Water Intake in ml 
Groups Control Low Dose Middle Dose High Dose 
 
DAY 
Male Female Male Female Male Female Male Female 
Day 1 60 120 130 40 120 65 40 85 
DAY2 90 135 165 70 130 80 50 90 
DAY3 130 40 150 55 60 95 80 65 
Day 4 115 85 85 60 60 150 40 140 
DAY5 85 100 70 65 40 120 65 40 
Day 6 85 90 110 100 110 60 90 85 
DAY7 150 55 60 95 80 90 135 165 
DAY8 85 60 60 150 40 130 40 150 
Day 9 70 65 40 120 65 115 85 85 
DAY10 110 100 110 60 90 85 100 70 
Day 11 80 95 110 120 90 85 90 110 
DAY12 70 80 35 60 60 120 110 95 
DAY13 90 40 80 85 30 110 125 110 
Day 14 40 65 50 70 60 130 80 115 
DAY15 80 120 80 60 110 55 85 70 
Day 16 110 80 75 70 40 80 105 80 
DAY17 80 65 45 90 105 65 40 40 
DAY18 50 80 30 100 60 90 65 55 
Day 19 140 70 75 120 100 110 80 55 
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DAY20 90 65 90 95 80 130 75 90 
DAY21 80 95 110 120 90 85 80 120 
Day 22 70 80 35 60 60 120 110 80 
DAY23 90 40 80 85 30 110 80 65 
DAY24 40 65 50 70 60 130 50 80 
Day 25 80 120 80 60 110 55 90 110 
DAY26 85 30 110 125 110 140 70 75 
DAY27 70 60 130 80 115 90 65 90 
DAY28 60 110 55 85 70 80 95 110 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated by one 
way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group 
 
  
0
100
200
300
400
500
600
700
800
900
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
in
 m
l
WATER INTAK
F
M
F
M
F
M
F
M
160 
 
Table-4 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON ORGAN WEIGHT in gms 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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GROUP CONTROL Low Dose Middle Dose High Dose 
LIVER  
WEIGHT 
6.659±0.133
4 6.103±0.392 5.947±0.04517 6.449±0.2211 
KIDNEY 
WEIGHT 
L 0.8403±0.02
97 0.798±0.0433 
0.7573±0.0147
2 
0.7803±0.0089
5 
R 0.909±0.014
43 
0.7293±0.030
31 
0.687±0.00115
5 0.772±0.05196 
HEART 
WEIGHT 0.83±0.0358 
0.841±0.0877
6 
0.7263±0.0031
8 0.997±0.1339 
LUNGS  
WEIGHT 
1.384±0.233
6 
0.791±0.0588
9 0.812±0.0254 1.558±0.4443 
TESTIS 
WEIGH 
2.593±0.291
6 
2.903±0.0698
6 1.888±0.2656 2.004±0.01299 
UTERUS 0.4903±0.01
81 
0.4213±0.019
34 
0.4373±0.0493
6 0.514±0.1085 
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Table-5 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON HAEMATOLOGICAL 
PARAMETERS 
. 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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GROUP CONTROL LOW DOSE  MIDDLE 
DOSE  
HIGH DOSE  
 
RBC (X10^6/µL) 
 
4.573±0.1139 
 
5.39±0.3035 
 
4.853±0.6894 
 
5.8±0.3617 
 
 
WBC(X10^3/µL) 
 
12.5±1.531 
 
11.47±0.5783 
 
13±1.007 
 
11.43±0.3756 
 
 
HB (g/dl) 
 
10.5±0.5859 
 
13.2±0.8963 
 
11.83±1.683 
 
14.03±0.809 
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Table-5 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON BIOCHEMICAL 
PARAMETERS (LIVER PROFILE) 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group. 
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GROUP CONTROL LOW DOSE  MIDDLE 
DOSE  
HIGH 
DOSE  
SGOT(units/min/liter/mg 
protein) 
97.2±6.835 
 
116.1±11.08 
 
98.37±10.16 
 
91.5±3.523 
 
SGPT 
(units/min/liter/mg 
protein) 
44.77±8.151 
 
90.73±17.71 
 
45.3±5.852 
 
48.6±6.012 
 
ALP (units/min/liter/mg 
protein) 
210.1±69.74 
 
175.9±11.87 
 
169.9±27.35 
 
186.6±24.95 
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Table-5 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON BIOCHEMICAL 
PARAMETERS (LIVER PROFILE) 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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GROUP CONTROL LOW DOSE MIDDLE DOSE 
HIGH 
DOSE 
 
TOTAL 
BILIRUBIN 
(mg/dl) 
 
1.303±0.2452 
 
1.453±0.2822 
 
0.8193±0.3371 
 
0.99±0.194 
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Table-5 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON BIOCHEMICAL 
PARAMETERS (KIDNEY PROFILE) 
 
GROUP CONTROL LOW DOSE 
300mg/kg 
MIDDLE DOSE 
600mg/kg 
HIGH DOSE 
900mg/kg 
 
CREATININE (mg/dl) 
 
0.6133±0.03844 
 
0.58±0.08327 
 
0.4767±0.0441 
 
0.5867±0.0202
8 
 
 
URIC ACID (mg/dl) 
 
1.747±0.2761 
 
1.74±0.155 
 
2.06±0.6612 
 
1.983±0.2924 
 
 
Urea (mg/dl) 
 
42.4±1.992 
 
45.83±5.802 
 
30.73±1.068 
 
34.4±6.034 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
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Table-5 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON BIOCHEMICAL 
PARAMETERS (LIPID PROFILE):- 
 
GROUP CONTROL 
LOW DOSE 
300mg/kg 
MIDDLE 
DOSE 
600mg/kg 
HIGH DOSE 
900mg/kg 
Total 
cholesterol 
(mg/dl) 
29.8±1.674 
 
41.73±0.6064** 
 
37±3.58 
 
35.13±0.7796 
 
Triglycerides 
(mg/dl) 
91.6±0.6928 
 
66.4±3.291** 
 
64.1±0.866*** 
 
65.3±5.138*** 
 
HDL-
Cholesterol 
(mg/dl) 
7.75±0.2598 
 
6.25±0.5485 
 
5.9±0.5774 
 
5±0.2309 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6);  NS- non significant, *p<0.05, 
**p<0.01, ***p<0.001, calculated by comparing treated groups with control group.  
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY  ON FOOD INTAKE In Gram  
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 34 28 15 10 18 60 12 24 
DAY2 38 62 56 31 28 80 8 58 
DAY3 38 30 44 52 66 32 34 14 
Day 4 
56 18 34 24 18 22 42 22 
DAY5 
34 10 18 6 44 58 38 26 
Day 6 
60 12 58 68 32 38 58 64 
DAY7 
50 14 61 88 58 34 62 74 
DAY8 
32 44 18 40 26 64 58 62 
Day 9 
80 56 22 60 48 56 56 64 
DAY10 
74 62 45 56 64 74 24 58 
Day 11 
44 54 68 58 30 62 70 56 
DAY12 
54 60 38 62 56 64 62 48 
DAY13 
72 56 38 44 57 74 54 78 
Day 14 
38 19 54 50 16 74 72 56 
DAY15 
48 36 64 71 82 56 56 28 
Day 16 
56 78 54 42 56 80 56 77 
DAY17 
56 78 64 58 44 56 56 74 
DAY18 
45 52 34 56 72 64 62 54 
Day 19 
50 48 62 56 88 64 64 58 
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DAY20 
16 35 20 75 35 56 72 34 
DAY21 
34 56 64 68 56 64 45 62 
Day 22 
56 34 18 58 64 78 56 42 
DAY23 
46 28 64 56 67 58 18 34 
DAY24 
54 42 34 78 46 64 30 68 
Day 25 
40 80 55 44 88 80 34 64 
DAY26 
64 42 56 64 52 46 58 56 
DAY27 
68 45 32 38 56 80 56 58 
DAY28 
88 36 58 34 24 74 62 61 
 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON WATER INTAKE IN ml 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 70 75 85 140 70 100 50 70 
DAY2 105 60 85 60 50 85 140 105 
DAY3 130 60 85 60 70 150 165 130 
Day 4 
70 90 40 55 80 100 90 70 
DAY5 
130 210 60 70 130 70 75 60 
Day 6 
50 70 90 50 65 60 70 85 
DAY7 
70 80 50 130 60 70 90 55 
DAY8 
130 60 50 70 75 50 70 55 
Day 9 
110 40 80 55 130 20 130 85 
DAY10 
65 130 40 130 70 50 60 70 
Day 11 
80 60 55 70 60 60 70 30 
DAY12 
70 60 75 40 45 80 60 40 
DAY13 
50 60 40 65 55 50 30 60 
Day 14 
40 40 65 60 85 65 20 70 
DAY15 
60 65 20 60 65 80 60 70 
Day 16 
45 60 50 65 30 70 60 40 
DAY17 
80 60 40 70 30 60 20 55 
DAY18 
60 80 65 60 40 90 170 140 
Day 19 
70 115 125 120 20 95 185 140 
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DAY20 
70 90 95 50 65 60 75 50 
DAY21 
70 60 85 130 90 50 95 85 
Day 22 
140 40 60 105 70 60 90 60 
DAY23 
60 95 60 65 80 95 70 50 
DAY24 
110 90 75 60 70 50 60 70 
Day 25 
130 60 125 110 85 60 70 60 
DAY26 
70 110 90 60 50 70 110 40 
DAY27 
70 90 50 70 40 110 60 140 
DAY28 
65 50 110 60 85 75 60 125 
 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON ORGAN WEIGHT in gm 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated 
by one way ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001, calculated by comparing treated groups with control group.  
GROUP CONTROL 
 
Low Dose 
 
Middle Dose 
 
High Dose 
LIVER  
WEIGHT 
7.015±0.380
5 5.468±0.7463 5.987±0.0561 6.24±0.3043 
KIDNEY 
WEIGHT 
L 0.921±0.085
82 
0.7613±0.056
74 
0.7443±0.0197
5 
0.8363±0.0565
5 
R 1.165±0.256
7 
0.717±0.0327
9 
0.696±0.00907
4 
0.8233±0.0730
4 
HEART 
WEIGHT 
0.8463±0.03
93 
0.8493±0.088
15 
0.7603±0.0339
8 0.972±0.1363 
LUNGS  
WEIGHT 
1.721±0.407
1 
0.8027±0.060
03 1.016±0.2056 1.601±0.4463 
TESTIS 
WEIGH 2.841±0.383 2.511±0.3985 2.101±0.3407 2.412±0.4074 
UTERUS 0.4477±0.04
65 
0.463±0.0457
9 
0.4347±0.0494
4 0.6013±0.1393 
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON HAEMATOLOGICAL 
PARAMETERS 
Groups Control Low Dose Middle Dose High Dose 
Rbc (X103/µl)  
 5.33±0.8585 6.403±0.289 5.96±0.2173 6.213±0.3619 
Wbc(X106/µl)  
 11.17±0.8762 11.87±0.8212 13.73±0.636 13.3±0.3606 
 
Hb (g/dl) 
 
16.4±1.29 
 
16.37±1.707 
 
13.5±0.3055 
 
14.37±0.977 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON BIOCHEMICAL 
PARAMETER (LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Total 
Bilirubin(mg/dl) 
 
0.625±0.125 
 
 
0.865±0.195 
 
 
0.79±0.06 
 
 
1.015±0.055 
 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON BIOCHEMICAL 
PARAMETER (LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
 
SGOT (U/L) 
 
85.95±9.25 
 
133.2±37.95 
 
77.9±14.9 
 
81.35±3.05 
 
SGPT (U/L) 69.79±15.72 
 
45.4±3.8 
 
48.15±21.85 
 
38.15±3.95 
 
ALP (U/L) 308.2±24.55 
 
321.8±15.75 
 
247.8±10.55 
 
267.3±1.9 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p) calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON BIOCHEMICAL 
PARAMETER (KIDNEY PROFILE) 
 
Groups Control Low Dose Middle Dose High Dose 
Urea (mg/dl) 26.03±1.01 
 
33.45±0.25 
 
39.08±1.18 
 
26.74±1.13 
 
Uric acid 
(mg/dl) 
1.615±0.135 
 
1.2±0.04 
 
1.31±0.07 
 
1.64±0.1 
 
Creatinine 
(mg/dl) 
0.33±0.05 
 
0.275±0.005 
 
0.23±0.02 
 
0.29±0.09 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F   VISHNU CHAKRA 
MATHIRAI WITH INJI JUICE AND HONEY ON BIOCHEMICAL 
PARAMETER (LIPID PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Total 
cholesterol 
(mg/dl) 
34.3±3.6 
 
44.85±0.75 
 
44.95±8.05 
 
41.2±1.1 
 
Triglycerides 
(mg/dl) 
101.3±5 
 
71.55±4.85 
 
68.28±2.48 
 
80.4±3.8 
 
HDL-
Cholesterol 
(mg/dl) 
10.12±0.185 
 
6.625±1.945 
 
6.65±2.05 
 
3.9±0.7 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated 
by one way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, 
***P < 0.05 calculate by comparing treated group with CONTROL group.         
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RESULTS: 
    CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the 
dosing   period of 28 days. 
 Mortality: 
All animals in control and in all the treated dose groups survived throughout 
the dosing period of 28 days. 
 Body weight: 
Results of body weight determination of animals Table-1 from control and 
different dose groups exhibited comparable body weight gain throughout the dosing 
period of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food 
consumed by animals from different dose groups was found to be comparable with 
that by control animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in 
Table No.4 Comparison of organ weights of treated animals with respective control 
animals on day 29 was found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations (Table 4) conducted on day 29 
revealed following significant changes in the values of different parameters 
investigated when compared with those of respective controls; however, the increase 
or decrease in the values obtained was within normal biological and laboratory limits 
or the effect was not dose dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on days 29 and recorded in 
Table 2 revealed the following significant changes in the values of hepatic serum 
enzymes studied. When compared with those of respective control. However, the 
increase or decrease in the values obtained was within normal biological and 
laboratory limits. 
Histopathology: 
In histopathological examination, revealed normal architecture in comparison 
with control and treated animal. 
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 DISCUSSION: 
1)  All the animals from control and all the treated dose groups up to 500 mg/kg 
survived throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during 
the dosing period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain 
with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29, 
revealed no abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29 no 
abnormalities attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was found 
to be comparable with that of respective controls. 
8) Histopathological examination revealed normal architecture in comparison with 
control and treated animal. 
 
SUMMARY AND CONCLUSION:  
In conclusion   VISHNU CHAKRA MATHIRAI WITH INJI JUICE AND 
HONEY can be considered safe, as it did not cause either any lethality or adverse 
changes with general behavior of rats and also there were no observable detrimental 
effects (100 to 300 mg/kg body weight) over a period of 28 days. Our results have 
demonstrated that the   VISHNU CHAKRA MATHIRAI WITH INJI JUICE AND 
HONEY is relatively safe when administered orally in rats. 
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9.0 ABBREVATION 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o.  peros 
mL  Milliliter 
%   percentage 
R&D   Research and Development 
EDTA  Ethylene Diamine Tetra Acetic Acid 
M   Male 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD  Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments  
on Animals 
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HISTOPATHOLOGY   -  TOXICITY STUDY 
SPECIMEN     : A) Liver.    Group –    : Vishnu chakra mathirai . 
 
                                                       
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
 Section from liver shows lobular architecture with interface hepatitis. Individual Hepatocytes 
shows reactive atypia. Portal triad shows no significant pathology. Central vein and Sinusoids 
show dilatation. 
10x shows mild altered architecture with 
peripotal inflammation 
40x show kupffer cell hyperplasia 
40x shows bile uct hyperplasa 40x shows central vein congestion 
40x shows hepatocytic necrosis with sinusoidal 
dilatation 
40x shows sinusoidal dilatation and central vein 
congestion 
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SPECIMEN    :  B) spleen. 
Group – :  Vishnu chakra mathirai  
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
        Section studied from spleen shows normal white pulp and red pulp. Red pulp shows pigment 
laden macrophages and congested vessels. White pulp shows lymphocytic infiltrates forming 
germinal centre. The pencillar artery shows normal morphology. Megakaryocytes 
    
10x shows normal spleen with red and white pulp 40 x show slymphocytic infiltrates 
40x shows megakaryocytes 40x shows pencillar artery 
40x shows white pulp with lymp[hocytic infiltrates 
193 
 
SPECIMEN  :  C)  Kidney. 
Group – :  Vishnu chakra mathirai 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE: 
 
 Section from kidney shows both cortex and medulla. Glomeruli and tubules shows no significant 
pathology. Interstitium shows no significant pathology. Blood vessels show congestion. There is 
no evidence of toxic changes. 
  
10x shows normal interstitium 10x shows normal kidney with cortex and 
medulla 
40x shows interstitium 40x shows normal tubules 
40xc shows normal glomeruli 
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SPECIMEN  :  D) Testis 
Group – :  Vishnu chakra mathirai  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
          Section from testes with seminiferous tubules showing maturation arrest with lacking of 
spermatogenesis.  
  
 
10x shows focal maturation arrest 10x shows variying stages of maturation with 
focal maturation arrest 
40x shows maturation arrest 40x shows spermatogenesis 
40x shows normal spermatogenesis 
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Name   : 
Ref. No. : [H0 331A/18] 
 
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
              TOXICITY STUDY            
 
SPECIMEN                   : A) Liver 
   Group –                   : Kirubakaran - VCM. 
 
GROSS APPEARANCE: 
 
                     Received a specimen of liver measuring 3.6x2.5x1.4cms.                     
  
(PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section from liver shows mild altered lobular architecture with kupffer cell hyperplasia. 
Individual Hepatocytes shows mild hepatocytic necrosis. Portal triad shows bile duct hyperplasia and 
periportal inflammation. Central vein shows congestion. Sinusoids show dilatation. 
                                                                                                                                                    
Dr.C.R.Ajeethkumar.M.D. (Path). 
             
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
Checked 
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Name   : 
Ref. No. : [H0 331B/17] 
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
         Toxicity study                
 
SPECIMEN                   :  B) spleen. 
    
Group –I                  : Kirubakaran - VCM 
 
GROSS APPEARANCE:  
 
                     Received a specimen of spleen measuring 2.0x0.6x0.5cms. 
 
 (PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section studied from spleen with white pulp and red pulp shows normal morphology. 
The pencillar artery shows normal morphology. Megakaryocytes are also seen. There is no evidence 
of toxic changes. 
 
 
 
    
 
                                                                                      
                                                                                Dr.C.R.Ajeeth kumar. M.D. (Path), 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path), Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
Checked 
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Name   : 
Ref. No. : [Ho 331C/18] 
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : C) Kidney. 
 
Group – I                      : Kirubakaran - VCM 
 
GROSS APPEARANCE    : 
 
Received specimen of kidneys each measuring 1.4x0.7x0.5cms and 1.3x0.6x0.5cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from kidney shows both cortex and medulla. Glomeruli and tubules shows no 
significant pathology. Interstitium shows no significant pathology. Blood vessels show congestion. 
There is no evidence of toxic changes. 
 
 
                                                                       Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
Checked 
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Name   : 
Ref. No. : [Ho 331D/18] 
 
Rec.On :  21/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          :  D) Testis. 
 
Group – I                      : Kirubakaran - VCM   
 
GROSS APPEARANCE    : 
 
Received specimen of both testis measuring each 1.1x0.5x0.4cms and 1.0x0.5x0.4cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from testes with seminiferous tubules showing focal maturation arrest with 
lacking of spermatogenesis.  
 
 
 
                                                                       Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
 
